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An additional summary is included at the conclusion of Chapters 2-4 and again for Chapter 5-
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It is approaching 35 years since human immunodeficiency virus (HIV)-1 was first identified 
in Western Australia (WA) and 20 years since introducing highly active antiretroviral therapy 
(HAART) transforming HIV management, in the majority of cases, by maintaining 
‘undetectable’ HIV-1 RNA and restoring CD4 T cell counts to healthy levels. Despite these 
advances patients are at increased risk of developing age-associated diseases. This thesis 
therefore investigates whether expanding laboratory approaches to incorporate aspects of the 
disease process, that are currently 'invisible' in clinical practice but may be prognostically 
important or which may inform treatment and prevention strategies at a population level, is 
warranted.  
The following aims were addressed; 1) analysing determinants of HIV-1 RNA residual 
viraemia; 2) investigating monocyte activation during chronic HIV-1 infection and; 3) 
assessing HIV-1 diversity from large scale sequences throughout WA and Australia, 
including the collaboration and formation of the Australian Molecular Epidemiology 
Network (AMEN).  
The main findings demonstrated HIV-1 residual viraemia was powerfully associated with the 
pre-treatment level of viraemia even after 10-15 years of starting HAART. Analysis of 
monocyte activation revealed multiple pathways involved in chronic immune activation 
responses to HIV-1, by altering CD16+ monocyte expression and elevated levels of sCD14 
(previously associated with all-cause mortality), that were not corrected by HAART and 
therefore prognostically significant. In contrast, levels of other biomarkers (e.g. CXCL10 and 
sCD163) declined with HAART.  
Investigations of HIV-1 genetic diversity within the WA cohort (n=1021) and the Australian 
cohort (n=4873) revealed new challenges for HIV-1 prevention due to significant increases in 
HIV-1 non-B-subtypes, consistent with an increasing impact of migration, while local 
transmissions were predominantly HIV-1 B-subtypes.  
Overall, this thesis provides evidence for possible new approaches that may enhance HIV-1 
laboratory practice that could aid clinical management, improve long-term health outcomes 






Table of Content 
Title page ........................................................................................................................... i  
Faculty............................................................................................................................... ii 
Declaration ....................................................................................................................... iii  
Notes regarding the formatting of this thesis ................................................................... iv  
Acknowledgements ........................................................................................................... v  
Abstract .......................................................................................................................... viii  
Table of contents .............................................................................................................. ix  
Abbreviations ................................................................................................................. xiv  
List of figures ................................................................................................................. xix  
List of tables ................................................................................................................. xxiii 
List of boxes .................................................................................................................. xxv 
Academic output during candidature 
       List of Presentations .............................................................................................. xxvi 
       List of Publications ................................................................................................ xxx 
Ethical considerations .................................................................................................. xxxi 
Chapter 1: A general introduction to the history of the Human Immunodeficiency Virus 
(HIV) in Western Australia and the impact on current era clinical care. 
1.1  The worldwide HIV/AIDS epidemic  ........................................................................ 2 
1.2  Epidemiology and phylogenetic analysis of HIV ...................................................... 6 
1.3  The early years of HIV-1 in Western Australia and current trends ........................... 7 
1.4  HIV clinical progression and the current treatment era ........................................... 12 
1.5  Innate immunity and the role monocytes play to combat disease ........................... 17 
1.6  The dynamics of ageing, monocytes and HIV infection.......................................... 20  
1.7  Co-morbidity: HIV-1/cardiovascular disease in an ageing HIV population ........... 23  
1.8  In with the new and out with the old: A shift in the HIV monitoring paradigm ..... 25  
1.9  Structure and goals of this thesis ............................................................................. 25 
Chapter 2: Determinants of residual viraemia during combination HIV treatment: 
Impacts of baseline HIV RNA levels and treatment choice. 
Additional comments ……………………………………………………………………30  
Funding ........................................................................................................................... 31 
ix 
 
Attributions ..................................................................................................................... 31 
Abstract ........................................................................................................................... 32 
Introduction ..................................................................................................................... 32 
Methods........................................................................................................................... 33 
Results ............................................................................................................................. 33 
Discussion ....................................................................................................................... 38 
Acknowledgements ......................................................................................................... 40 
References ....................................................................................................................... 40 
Summary for Chapter 2 ................................................................................................... 43 
Chapter 3: Elevated plasma soluble CD14 and skewed CD16+ monocyte distribution 
persist despite normalisation of soluble CD163 and CXCL10 by effective HIV therapy: 
A changing paradigm for routine HIV laboratory monitoring? 
Additional comments ...................................................................................................... 45  
Attributions ..................................................................................................................... 46 
Abstract ........................................................................................................................... 47 
Introduction ..................................................................................................................... 48 
Methods........................................................................................................................... 49 
Results ............................................................................................................................. 52 
Discussion ....................................................................................................................... 58 
Acknowledgements ......................................................................................................... 60 
References ....................................................................................................................... 60 
Supplementary information for Chapter 3: The method development and validation of 
the flow cytometry, monocyte activation marker panel. 
3.1 Background............................................................................................................ 63 
3.2 Fluorochrome selection for the eight colour monocyte activation marker assay... 63 
3.3 Instrument set up  .................................................................................................. 64 
3.4 Compensation evaluation ...................................................................................... 64 
3.5 Establishing monocyte activation marker parameters ........................................... 65 
3.6 Gating strategy to identify MAM expression levels.............................................. 67 
3.7 Safety guidelines utilised for the MAM whole blood phenotyping assay............. 68 
Summary for Chapter 3 ................................................................................................... 70 
x 
 
Chapter 4: Plasma CXCL10, sCD163 and sCD14 levels have distinct associations with 
antiretroviral treatment and cardiovascular disease risk factors. 
Additional comments ...................................................................................................... 71 
Attributions ..................................................................................................................... 72 
Abstract ........................................................................................................................... 73 
Introduction ..................................................................................................................... 74 
Materials and Methods .................................................................................................... 74 
Results ............................................................................................................................. 76 
Discussion ....................................................................................................................... 80 
References ....................................................................................................................... 83 
Summary for Chapter 4 ................................................................................................... 89 
A collective summary for Chapters 2, 3 and 4 ........................................................... 90 
4.1 Impact plasma biomarkers have on HIV replication, associations with HIV 
treatment choice and response to HAART ............................................................ 91 
4.2 Implications of persistent residual viraemia .......................................................... 93 
4.3 Cardiovascular disease risk factors and associations with plasma biomarkers ..... 93 
4.4 Clinical relevance of plasma biomarkers and monocyte subsets during HIV 
infection ................................................................................................................. 95 
4.5 Type 1, 2 and 3 Interferon responses during HIV infection .................................. 99 
4.6 Therapeutic strategies to reduce systemic immune activation ............................ 102 
4.7 Importance of early treatment to reduce immune activation ............................... 106 
Preamble to Chapters 5 and 6.................................................................................... 109 
Chapter 5: Longitudinal trends in Western Australian HIV-1 sequence diversity and 
viral transmission networks and their influence on clinical parameters: 2000 – 2014. 
Acknowledgements ....................................................................................................... 113 
Additional comments .................................................................................................... 114  
Attributions ................................................................................................................... 114 
Abstract ......................................................................................................................... 115 
Introduction ................................................................................................................... 115 
Materials and Methods .................................................................................................. 116 
Results ........................................................................................................................... 117 
xi 
 
Discussion ..................................................................................................................... 120 
References ..................................................................................................................... 123 
Summary for Chapter 5 ................................................................................................. 127 
Chapter 6: Molecular surveillance of HIV-1 in Australia from 2005-2012 reveals 
increased subtype diversity linked to migration, overseas travels and distinct network 
dynamics.  
Acknowledgements ....................................................................................................... 129  
Additional comments .................................................................................................... 130  
Attributions ................................................................................................................... 130 
Abstract ......................................................................................................................... 131 
Introduction ................................................................................................................... 132 
Materials and Methods .................................................................................................. 134 
Results ........................................................................................................................... 135 
Discussion ..................................................................................................................... 144 
References ..................................................................................................................... 149 
Summary for Chapter 6 
6.1     Analyses of age distribution in the Australian HIV-1 cohort ............................. 155 
6.2     The analysis of networks within the Australian HIV-1 cohort ........................... 156 
A collective summary for Chapters 5 and 6…………………………………………161 
6.3     The challenges surrounding changes in HIV-1 subtype diversity ...................... 162 
6.4     Impact of HIV-1 inter-subtype recombination ................................................... 162 
6.5     Strength and limitations of phylogenetic approaches ......................................... 163 
6.6     Overview of automated HIV-1 subtype sequence tools ..................................... 164 
6.7     Implications for successful vaccine development ............................................... 164 
6.8    Updating strategies to assist in reducing the rate of HIV transmissions and 
end HIV in Australia ........................................................................................... 164 
 
Chapter 7: Final Discussion and concluding comments; Human Immunodeficiency 
Virus (HIV) in Western Australia, Australia and the impact on current era clinical care. 
7.1 Final Discussion .................................................................................................. 167 
xii 
 
7.2 Translating science into laboratory practice ........................................................ 172 
7.3 Costs  ................................................................................................................... 175 
7.4 Future studies....................................................................................................... 176 
7.5 Final Conclusion .................................................................................................. 178 


























ACE  angiotensin converting enzyme 
ADAM17   a disintegrin and metalloproteinase 17 
ADCC  antibody dependant cellular cytotoxicity 
AIDS  acquired immunodeficiency syndrome 
AMEN  Australian Molecular Epidemiology Network 
ANOVA  analysis of variance 
APOBEC3G apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 
3G 
ARG  arginine 
ART(s)  antiretroviral therapy (therapies) 
AZT  zidovudine 
BMI  body mass index 
BS  bootstrap value 
CCR2  MCP-1 receptor C-C chemokine receptor type 2 
CCR5  chemokine receptor 5 
cDNA copy DNA  
CD  cluster of differentiation (i.e.CD14, CD16, CD143, CD64, CD163, 
CD62L, CD45) 
CD4+T  CD4 positive T cell 
CD8+T  CD8 positive T cell 
CD4:8  CD4 to CD8 ratio 
CHD  coronary heart disease 
Cm  centimetres 
CpG DNA  cytosine phosphate guanine deoxyribonucleic acid  
cpm  copies per millilitre 
CRF(s)  circulating recombinant form(s) (i.e. CRF01_AE, CRF02_AG) 
CRP  C-reactive protein (hsCRP- highsensitivityCRP) 
CST  cytometer setup beads 
CVD  cardiovascular disease 
CX3CR1  CX3C chemokine receptor 1 
CXCL10  C-X-C motif chemokine 10 
CXCR  C-X-C receptor (i.e. CXCR3, CXCR4) 
CYP3A4  cytochrome P450 3A4 enzyme inhibitor 
DNA  deoxyribonucleic acid 
xiv 
 
EDTA  ethylenediamine tetraacetic acid 
ELISA(s)  enzyme-linked immunosorbent assay 
ERK  extracellular-signal-regulated kinases (ERK1/2)  
FcγR1  high affinity IgG Fc receptor 
FcγRIII  Fc fragment of IgG, low affinity III, receptor 
FDiaBP  fasting diastolic blood pressure 
FI(s)  fusion inhibitor(s) 
FMO  fluorescence minus one 
FSC  forward-light scatter 
FSysBp  fasting systolic blood pressure 
GD  genetic distance 
GPCR  G protein-coupled receptor 
GTR   general time reversible 
HAART  highly active antiretroviral therapy 
HAND  HIV associated neurocognitive disorders 
HCV  hepatitis C virus 
HDL  high density lipoprotein 
HIV  human immunodeficiency virus 
HIV+  human immunodeficiency virus positive 
HIV-1   human immunodeficiency virus-1 
HIV-1 RNA human immunodeficiency virus-1 ribonucleic acid  
HLA  human leukocyte antigen (i.e. HLA-DR) 
IC(s)  isotype control(s) 
IDU  injecting drug use(r)  
IFN-α  interferon alpha (i.e. IFNα-2b) 
IFNAR  interferon alpha receptor (i.e. IFNAR1, IFNAR2) 
IFN-β  interferon beta 
IFN-ε   interferon epsilon 
IFN-γ  interferon gamma 
IFNGR  interferon gamma receptor (i.e. IFNGR1, IFNGR2) 
IFN-λ  interferon lambda (i.e. IFNλ3) 
IFNLR  interferon lambda receptor (i.e. IFNLR1) 
IKK    IκB kinase 
IL  interleukin (i.e. IL-1β, IL-6, IL-10. IL-21, IL-10R) 
INI(s)  integrase inhibitor(s) 
xv 
 
IP-10  interferon gamma-induced protein 10 
IRF(s)  interferon response factors(s) (i.e. IRF3, IRF7) 
ISG(s)  interferon stimulatory gene(s) 
JAK  janus kinase 
kg  kilograms 
kg/m2  kilograms per metre squared 
LBP  LPS binding protein 
lcpm  log copies per millilitre 
LDL  low density lipoprotein  
LPS  lipopolysaccharide 
LTR  long terminal repeat (i.e. 2-LTR) 
M1  acute inflammatory activated macrophages 
M2  anti-inflammatory activated macrophages 
MAM  monocyte activation marker 
MAPK  mitogen-activated protein kinase 
MAVS   mitochondrial antiviral-signalling protein 
MCP-1  monocyte chemoattractant protein-1 
MEGA-V6  Molecular Evolutionary Genetics Analysis version 6 
MHC  major histocompatibility complex 
mins  minutes 
mL  microlitre 
MSM  men who have sex with men 
MyD88  myeloid differentiation primary response gene 88 
NATA  National Association of Testing Authority 
Nef  negative regulatory factor 
NFκB  nuclear factor kappa-light-chain-enhancer of activated B cells  
ηg/μl   nanograms/microlitre 
NK  natural killer 
NNRTI(s)  non-nucleoside reverse transcriptase inhibitor(s) 
NRTI(s)  nucleoside reverse transcriptase inhibitor(s) 
PAMP(s)  pathogen associated molecular pattern(s) 
PBMCs  peripheral blood mononuclear cells 
pDC  plasmacytoid dendritic cells 
peg IFNα-2b pegylated interferon alfa-2a 
ρg/μl   pictograms/microlitre 
xvi 
 
PI(s)  protease inhibitor(s) 
PMT  photomultiplier tube  
pol  polymerase gene 
PR  protease 
PRR(s)  pattern recognition receptor(s) 
RCPA  Royal College of Pathologists of Australasia 
RNA  ribonucleic acid 
RPH  Royal Perth Hospital 
rpm  revolutions per minute 
RT  reverse transcriptase 
SAMHD1  SAM domain and HD domain-containing protein 1 
sCD14  soluble CD14 
sCD163  soluble CD163 
SD  standard deviation 
SER  serine 
SIV  Simian Immunodeficiency Virus 
SLE  systemic lupus erythematosus 
SMART  Strategies for Management of Antiretroviral Therapy 
SNAE(s)  serious non AIDS event(s) 
SPSS  Statistical Package for the Social Science 
SSC  side-light scatter 
ssRNA single stranded ribonucleic acid  
STAT Signal Transducer and Activator of Transcription (i.e. STAT1, 
STAT2) 
STING  stimulator of interferon genes 
Tat  trans-activator of transcription 
TB  tuberculosis 
TBK1  TANK-binding kinase 1 
Th  T helper cells (i.e. Th17, Th22) 
TLR(s)  toll like receptor(s) (i.e. TLR3, TLR4, TRL5, TLR6, TLR7, TLR8, 
TLR9) 
TNF  tumor necrosis factor 
TNF-α  tumor necrosis factor alpha 
TREX1  three prime repair exonuclease 1 
TRIF  TIR-domain-containing adapter-inducing interferon-β 
TRIM  tripartite motif (i.e. TRIM5) 
xvii 
 
TUR  The United Republic of Tanzania 
UK  United Kingdom 
UNAIDS  The Joint United Nations Programme on HIV and AIDS 
URF(s)  unique recombinant form(s) 
US(A)  United States (of America) 
US DHHS  United States Department of Health and Human Services 
vif  viral infectivity factor 
vpr  viral protein R 
vpu  viral protein U 
vpx  viral protein X 





















List of Figures  
Chapter 1 
Figure 1: Global map of HIV infections in 2013 .............................................................. 2  
Figure 2: Country distribution of HIV infections in 2013 ................................................ 3  
Figure 3: Country distribution of new HIV infections in 2013 ........................................ 4 
Figure 4: HIV infections in Asia/Pacific region in 2013 .................................................. 5  
Figure 5: New HIV notification in the Asian/Pacific region reached 350,000 in 2013.... 6  
Figure 6: Trends in notification of HIV-1 infection, AIDS and Deaths from AIDS in 
Western Australia from 1983 to 2014 ................................................................ 9 
Figure 7: Prevalence of HIV infections worldwide in Adults 18-45 .............................. 10 
Figure 8: Comparisons of the birth countries of settlers into Australia (orange bars) 
and into Western Australia (black bars) from 2006 to 2011 .......................... 10 
Figure 9: HIV infection and short term visitors to Australia .......................................... 11  
Figure 10: HIV infection and short term resident departures from Australia ................. 12 
Figure 11: The natural progression of HIV infection ..................................................... 13 
Figure 12: Australian antiretroviral regimes for the treatment of HIV ........................... 15 
Figure 13: Development and migration of differentiating monocytes from bone 
marrow into blood and to tissue compartments ............................................ 19 
Figure 14: Improving HIV surveillance and monitoring in Western Australia by 
focusing on four key points throughout this citation .................................... 27 
Chapter 2 
Figure 1: A schematic representation of the available data from 11 575 consecutive 
HIV RNA tests performed between 2007 and 2010....................................... 34 
Figure 2: Observed categories of virological suppression as proportions of the HIV 
RNA measurements < 200 copies/mL, according to the initial class of 
combination antiretroviral therapy (cART) [protease inhibitor (PI) or 
nonnucleoside reverse transcriptase inhibitor (NNRTI)] and era of treatment 
initiation.......................................................................................................... 36 
Figure 3: Odds ratios (± 2 standard errors) from longitudinal logistic regression 
modelling of virological suppression rates according to class of current 
therapy. ........................................................................................................... 38 
xix 
 
Supplementary Figure S1: Representative real-time PCR amplification plots 
demonstrating HIV-1 amplification (lower red trendline) relative to control 
(upper blue trendline) ..................................................................................... 42 
Chapter 3 
Figure 1: Phenotypic identification of monocytes and monocyte subsets ...................... 54 
Figure 2: The median cell surface expression and 95% confidence intervals are shown 
for CD64 (A), CD163 (B) and CD143 (C) on monocyte subsets in HIV and 
control subjects ............................................................................................... 55 
Figure 3: HIV viral load status has different influences on monocyte cell surface 
expression ...................................................................................................... 56 
Figure 4: sCD14 levels are significantly elevated in HIV patients irrespective of HIV 
viral load status ............................................................................................... 56 
Supplementary Figure S1: Monocyte activation marker panel matching procedure ...... 64 
Supplementary Figure S2: The effect of “washing” monocyte cell populations ............ 67 
Supplementary Figure S3: The effect of temperature and time on monocyte subsets .... 68 
Supplementary Figure S4: The gating strategy for CD14 and CD16 monocytes ........... 69 
Chapter 4 
Figure 1: Differing correlation outcomes between the three plasma biomarkers and 
HIV-1 RNA levels ........................................................................................... 77 
Figure 2: The effect of smoking and integrase use on sCD14 levels .............................. 78 
Figure 3: CXCL10, soluble CD14 and soluble CD163 have distinct although 
overlapping associations with cardiovascular disease risk factors, HIV 
treatment, ethnicity and age (A) along with different aspects of HIV 
infection (B) ................................................................................................... 81  
Supplementary Figure S1: Correlations between plasma biomarkers ............................ 88 
Supplementary Figure S2: Plasma biomarker marker levels correlate with ethnicity .... 88 
Collective summary for Chapters 2, 3 and 4  
Figure 1: The effect HIV-1 and HAART has on plasma biomarkers ............................. 92 
Figure 2: The potential role Nef particles play in stimulating and activating 
ADAM17 ........................................................................................................ 95 
xx 
 
Figure 3: The impact of raltegravir intensification on HIV-1 2-LTR circles in 
HAART-suppressed subjects ......................................................................... 97 
Figure 4: HIV pathogenesis is altered by antiretroviral therapy, as are plasma 
biomarkers and monocyte activation associated with immune activation ..... 98  
Figure 5: HIV infection can induce Type I, II and III IFNs ......................................... 101  
Figure 6: The secondary response pathways induced from Type I, II and III IFNs ..... 102 
Figure 7: IFN-λ3 inhibits HIV-1 infection of macrophages through JAK/STAT 
pathway ........................................................................................................ 106 
Preamble to Chapters 5 and 6 
Figure 1: New HIV infections diagnosed, per year, since 1984 ................................... 110 
Figure 2: The concept behind the phylogenetic analysis approach .............................. 112 
Chapter 5 
Figure 1: The HIV-1 subtype distribution and proportions identified in Western  
Australia during 2000-2014 ........................................................................... 118 
Figure 2: The proportion of males and females within HIV-1 B subtype, non-B  
subtype, and recombinants represented by the HIV notification era and  
the number of HIV sequences ...................................................................... 118 
Figure 3: A radial representation from the phylogenetic analysis performed on  
HIV-1 partial pol sequences. ........................................................................ 119 
Figure 4: A large cluster (n=53) showing clinical dynamics over time ........................ 120 
Figure 5: Dynamics of earliest HIV-1 RNA and earliest CD4 T cell count for  
sequences within a cluster or defined by HIV subtype group ...................... 121 
Figure 6: Multivariate regression results showing significant associations of HIV  
clinical parameters with notification era, age, cluster group and HIV  
                subtype .......................................................................................................... 121 
Summary for Chapter 5 
Figure 1: The age distribution plots for patients in the Western Australian HIV  






Figure 1: HIV-1 subtype distribution in Australia over time ........................................ 136 
Figure 2: The distribution and proportion of HIV-1 subtypes present in each 
Australian state ............................................................................................. 138 
Figure 3: The phylogenetic tree constructions based on HIV-1 pol sequences for (A) 
HIV-1 B and (B) non-B subtypes assessed in the AMEN study .................. 140 
Figure 4: Differences in the distribution and proportions of pairs and larger cluster size 
for HIV-1 subtypes ....................................................................................... 141 
Figure 5: Gender distribution within clusters according to HIV-1 subtypes (A) and 
for clusters in each state with B subtype (B) or a non-B subtype (C) .......... 142 
Figure 6: Multivariate regression analysis reveals factors associated with a sequence 
being in a cluster ............................................................................................ 143 
Summary Chapter 6 
Figure 1: Age and gender according to HIV-1 subtype and network size .................... 156 
Figure 2: An Australian, state by state approach on network size within HIV-1 B (A) 
and non-B subtypes (B) ................................................................................. 157 
Figure 3: The proportion of HIV-1 subtype pairs and networks established nationally 
(A), for HIV-1 non-B (B) and B subtypes (C) overtime .............................. 158  
Figure 4: The proportion of “interstate” or “intrastate” networks based on the number 
of sequences in the network (>2 in size) and either having an HIV-1 B (A) 
or non-B (B) subtype ................................................................................... 159 
Chapter 7 
Figure 1: A potential T, B and monocyte (TBM) flow cytometry panel .....................  173 
Figure 2: Model I - A proposed protocol for HIV-1 clinical laboratories to follow 
for the accurate assignment of HIV-1 subtypes ............................................ 174 
Figure 3: A proposed flow chart representing the possible laboratory assays to be 






List of Tables 
Chapter 2 
Table 1: Demographic variables among individuals with virological suppression <200  
copies/mL and on documented combination antiretroviral therapy (cART) > 1 
year (n=356)... .................................................................................................. 35 
Table 2: Predictors of viral suppression to HIV RNA levels < 40 copies/mL among          
356 individuals with viral load < 200 copies/mL and on combination  
antiretroviral therapy (cART) for at least 1 year .............................................. 36 
Table 3: Predictors of detectable HIV RNA among 348 individuals with HIV  
RNA levels < 40 copies/mL and on combination antiretroviral therapy  
(cART) for at least 1 year ................................................................................. 37 
Chapter 3 
Table 1: Demographic and clinical characteristics of HIV-infected and healthy control 
subjects ........................................................................................................... 53 
Supplementary Table S1: The antibody-fluorochrome pairs were selected by using the 
BD multicolour panel designer ....................................................................... 65 
Chapter 4 
Table 1: Demographics and patient characteristics from 474 HIV positive patients who 
underwent CVD risk assessments in 2010 ....................................................... 76    
Table 2: Model 2 - Multivariate regression analyses results .......................................... 79 
Supplementary Table S1: Model 1- Multivariate regression analyses results ................ 87 
Collective summary for Chapters 2, 3 and 4  
Table 1: The antiviral capability of important host restriction factors during HIV 
infection. ........................................................................................................ 100 
Chapter 5 
Table 1: Patient characteristics and clinical parameters at time of HIV notification ... 117 
Table 2: HIV-1 subtype transmission clusters identified 2000-2014 ........................... 119 
Supplementary Table S1: HIV-1 Protease and Reverse Transcriptase primers  
sequences ........................................................................................................ 124 
xxiii 
 
Supplementary Table S2: The distribution of HIV-1 clusters according to subtype,  
cluster size and gender .................................................................................... 125 
Supplementary Table S3: HIV-1 inter-subtype recombinants identified 2000-2014  
(n=38) via Stanford HIV drug resistance database ......................................... 126 
Chapter 6 
Table 1: Contribution toward the AMEN epidemiological and diversity study, by 
state, showing HIV subtype characteristics and baseline sequence 
information ..................................................................................................... 137  
Table 2: Demographics for HIV-1 B subtype, non-B subtypes and sequences in a 
network including age, gender, AMEN centre and sequencing era ............... 139  
Table 3: A comparison of Stanford HIV-1 subtyping results compared to the 
consensus reached from COMET, SCUEAL, jpHMM and REGA for pure 
subtypes and inter-subtype recombination ..................................................... 146 
Chapter 7 
Table 1: A representation of when HIV monitoring assays should be performed within 













List of Boxes 
Chapter 1 
Box 1: WA HIV Strategy 2015–2018 ............................................................................. 28 
Box 2: The7th National HIV Strategy for 2014-2017 ..................................................... 29 
Box 3: United Nations declaration on HIV and AIDS 2011  ......................................... 29 
 
Chapter 7: 
Box 1: Key findings from chapter 2 ............................................................................. 168 
Box 2: Key findings from Chapter 3............................................................................. 169 
Box 3: Key findings from Chapter 4............................................................................. 170 
Box 4: Key findings from Chapter 5............................................................................. 171 




















Academic output during candidature 
List of presentations during candidature  
(OP= Oral presentations, PP= poster presentations) 
 
Royal Perth Hospital (RPH)-Medical Research Foundation (MRF) research day 2015, 
Perth, Western Australia September 30th 2015. 
Award: Early Career Scientist Investigator Award 
OP Castley A Gizzarelli L, Guelfi G, Gaudieri S, John M, Nolan D. Changing 
face of HIV: A longitudinal analysis of HIV-1 sequence diversity, 
transmission networks and the impact of clinical parameters in Western 
Australia from 2000-2014. 
Australian Molecular Epidemiology Network (AMEN) workshop. Brisbane, Australia, 
September 17th 2015.   
OP Castley A. Engaging with community groups: Workshop Introduction: A 
history and timeline into the formation of the Australian Molecular 
Epidemiology Network (AMEN).  
World STI/HIV conference in conjunction with the Australasian Society for HIV 
Medicine (ASHM), Brisbane Australia, September 13th-18th 2015. 
Award: ISSTDR scholarship holder. 
OP Castley A, Sawleshwarkar S, Varma R, Herring B, Thapa K, Chibo D, 
Nguyen N, Hawke K, Ratcliff R, Dwyer DE, Nolan D: The Australian 
Molecular Epidemiology Network-HIV (AMEN-HIV). The challenges of 
diversity: HIV-1 subtype distribution and transmission networks within the 
Australian Molecular Epidemiology Network-HIV 2005-2012. 
OP Castley A, Gizzarelli L, Guelfi G, Gaudieri S, John M, Nolan D. HIV-1 
sequence diversity and transmission networks in Western Australia from 
2000-2014, and their impact on baseline clinical characteristics. 
OP  Castley A, James I, Williams L, Berry C, Nolan D. One profile or many? 
Plasma biomarkers CXCL10, sCD163 and sCD14 reveal distinct associations 
xxvi 
 
with HIV treatment response, choice of treatment regimen, and cardiovascular 
risk factors. 
Western Australian STI/BBV Quarterly seminar, December 2014. 
OP Alison Castley. HIV does not require a VISA or does it? Monitoring HIV 
subtype diversity and mobility in the Western Australia HIV cohort. 
 
AIDS 2014: Victoria, Australia, July 20-25th 2014. 
OP+PP Alison Castley, Shailendra Sawleshwarkar, Rick Varma, Belinda Herring, 
Kiran Thapa, Doris Chibo, Nam Nguyen, Karen Hawke, Rodney Ratcliff, 
Dominic E Dwyer, David Nolan. An epidemic in transition: impacts of 
migration and local networks on HIV sequence diversity and infection 
transmission in Australia 2005-2012. 
PP Elizabeth McKinnon, Alison Castley, Leanne Payne, Stephen Pummer, David 
Nolan. Determinants of residual viremia during combination HIV treatment: 
impacts of baseline HIV RNA levels and treatment choice. 
 
Australian Centre for HIV and Hepatitis virology research (ACH2) 2014, Lorne 
Victoria, June 4-6 2014. 
OP Alison Castley. Monitoring HIV-1 drug resistance mutations among newly 
diagnosed Western Australian HIV patients. 
 
Australasian Society for HIV Medicine (ASHM) dinner presentation, Perth WA; 
February 5th 2014. 
OP Alison Castley. The changing face of HIV-1 in Western Australia. Monitoring 
HIV-1 subtype diversity and mobility in the Western Australia HIV cohort. 
 
Department of Clinical Immunology (DCI),  Royal Perth Hospital, Western Australia, 
December 9th 2013. 
OP Alison Castley. The changing face of HIV in WA! Monitoring HIV-1 subtype 
diversity and mobility in the Western Australia HIV cohort. 
 
School of Veterinary and Life Sciences Poster Day. Murdoch University, Perth, Western 
Australia, November 29th 2013. 
xxvii 
 
PP Alison Castley. An optimised eight colour flow cytometry protocol for the 
analysis of monocyte heterogeneity and monocyte activation markers during 
HIV infection. 
 
Australasian Society for HIV Medicine (ASHM), Darwin Northern Territory, October 
20-24th 2013. 
OP Alison Castley. An optimised eight colour flow cytometry protocol for the 
analysis of monocyte heterogeneity and monocyte activation markers during 
HIV infection. 
PP Alison Castley. An optimised eight colour flow cytometry protocol for the 
analysis of monocyte heterogeneity and monocyte activation markers during 
HIV infection. 
PP Alison Castley. The changing face of HIV-1 in Western Australia 
 
Department of Clinical Immunology Royal Perth Hospital: October 14th 2013. 
OP Alison Castley. Is MonitOring innate immuNe cell activatiOn diagnostiCallY 
imporTant in HIV disEase progreSsion? 
 
Murdoch University Postgraduate Student Association (MUPSA) multidisciplinary 
conference 2013: Murdoch campus, Western Australia, September 23rd 2013. 
OP Alison Castley. An optimised eight colour flow cytometry protocol for the 
analysis of monocyte heterogeneity and monocyte activation markers during 
HIV infection. 
 
Murdoch University Postgraduate Student Association (MUPSA) multidisciplinary 
conference 2013: Peel campus, Western Australia, September 11th 2013.  
OP Alison Castley. An optimised eight colour flow cytometry protocol for the 
analysis of monocyte heterogeneity and monocyte activation markers during 
HIV infection. 
 
Combined Biological Science Meeting (CBSM), University of Western Australia, Perth 
Western Australia, August 30th 2013. 




Institute for Immunology and Infectious Diseases (IIID), Murdoch, Western Australia, 
August 27th 2013. 
OP Alison Castley. The changing face of HIV in WA! Monitoring HIV-1 subtype 
diversity and mobility in the Western Australia HIV cohort. 
 
School of Veterinary and Life Science presentation, Murdoch University, Perth, 
Western Australia, July 5th 2013.  
OP Alison Castley. Filling the gaps: working towards improved monitoring of 
immunological status relevant to long-term co-morbidities in HIV-1 infection. 
 
Australian Centre for HIV and Hepatitis virology research (ACH2) 2013: The 
Carrington Hotel Katoomba New South Wales; June 5-7th 2013. 
OP Alison Castley, Cassandra Berry and David Nolan. The expression of cell 
surface monocyte activation markers on CD14pos/CD16pos monocytes show 
increased activation in HIV patients. 
OP Alison Castley, Silvana Gaudieri, Laila Gizzarelli , George Guelfi, Mina John 
and David Nolan. Monitoring HIV-1 subtype diversity and mobility in the 
Western Australia HIV cohort-Where are HIV infections coming from and are 












List of publications during candidature 
McKinnon E & Castley A, Payne L, Pummer S, Nolan D (2016). Determinants of residual 
viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and 
treatment choice. HIV Medicine 17(7), 495-504. 
 
Castley A, Berry C, French M, Fernandez S, Krueger R, Nolan D (2014) Elevated plasma 
soluble CD14 and skewed CD16+ monocyte distribution persist despite normalisation of 
soluble CD163 and CXCL10 by effective HIV therapy: a changing paradigm for routine HIV 
laboratory monitoring? PLoS One 9(12), e115226. 
 
Castley A, Williams L, James I, Guelfi G, Berry C, Nolan D (2106). Plasma CXCL10, 
sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and 
Cardiovascular Disease Risk Factors. PLoS One 29;11(6), e0158169. 
 
Castley AS, Gaudieri S, James I, Gizzarelli LS, Guelfi G, John M, Nolan D (2016). 
Longitudinal Trends in Western Australian HIV-1 Sequence Diversity and Viral 
Transmission Networks and Their Influence on Clinical Parameters: 2000-2014. AIDS 
Research and Human Retroviruses 32(3), 211-9. 
 
Cha L, Berry CM, Nolan D, Castley A, Fernandez S, French MA (2014). Interferon-alpha, 
immune activation and immune dysfunction in treated HIV infection. Clinical and 









Ethical considerations throughout candidature 
To ensure integrity was attained throughout this thesis, informed written consent was 
obtained from the patients participating in all investigations. Consent forms were reviewed 
and accepted by the appropriate ethics committees while written ethics committee approvals 
were granted and received from Royal Perth Hospital (EC2012/170), Murdoch University 
(2012/216), the Australian Red Cross Blood Service (11-08WA-15) and for Chapter 6, ethics 
was granted through each participating state including Royal Perth Hospital (REG-14/112) 
and Murdoch University (updated; 2012/216). 
Patients attending the Royal Perth Hospital (RPH) Immunology clinic and healthy control 
blood donors attending the Australian Red Cross Blood Service (ARCBS) were recruited for 
the studies presented in Chapter 2-4.  
Confidentiality and anonymity was paramount throughout the studies, therefore all patient 
information was subsequently de-identified by assigning a unique anonymised assessment 
number. This system was utilised throughout the study.  
For Chapter 5, all viral HIV-1 sequences and clinical parameters were collated and linked 
through the Royal Perth Hospital routine HIV laboratory service and safely stored at Royal 
Perth Hospital.  
For Chapter 6, all viral HIV-1 sequences were supplied by each state as de-identified samples 
(including Royal Perth Hospital) and the data was collated and linked through Royal Perth 
Hospital. The sequences were identified by the “State, identification number, year of 





Chapter 1:  
A general introduction to the history of the Human 
Immunodeficiency Virus (HIV) in Western Australia and 









1.1 The worldwide HIV/AIDS epidemic 
We are now in the fourth decade since the start of the human immunodeficiency virus 
1 (HIV, HIV-1) epidemic, the virus causative of acquired immunodeficiency 
syndrome (AIDS). To date around 78 million people worldwide have been infected 
with HIV while 39 million people have reportedly died of AIDS related illnesses, 
including 1.5 million in 2013. In 2013/2014 there were approximately 35 million 
people living with HIV worldwide (Figure 1) whilst only 13.6 million HIV positive 
persons were receiving antiretroviral treatment for their infection [1]. This indicates 
that over 20 million people were without adequate treatment for their illness and at 
risk of developing AIDS. Of the 35 million people identified with HIV infection in 
2013, 2.1 million were newly identified infections. Together, these numbers put 
incredible strain on resources especially in resource limited regions where the 
epidemic is at its highest.   
 
Figure 1: Global map of HIV infections in 2013. Worldwide map showing the number 
of people living with HIV (blue), the number of new infections (orange) and the 
number of deaths from AIDS related illnesses (green) per region. Data was adapted 
from the World Health Organisation (WHO) 2014 [1] and UNAIDS update 2014 [2]. 
 
Interestingly, 10 countries account for 61% of the current worldwide HIV infections 
(Figure 2). The country contributing to most worldwide infections in 2013 was South 
Africa (18%), however, other African countries also represented in Figure 2 include 
Zimbabwe (4%), Zambia (3%), eastern African countries; Kenya (5%), Uganda (4%), 
the United Republic of Tanzania (TUR-4%), Mozambique (4%) and the west African 
country Nigeria (9%), totalling 51% of worldwide infections in Africa alone. India 
(6%) and the United States of America (4%) round out the top 10 countries with the 
“rest of the world” accounting for 39% of worldwide infections. 
  
 
Figure 2: Country distribution of HIV infections in 2013. In 2013 there were an 
estimated 35 million people living with HIV worldwide. Ten countries account for 
61% of the people living with HIV infections. Adapted from UNAIDS update 2014 
[2]. 
 
Furthermore, 10 countries account for 63% of the new HIV infections identified in 
2013 (Figure 3). Although new infections were highest in South Africa (16%), five 
other African countries (30%), India (6%), China (3%), Indonesia (4%) and the 
Russian Federation (4%) contributed to the high rates of new notifications in 2013. 
The number of HIV infections identified in eastern Europe and central Asia were on 
the rise, and rising trends in the Middle East and north Africa (31% increase) have 
also been recognised. There were also small increases in Europe and North America 
(6%) as well as Indonesia [2]. 
 
Figure 3: Country distribution of new HIV infections in 2013. In 2013 there were an 
estimated 2.1 million people with new HIV infections worldwide. Ten countries 
account for 63% of the new infections. Adapted from UNAIDS update 2014 [2]. 
 
In Australia there have been 35287 cases of HIV diagnosed since 1982, of which 
around 10000 people have died from AIDS related illnesses. At the end of 2013, there 
were an estimated 27000 people living with HIV infection (Figure 1) with the 
prediction of approximately 14% of all HIV cases being undiagnosed [3]. This 
increase is set against an overall downward global trend in new HIV diagnoses, most 
notably in sub-Saharan Africa and also evident in the overall Asia Pacific region [2]. 
Recent data from the Asia/Pacific region for 2013 is remarkable. According to the 
current UNAIDS report (represented in Figure 1), people living with HIV in the 
Asia/Pacific region accounted for 4.8 million infections in 2013 which is the second 
largest region worldwide with HIV infections [2]. Four countries within this region 
account for 83% of the infections (India- 44%, China-17%, Indonesia-13% and 
Thailand- 9%), while a total of 11 countries account for 97% of infections (Figure 4). 
In India alone the UNAIDS gap report [2] concluded “India has the third largest 
number of people living with HIV in the world — 2.1 million at the end of 2013 — 
and accounts for about 4 out of 10 people living with HIV in the region”. In 2013 the 
number of new HIV notifications in the Asia/Pacific region was 350,000 (Figure 1).  
India (38%), Indonesia (23%) and China (20%) account for 81% of new notifications 
within this region (Figure 5). Although reports suggest a decline in new HIV 
notifications in India, this country still accounts for 38% of new infections in 2013. It 
has been recognized that new HIV infections in Thailand, Vietnam and Papua New 
Guinea have also reportedly declined while the number of new HIV infections has 
increased in Indonesia, Pakistan and Australia. Indonesia has been identified as the 
country in this region with the second highest number of new infections. Also of 
relevance is that sex workers in Indonesia and Pakistan have the lowest rate of using 
preventative coverage [2]. 
The prevalence of HIV among men who have sex with men (MSM) in 2013 was high 
in Malaysia (12%), Myanmar, Mongolia and Australia (10% each), Indonesia (8%), 
Thailand (6.5%) and China (6%).  
                       
 
Figure 4: HIV infections in Asia/Pacific region in 2013. In 2013 there were 4,800,000 
people living with HIV in the Asian/Pacific region many of whom live in India, China 





Figure 5: New HIV notification in the Asian/Pacific region reached 350,000 in 2013. 
Three countries in this region (India, Indonesia and China) accounted for 283,500 of 
the new notifications. Adapted from UNAIDS [2] 
1.2 Epidemiology and phylogenetic analysis of HIV 
To understand the impact of changes to HIV notifications worldwide it is important to 
comprehend the diversity of HIV subtypes present around the world.  
There are known characteristics of HIV-1 genetic diversity including historical 
associations between geographical location and distinct HIV-1 subtype groups M, N 
and O (and a more recently identified fourth group, the P group) [4]. Within this 
phylogenetic structure, the M group is responsible for the majority (90%) of 
worldwide infections. The M group comprises nine defined subtypes (A, B, C, D, F, 
G, H, J, and K) of which the C subtype accounts for the majority (50%) of HIV 
infections worldwide and is prevalent in sub-Saharan and eastern Africa as well as 
India, while the B subtype accounts for infections within Caucasian populations 
(mainly in Europe, United States of America and Australia). Together the B and C 
subtypes account for approximately 60% of HIV-1 infections worldwide [5]. The B 
subtype is typically characterized by transmission via male-to-male sexual contact, as 
previously documented in 2002 for the Western Australian HIV population [6]. 
Genetic diversification of HIV-1 is also promoted by high rates of recombination 
events [7] that generate stable circulating recombinant forms (CRFs) as well as unique 
recombinant forms (URFs) of HIV, which together account for 20% of global HIV-1 
infections [5]. A recombinant form of the HIV virus results from recombination 
events between two or more HIV strains within a host, however, to be classified as a 
new CRF three unlinked viruses of the same genetic makeup must be identified. Until 
this occurs the term URF is used to address the recombination forms of HIV.  
While CRFs are increasing in number within the Los Alamos National Laboratory 
repository (as at 1 October 2015, 72 CRFs were identified compared with 10 in 2003), 
it is also relevant to identify the more common form of recombinant virus such as the 
CRF01_AE subtype. This is thought to have originated in Africa (as the HIV-1 E 
subtype) then progressed to south-east Asia where it established itself as a major 
circulating form by recombining with the HIV-1 A subtype. The CRF01_AE 
epidemic exploded and more recently dispersed to other areas worldwide [8], while 
the HIV CRF02_AG virus originated in west and central-west Africa [7,9]. World 
maps showing the HIV epidemic and epidemiological studies before 2010 indicate 
HIV-1 diversity was widespread in central regions of Africa [9-11] but little subtype 
diversification existed in other regions of the world. Recent studies, however, show 
increasing HIV-1 diversification existing elsewhere in the world [12-14]. These 
results suggest there has been an increase in the pervasiveness of non-B subtypes in 
populations previously defined as predominantly B subtype, potentially introduced 
through migration or travel and it is almost certain new strains of the HIV virus, 
including new CRFs, will be discovered in the future. 
1.3 The early years of HIV-1 in Western Australia and current trends 
The first case of HIV-1 was recognised in Western Australia in 1983 after a male 
presented with an opportunistic infection that was otherwise unexplained. He was 
admitted to Royal Perth Hospital where doctors recognised his acquired immune 
deficiency syndromes but, as this preceded the availability of antiretroviral therapy, 
they were unable to treat him in his dying days. Nurses wore multiple gowns, gloves 
and masks, simply because of the lack of information relating to HIV and AIDS. 
Little was known about its potential impact on society except to acknowledge that it 
was a contractible disease, identified in the early years in homosexual men, which 
attacked the immune system.   
By the mid-1980s there was a dramatic rise in new HIV notifications in Western 
Australia and by 1986 around 200 people were infected with HIV (Figure 6). By this 
time clinicians and researchers worldwide were employing considerable effort to 
search for the causes, to find ways to stop the virus from being transmitted and to 
reduce HIV replication after infection, while providing patients with the best possible 
care in an era where HIV was quickly becoming an epidemic.  
These efforts lead to the introduction of antiretroviral therapy (ART) in Australia. A 
nucleoside reverse transcriptase inhibitor (NRTI) was initially introduced as a clinical 
trial in 1986 and became more widely available in 1988-9. This NTRI interfered with 
the action of HIV reverse transcriptase, which the virus needs to make new copies of 
itself. The first available treatment was called zidovudine (also known as AZT), 
which was initially used as monotherapy and then combined with other NRTI drugs 
such as didanosine, zalcitabine and lamivudine. These treatment regimens were not 
well tolerated by patients and were largely ineffective in producing sustained 
treatment responses due to the emergence of drug resistance. In this context, the 
introduction in 1996 of highly active antiretroviral therapy (HAART) as a treatment 
option offered much hope. As will be discussed further (see section 1.4), this 
approach combined a ‘backbone’ of two NRTI drugs with a third antiretroviral agent 
derived from a different drug class, either non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) or HIV protease inhibitors (PIs). It was clear very soon after the 
initiation of HAART that this combination treatment strategy was successful in 
controlling HIV-1 replication in many patients, and that virological suppression could 
then be maintained for long periods of time. This is in contrast with the previous 
experience of virtually inevitable emergence of drug resistance and treatment failure 
with NRTI monotherapy and dual therapy. Not only did the clinical parameters of 
patients improve (CD4+ T cell counts were rising) but, as shown in Figure 6, there 
was a dramatic decrease in the number of AIDS related cases being notified in 
Western Australia and importantly, the number of AIDS related deaths dropped to 
very low levels. There was also a decline in the number of new HIV notifications to a 
nadir of 34 cases in 1999 indicating that forward transmission of HIV was being 
successfully reduced with HAART treatment and marked changes in risk behaviour in 
the MSM population.  
This was followed by a period of stability from 2000-2004 where HIV notifications 
remained constant (at around 50/year), but this steady state changed after 2004, when 
the number of new HIV notifications in Western Australia began to increase (blue 
line, Figure 6) despite effective HIV therapy being used (as shown by the decline in 
AIDS cases, yellow line, and AIDS related deaths, green line). In 2014 Western 
Australia recorded its highest number of HIV notifications (n=141) since records 
began. This indicates there may have been other reasons why new HIV notifications 
were on the increase. The gap between HIV notifications and AIDS related deaths has 
become dramatically larger over recent times representing a growing population of 
people infected with HIV and suggesting the HIV epidemic in Western Australia is 
not contained or under control.  
 
 
Figure 6: Trends in notification of HIV-1 infection, AIDS and Deaths from AIDS in 
Western Australia from 1983 to 2014. Adapted from; The Government of Western 
Australia, Department of Health 2014 [15]. 
 
The increase in HIV notifications could be explained in part by increases in overseas 
migration from countries where HIV is highly prevalent. Figure 7 shows the close 
proximity of Australia to south and eastern Africa, Thailand, Indonesia, India and 
China. The adult HIV prevalence rate differs among these countries (19.1%, 1.1%, 
0.5%, 0.3%, 0.05% respectively in 2013) although interestingly, all (excluding 
Thailand) are listed in the top 10 countries accounting for new HIV infections 
worldwide (Figure 3).   
 
 
Figure 7: Prevalence of HIV infections worldwide in Adults 18-45. Based on 
UNAIDS data [2].   
 
 
Data collected between 2006 and 2011, on birth countries for settlers in Western 
Australia when compared to national data, shows a number of these countries are 
proportionally larger contributors to the growing number of overseas settlers in 
Western Australia (Figure 8). This is especially so for people settling in Western 




Figure 8: Comparisons of the birth countries of settlers into Australia (orange bars) 
and into Western Australia (black bars) from 2006 to 2011 [16]. 
Furthermore, Figure 9 illustrates the top 10 countries where short term visitor arrivals 
to Australia originate from. Some of these countries have a higher prevalence of 
people living with HIV or are countries where new HIV infections were highest in 
2013 (i.e. China, Malaysia and India), while Figure 10 reflects the top 10 countries 
Australian residents visit on overseas short term stays. This indicates Australians are 
travelling to countries where the number of people living with HIV is high or where 
new HIV infections are high. From 2013 to 2014, 8,940,000 Australians travelled 




Figure 9: HIV infection and short term visitors to Australia. Ten countries accounted 
for 71.5% of short term visitor arrivals into Australia from 2013-2014 including 
arrivals from countries in the Asia/Pacific region where new HIV notifications were 
high (China, Malaysia and India). Compiled from the Australian Bureau of Statistics 
[17]. 
 
It is therefore relevant to assess the impact short term overseas travellers, short term 
arrivals and long term settlers have on the increase in HIV notifications seen in 
Western Australia and Australia. Since the subtypes of HIV have been shown to be 
associated with distinct geographical locations, HIV genotyping and subtype 
assignment can aid in determining if HIV subtype diversity has changed in Western 
Australia and Australia more generally; and if there is a change, what impact it may 
have on transmission patterns, laboratory monitoring and on public health 
surveillance especially if eradicating HIV infections in Australia is going to be an 
achievable goal.   
 
 
Figure 10: HIV infection and short term resident departures from Australia. Ten 
countries accounted for 66.8% of short term resident departures from Australia during 
2013-2014 including departures to countries in the Asia/Pacific region where new 
HIV notifications were high (Indonesia, China, India and Malaysia). Compiled from 
the Australian Bureau of Statistics [17]. 
 
1.4  HIV clinical progression and the current treatment era  
The clinical progression of untreated HIV infection has been well documented, 
particularly with respect to CD4+ T cell counts and HIV-1 RNA levels, from primary 
HIV infection to the acute infection stage, progressing to the clinical latency stage and 
to the impact of opportunistic diseases that define AIDS and death (Figure 11A). 
Those infected with HIV progress through the infection at different rates depending 
on a variety of factors including how early the infection is diagnosed and treated, 
HIV-1 subtype, co-morbidities (e.g. cardiovascular disease (CVD)) and genetic 
influences (chemokine receptor 5 (CCR5) and human leukocyte antigens (HLA)). The 
implementation of antiretroviral therapy in Australia in the late 1980s and early 1990s 
was the beginning of successful HIV treatment but not eradication. These regimens 
disrupt various points of the HIV replication cycle to halt replication and to reduce the 
virus to undetectable levels while establishing and maintaining near to normal healthy 
levels of CD4+ T cell counts in the majority of patients (Figure 11B). Interestingly, 
there are a small percentage of virally supressed patients and immune non responders, 
where CD4+ T cell counts do not adequately recover, that are at a higher risker of 
CVD. 
 
Figure 11: The natural progression of HIV infection. Generalised timeline showing 
the impact on CD4+ T cell counts, HIV RNA viral load levels and immune activation 
during the natural progression of HIV from initial exposure in an untreated setting (A) 
and in a treated setting (B). Modified from Pantaleo G [18]. 
 
Zidovudine (also known as AZT), a nucleoside reverse transcriptase inhibitor (NRTI) 
that targeted viral replication, was used in clinical trials in 1986 however it became 
widely available in Australia in 1991 (Figure 12). Other NRTIs were introduced a 
short time later, followed by the first generation of protease inhibitors (PIs) in 1996 
(not shown in Figure 12 but included indinavir, nelfinavir, saquinavir and high-dose 
ritonavir), first non-nucleoside reverse transcriptase inhibitors (NNRTIs) in 1997, 2nd 
generation PIs (ritonavir boosted regimens) in 2004, and finally integrase inhibitors 
(INIs) and fusion inhibitors (FIs) in 2008. The NNRTIs also block HIV replication 
within a cell by inhibition of the reverse transcriptase protein, while PIs inhibit the 
HIV protease involved in the later stages of the viral replication cycle including virion 
assembly. Integrase inhibitors interfere with the integrase enzyme, minimising viral 
integration into the deoxyribonucleic acid (DNA) of the host cell, while fusion 
inhibitors prevent HIV binding to T cells and therefore limit HIV entry into the cell.   
The choice of ART for HIV treatment is somewhat dependent on individual case 
factors. Some ARTs are preferentially used during pregnancy (Combivir: combination 
of zidovudine and lamivudine) while others such as abacavir and nevirapine have 
been associated with hypersensitivity reactions in some persons [19]. Recent years has 
seen a swing from prescribing patients with multiple antiretroviral tablets, to the use 
of single multi-class tablets. Atripla, combining tenofovir and emtricitibine (NRTIs) 
with efavirenz (NNRTI), was the first multi-class tablet available and used in 
Australia in 2009. This has been followed by Eviplera (tenofovir, emtricitabine and 
rilpivirine (NNRTI), Stribild (tenofovir, emtricitabine and elvitegravir (INI) with 
cobicistat added as a cytochrome P450 3A4 (CYP3A4) enzyme inhibitor, and most 
recently Triumeq tablet which combines dolutegravir (INI) with abacavir and 
lamivudine (NRTIs). 
In the current treatment era it is now clear that HIV infection can be durably 
controlled with suppressive antiretroviral medication regimens that are both effective 
and mostly well tolerated, to delay the onset of AIDS and to extend the life 
expectancy of those infected [20-22].  
There are limitations when using antiretroviral therapies as their clinical utility can be 
limited due to drug resistance, toxicity and adherence. Antiretroviral regimens cannot 
prevent HIV from infecting some cells leading to persistent chronic HIV infection. 
This is due to immune evasion that exists during early HIV infection via the 
integration of proviral DNA into the host genome. This allows for the production of 
the provirus that can lead to the expression of antigens and the activation of the cell, 
however, the infected cell evades immune surveillance if the expression levels are low 
thus allowing HIV to persist regardless of successful ART. There are a number of 
cellular reservoirs that exist within a host that can avoid the challenge by the innate 
immune system. Enormous effort has recently concentrated on eradicating latent HIV 
in CD4+ T cells, however, CD16+ monocytes are another source of latent HIV [23-
25], primarily due to the cells being more resistant to apoptosis induced by HIV or 
due to poor drug penetration. Adding to the interest in this area, proviral HIV can be 
isolated from monocytes, despite patients being on successful ART [23-25], 
indicating HIV can maintain viral fitness even in the current era of sophisticated 
antiviral therapy. Furthermore, ART successfully reduces HIV infection to below 
detectable levels however treatment interruptions result in detectable viraemia in HIV 
patients thus indicating resumption of viral replication. 
 
 
Figure 12: Australian antiretroviral regimes for the treatment of HIV. A timeline 
showing when HIV antiretroviral therapies became widely available for use in 
Australia. Treatments groups are represented in colour: NRTIs - represented in black; 
PIs - represented in light blue; NNRTIs - represented in green; INIs and FIs – 
represented in purple; and single tablet regimens represented in grey. 
 
As the life expectancy of HIV patients increase so to do the possibilities of 
experiencing a serious non AIDS event (SNAE) including bone disorders, renal 
disease and cardiovascular events. These SNAEs are the major causes of mortality in 
the current ART era (SMART study).The pathogenesis and development of SNAEs is 
thought to be multifaceted and warrants ongoing research however immune activation 
and inflammation are thought to play a significant role therefore the focus of this 
thesis is largely on immune activation, particularly monocyte activation and CVD risk 
in an HIV cohort and will be introduced further in section 1.7.  
It is now clear that HIV-associated mortality is more commonly associated with 
prevalent diseases of ageing, rather than traditional ‘AIDS-defining’ illnesses and that 
chronic HIV infection may have an association with a greater risk of these co-morbid 
illnesses. Despite their sophistication, current strategies for monitoring HIV infection 
in the clinical setting (focusing on CD4+ T cell counts and HIV-1 RNA levels, as well 
as the T cell immune activation levels being monitored in Western Australia) do not 
appear to predict these outcomes. On the other hand, recent studies have identified 
novel markers of systemic inflammation that appear to be robust and predictive of 
adverse events including serious morbidity and mortality [26-29]. These markers 
appear to reflect activation of monocyte/macrophage cell populations, indicating that 
HIV infection may contribute to a chronic inflammatory state that is only partially 
reversed by HIV treatment. At this stage, however, it is not possible to assess 
relationships between systemic inflammation and HIV management strategies (e.g. 
decisions about when to commence treatment, or which antiretroviral medications to 
use), as potential ‘biomarkers’ have not been fully assessed and validated in a routine 
laboratory setting.  
A proposed cause of immune activation is through circulating microbial products 
derived in the gastrointestinal tract. It is crucial these bacteria avoid contact with the 
immune system hence there are structural barriers (epithelial cells) and 
immunological host factors (monocytes, T cells, dendritic cells) that exist to prevent 
microbial products translocating across the intestine barrier to the systemic 
circulation. During the early phase of HIV exposure and infection however, damage 
to the gastrointestinal tract occurs and microbial products do transverse the epithelial 
barrier. Lipopolysaccharide (LPS) is a component of the cell wall of gram negative 
bacteria. It has previously been shown plasma levels of LPS and to a lesser extent 
bacterial DNA correlate with immune activation [30]. Added to this, the monocytes, T 
cells and dendritic cells express the viral co-receptor CCR5 providing a setting for 
HIV to replicate leading to the depletion of CD4 + T lymphocytes in the 
gastrointestinal tract. Together, there is an increased production of inflammatory 
cytokines including IFN-α, CXCL10 and TNF-α. 
Classical monocytes (CD14+) secrete sCD14 which binds LPS and although sCD14 
can be released from monocytes in response to LPS it can also be released by other 
stimuli that are not solely specific to the gut translocating pathway. A recent study has 
shown inflammatory cytokines can induce the release of sCD14, and TLR ligands 
(flagellin and CpG oligodeoxynucleotides) can decrease the cell surface expression of 
CD14 therefore showing sCD14 as a marker of monocyte activation  that is not 
restricted to activation by LPS [31]. 
1.5 Innate immunity and the role monocytes play to combat disease 
The host immune system comprises innate and adaptive arms of immunity. The innate 
immune response is triggered by the recognition of determinants that may be shared 
by a range of pathogens, distinguishing “self” from “non-self” through pattern 
recognition receptors (PRRs), while the adaptive immune response is antigen-specific 
and generates an immunological memory. Generally, the adaptive response will not 
provide an antigen-specific response until after HIV infection has established itself. 
Toll like receptors (TLRs) are PRRs that recognise unique pathogen associated 
molecular patterns (PAMPs) present on the infecting pathogen [32, 33]. There are 10 
TLRs found in humans, many of which recognise a specific PAMP (e.g. TLR4 
recognises lipopolysaccharide (LPS) [34]; TLR7 recognises single stranded RNA [32] 
while TLR9 recognises CpG DNA [35]). The extracellular TLRs (TLR1, 2, 4-6, 10) 
recognise molecules unique to microbes but not produced by the host, and the 
endosomal TLRs (TLR3, 7-9) specialise in the recognition of nucleic acids.  
The innate immune response to HIV infection is driven primarily through interactions 
with endosomal TLR7, 8 and 9 [36, 37] although some studies show interactions with 
TLR2 and 4 are also relevant [38]. Activation of TLRs by PAMPs results in triggering 
of either an antiviral cascade provoked by interferon response factors (IRFs) or an 
inflammatory cascade mediated by nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB) [36]. It is thought that the magnitude of the inflammatory 
response is dependent on the level of TLR expression, either extracellular or 
intracellular. This diverse array of TLR expression, found on and within monocytes, 
may be critical in mediating a response during HIV infection both in the acute and 
chronic phases of infection and may provide the key in immune activation and co-
infections with HIV.   
Monocytes are derived from the myeloid lineage, originating from precursor stem 
cells in the bone marrow. The monocytes undergo three main cycles of differentiation 
from hematopoietic stem cells to monoblasts then to pro-monocytes and finally to 
monocytes where they are released into circulation into the blood stream accounting 
for 2-10% of circulating leukocytes [39-41]. As a part of normal immune surveillance, 
monocytes leave the bone marrow to circulate in the blood for 3-5 days where they 
express relatively high levels of TLRs, cytokines and chemokines [37, 40-42]. 
Monocytes migrate into the endothelium and body’s tissues where they proceed to 
differentiate further into M1 (acute inflammatory phenotype) and M2 (anti 
inflammatory phenotype) activated macrophages and dendritic cells (Figure 13).  
Macrophages play a key role in the transition from innate immunity to adaptive 
immunity and the activation of macrophages is also pivotal in the pathogenesis of 
HIV infection. When monocytes migrate into the tissue compartments, TLR 
expression becomes refined [40-42]. They are considered to be resistant to the 
cytopathic effects of HIV [43, 44] and therefore the macrophages can survive for long 
periods enabling the establishment of a long-lived reservoir of HIV-infected cells 
capable of releasing HIV particles into the plasma compartment. It is now clear 
monocytes and macrophages are both critical in the pathogenesis of HIV infection by 
providing three key roles including early viral transmission, dissemination within the 
host and as a reservoir for viral persistence. 
Conventionally, monocytes (CD14+) were divided into two subsets based on their 
CD16+ and CD16– expression [39], however, it is now evident that monocytes are a 
heterogeneous population of cells that can be classified into at least three 
phenotypically independent populations, identified by the surface expression of CD14 
and CD16 [45].   
CD14 is the monocyte differentiation marker and a monocyte activation marker that 
mediates the innate immune response to bacterial LPS, with help from TLR4. CD14 is 
a receptor for the complex of LPS and LPS binding protein (LBP), resulting in the 
cleavage of CD14 from the cell, into circulation as soluble CD14 (sCD14).   
CD16, however, is expressed on many cells including neutrophils, natural killer (NK) 
cells, monocytes and macrophages. It is a component of the low affinity Fc receptor, 
FcγRIII, mediating phagocytosis, cytokine production and antibody dependent 
cellular cytotoxicity (ADCC).  
This more recent classification of monocyte sub-populations suggests the 
development of unique specialised functions within the three monocyte subsets, 
which has now been investigated further through genome-wide analyses that helped to 
define these cellular phenotypes further [46-48].  
 
 
Figure 13: Development and migration of differentiating monocytes from bone 
marrow into the blood and to tissue compartments. 
 
Under a steady state, classical monocytes account for approximately 85%-90% of all 
monocytes, expressing CD14 but not CD16 (CD14++ CD16-). Classical monocytes 
also express high levels of FcγR1 (CD64), monocyte chemoattractant protein-1 
(MCP-1) receptor also known as C-C chemokine receptor type 2  (CCR2), CD163 and 
release cytokines (IL-10 and IFN-β) while expressing low levels of CX3CR1(receptor 
for fractalkine and a minor co-receptor for HIV) [39, 46, 49]. Upon activation, 
monocytes actively shed CD163 from the cell surface into circulation as soluble 
CD163 (sCD163) [50].  
The percentage of CD16+ expressing monocytes is low under normal conditions 
however they expand in response to inflammatory conditions [41, 51]. Phagocytosis, 
the process used by cells to engulf foreign matter, is a primary role of the CD16+ 
monocytes and therefore important in primary defence to control the entrance of 
microbes and viral particles. The intermediate monocytes are the smallest set of 
monocytes only occurring at around 5% of the total monocyte population. They are 
known as the inflammatory monocytes and express high levels of both CD14 and 
CD16 (CD14++ CD16+), HLA-DR, CCR5 and CD163 and are thought to play a role in 
major histocompatibility complex (MHC) Class II processing and antigen 
presentation. Due to the expression of CCR5 it is thought that the intermediate 
monocytes are more susceptible to viral infection [52].  
The third monocyte subset is known as the non-classical monocytes. They are highly 
mobile, mature monocytes, whose functions include cytoskeletal rearrangement and 
patrolling vessel walls. They account for approximately 5%-10% of the total 
monocyte population. Non classical monocytes co-express CD16 and a low level of 
CD14 (CD14+ CD16+) while strongly expressing CX3CR1, expressing CCR2 and 
CD62L at low levels and producing high levels of pro-inflammatory cytokines (IFNγ, 
IL-6, IL-1β and TNFα) to RNA/DNA stimuli [46, 53]. Non-classical monocytes have 
shown to be more effective against viral infections as they produce higher amounts of 
pro-inflammatory cytokines via the activated TLR7 and TLR8 dependant pathways 
[54]. They have also been linked to the increased expression of a large number of 
genes required for maintaining effective cytoskeletal dynamics and structure integrity 
suggesting they play a more migratory role than the classical monocytes [46, 55] and 
may provide a molecular basis for the patrolling behaviour observed in vivo [54].  
Generally, a balance between the monocyte subsets is required to maintain 
homeostasis by regulating inflammation and tissue repair. Failure of these processes 
may result in aberrant inflammatory responses potentially leading to chronic 
inflammation and ongoing immune activation.   
1.6  The dynamics of ageing, monocytes and HIV infection  
Alterations in the phenotype and functionality of monocytes have been an increasing 
focus of attention in healthy ageing population studies with emphasis on the impact of 
these changes on immune dysfunction and specific inflammatory responses. Recent 
studies have found monocyte frequency and phenotype are altered in the aged and 
frail [56] and that these changes correlated with chronic diseases such as dementia 
[57]. Of interest, CD16+ monocytes have been shown to be increased in an ageing 
population and monocyte impairment has been identified with cytokine production 
and expression of TLR [56]. Added to this, a lower frequency of monocytes 
expressing CX3CR1 in the elderly was identified when compared to young adults, 
however, CD16+ monocytes expressed more CX3CR1 in patients with dementia than 
in controls [57]. In addition, CD16+ intermediate monocytes showed increased HLA-
DR and CX3CR1 expression than CD16- monocytes, although the expression on 
CD16+ monocytes declined in the elderly [58]. These findings could be functionally 
important given CX3CR1 has been linked to monocyte survival in atherosclerotic 
conditions [59]. Finally although these results appear to indicate that the ageing 
populations have immune dysfunction, the mechanisms associated with this 
dysfunction remain largely unclear. This warrants further investigation, particularly in 
relation to the role of monocyte subpopulations in promoting (and/or protecting 
against) chronic age-related diseases. 
This interest in altered monocyte phenotypes in healthy populations also extends to 
changes occurring during HIV infection. In 2013-2014, an estimated 36.3 million 
people were living with HIV and an estimated 3.6 million were older than fifty. 
Furthermore, in high income countries alone, around one third of adults living with 
HIV were over fifty [2] and as previously suggested, it will soon be the case that the 
majority of HIV infected individuals in the developed setting will be older than 50 
years of age [60]. In the context of HIV infection, the increased uptake of 
antiretroviral therapy throughout the world enables those living with HIV to have 
increased life expectancy [20-22]. For this reason, ageing with HIV infection presents 
a number of challenges as HIV not only reduces CD4+ T cell numbers but also causes 
immune dysfunction of cells responsible for combating infection that persists even in 
individuals on successful HIV suppressing therapy. HIV infection is associated with 
increased age-related changes to the immune system causing it to be less likely to 
adequately respond to foreign pathogens and therefore increases the level of 
damaging inflammation. There is now strong evidence of premature physiological 
ageing with HIV infection, with markers of physical frailty [60, 61], cerebral function 
[62] and atherosclerotic burden [63] noted to be 10-15 years more advanced than 
normally expected. 
It is not known whether accelerated ageing continues throughout the course of HIV 
infection and treatment, however, proposed associations with persistent immune 
activation [64] along with evidence from the SMART study [65] and numerous sub-
studies that have arisen from it [26, 27] have demonstrated increased rates of adverse 
events, including all-cause mortality, among patients with untreated HIV infection. 
Importantly, these studies have shown that markers of innate immune activation and 
coagulation such as C-reactive protein (CRP), sCD14, IL-6, CXCL10 and D-dimer 
levels, were strongly associated with both infectious and non-infectious complications 
including mortality [28, 29, 66]. Interestingly a recent study confirmed higher rates of 
multiple morbidities in patients with long term-ART treated HIV when compared to 
patients with shorter term-ART treated HIV but acquiring HIV at an older age 
(>45yo) [67], indicating that HIV itself may contribute to increased risk of serious 
non AIDS illnesses even in the setting of HIV treatment. 
The link between HIV infection and monocyte activation is gaining growing attention. 
During HIV infection, monocyte responses occur early through the production of 
interferon (IFN) along with other cytokines. Type 1 IFNs however are produced 
primarily by plasmacytoid dendritic cells (pDC), monocytes and T cells playing a 
central role in mediating persistent inflammation during HIV infection and many 
studies focus on the role of pDC and T cells in these settings. Monocytes have been 
gaining increased attention in HIV studies as they have many functions particularly in 
immune defence by driving innate immunity as described in section 1.5. Briefly 
recapping, monocytes limit the access of a pathogen into cellular components by 
raising innate immune responses, aiding in tissue repair and responding to foreign 
invasions by promoting phagocytosis. Damage to monocytes, however, leads to a loss 
of the innate barrier thus allowing HIV to establish systemic infection [32, 33, 36]. 
One study, in an HIV cohort, suggests that low CD4+ T cell counts correlate with 
higher levels of intermediate monocytes (CD14++/CD16+) in particular those 
expressing CD163 [68]. This fits with the concept that higher sCD14 levels, resulting 
from being cleaved off monocytes, was deemed to be detrimental in the SMART 
study [28]. Several studies suggest that ageing and HIV infection have interrelated 
effects on monocyte function, including observations that CD16+ monocytes in young 
males with untreated or virologically suppressed HIV infection are similar in 
frequency to older HIV negative males [69], while two studies focusing on HIV in 
women have shown plasma levels of monocyte activation markers in HIV infected 
women were equivalent to HIV negative women 14 years older. Additionally, 
biomarkers of CVD and impaired cognitive function were elevated in HIV infected 
women and correlated with immune activation [70, 71]. 
Overall the monocyte phenotype during HIV infection shares the characteristics of 
those found in the elderly population, suggesting a prominent contribution of 
monocyte activation (and of interferon signalling pathways) towards adverse events 
during long-term HIV outcomes. Despite their predictive value and emerging 
biological importance in HIV infection, in other infections (e.g. tuberculosis (TB), 
hepatitis C virus (HCV) infection) and in other diseases (e.g. CVD, diabetes, renal 
failure), these biomarkers are not monitored in routine HIV clinical practice. For this 
reason, the diagnostic value of measuring monocyte expression and soluble levels of 
monocyte activation in HIV infection will be investigated in Chapter 3 and Chapter 4. 
1.7  Co-morbidity: HIV-1/cardiovascular disease in an ageing HIV population 
The challenge of HIV care in an era where plasma HIV-1 RNA levels are well 
controlled by HAART has increasingly focused on clinical problems associated with 
both infectious and non-infectious co-morbidities in an ageing HIV population. 
Among the most important clinical challenges facing HIV carers is the rising rate of 
CVD which has been found to occur earlier and at a higher rate in HIV patients than 
in the HIV negative population [63, 72]. Considering that the World Health 
Organisation (WHO) forecast shows ischaemic heart disease being one of the leading 
causes of death in the general population globally by 2030 [73], including in regions 
where HIV-1 prevalence rates are high, this signals an increasing need to better 
understand the mechanisms involved in co-morbidities during HIV infection, and to 
develop effective monitoring and treatment strategies based on this improved 
understanding of disease pathogenesis.   
In the early years of ART the interaction between antiretroviral exposure and 
increased risk of myocardial infarction was shown in large study cohorts [74-76]. 
Along with these results, other studies relate chronic inflammation to atherosclerosis 
and mortality in HIV patients [77-79] and T cell activation in HIV patients to early 
vascular damage even when on successful therapy [80, 81]. There has also been a 
great deal of interest in the potential role of monocytes in HIV infection, particularly 
CD14++/CD16+ intermediate monocytes, in disease pathogenesis given that these 
populations (which co-express CCR5) [82] are permissive to HIV infection [23] and 
are capable of transferring HIV infection across the genital mucosal barrier [83] as 
well as into the central nervous system [84]. Expansion of this intermediate monocyte 
population also appears to be associated with cardiovascular events in subjects 
referred for elective coronary angiography [85] and has been noted in acute coronary 
syndromes in the general population as well as in chronic HIV infection [86]. 
In addition cell surface markers may further characterise CD16+ monocyte function, 
particularly in the context of HIV infection and/or inflammation. These include the 
angiotensin converting enzyme (CD143), expressed predominantly on CD14++/CD16+ 
intermediate monocytes, which has been linked to mortality and cardiovascular 
disease in haemodialysis patients [87]; as well as the scavenger receptor CD163 
which has been shown to be significantly elevated in the context of HIV infection [88, 
89]. In contrast, the high affinity FcγR1 (CD64) is principally expressed on 
CD14++/CD16- classical monocytes, where it may serve as a biomarker of type I 
interferon activation in autoimmune diseases [49]. Monocyte CD64 expression may 
restrict productive HIV-1 infection by facilitating viral phagocytosis and degradation 
[90].   
Besides cell surface markers, several plasma biomarkers of monocyte activation have 
also been linked to associations between HIV and CVD, including sCD14 which has 
been shown to be associated with artery calcification [91], atherosclerosis [92] and 
all-cause mortality in HIV patients [28], even in the setting of undetectable plasma 
HIV-1 RNA levels that would generally define effective HIV therapy [93]. Elevated 
levels of sCD163 have also been shown to be associated with arterial inflammation 
and cardiovascular disease in HIV-infected patients [94] although sCD163 levels 
appear to be responsive to HIV therapy [68]. Similarly, plasma levels of CXCL10 
(also known as interferon gamma-induced protein 10 [IP-10]) are induced by HIV 
infection [95] but are also readily reduced by effective therapy [96]. The role of 
CXCL10 in predicting CVD in an HIV setting is largely unknown however CXCL10 
is likely to play a role in coronary heart disease (CHD) [97, 98]. 
It is therefore clear that identifying HIV patients at risk of CVD has become a focus in 
many clinics over recent years, being partially achieved by monitoring traditional risk 
factors. In recent studies, markers of immune activation promoting the increased risk 
of CVD in HIV have been identified however the mechanisms driving the immune 
activation (particularly monocyte activation) and causing serious non AIDS related 
conditions are likely to be multifactorial. In this thesis I will investigate the 
determinants of monocyte phenotypes and plasma biomarkers of monocyte activation 
in a large and well-characterised HIV cohort, considering a range of variables 
including plasma HIV-1 RNA levels, CD4+ T cell immune deficiency, HIV treatment 
choice, as well as traditional cardiovascular risk factors and other demographic 
variables. These studies will seek to address the clinical utility of measuring 
monocytes – both quantitatively and functionally – in the HIV laboratory setting, and 
to explore the relationships between different ‘biomarkers’ of monocyte function in 
this setting.  
1.8 In with the new and out with the old: A shift in the HIV monitoring 
paradigm 
After HIV infection has been diagnosed, monitoring systems, both laboratory and 
clinical, are required to provide information regarding the stage of HIV infection, 
likelihood of co-infections and to determine when ART should start. We have now 
entered a period where the long-term success of ART has created new challenges 
relating to the potential effects of HIV infection and its treatment on the onset and 
severity of prevalent age-associated diseases. This is becoming increasingly relevant 
now that the average age of male patients in the Royal Perth Hospital HIV cohort is 
50 years and preliminary data from 530 patients surveyed over 2 years found 25% 
with high CVD risk (>10%; 5-year risk), with 45% of the cohort currently smoking, 
suggesting that there is a significant risk of long-term illness in this population, as has 
been found in other HIV cohorts internationally [64, 94, 99, 100]. As previously 
mentioned sCD14, IL-6, CXCL10 and D-dimer levels have been shown to be strongly 
associated with both infectious and non-infectious complications including mortality. 
These biomarkers appear to indicate a prominent contribution of monocyte activation 
towards adverse events during long-term HIV outcomes however they are not 
monitored in routine clinical practice. A recent study supported the idea of testing 
CD4+ T cell counts less frequently in clinically stable settings as HIV patients who 
maintained HIV viral suppression below <200cpm and had CD4 counts >300cells/μl 
were highly unlikely to experience a CD4 count <200cells/μl [101, 102]. 
It would therefore be valuable to gain a better understanding of factors that contribute 
to immunological activation during routine management of HIV infection, particularly 
in long-term care when ‘traditional’ monitoring tests for virological and 
immunological response to treatment (i.e. HIV-1 RNA and CD4+ T cell count) 
indicate that treatment cannot be further optimised.  
1.9  Structure and goals of this thesis 
The hypothesis of this study is that chronic immune activation may be a feature of 
long-term HIV infection, even in the context of effective antiretroviral treatment with 
ongoing undetectable plasma HIV-1 RNA levels and normal-range CD4+ T cell 
counts. This immunological phenotype is likely to involve monocyte/macrophage 
activation and cytokine and chemokine production that are not currently assessed in 
routine HIV management, and are therefore ‘invisible’ from a clinical management 
(or therapeutic) perspective. An improved understanding of this immunological 
phenotype, and an ability to monitor it in a clinical setting, should allow for a better 
understanding of many non-infectious co-morbidities of ageing (e.g. cardiovascular 
disease, cognitive decline) that are clearly more common among HIV-infected 
individuals who are otherwise clinically stable. 
This thesis seeks to address four key aspects in HIV monitoring and care in Western 
Australia (Figure 14). Chapter 2 describes the investigation of determinants of HIV-1 
RNA suppression below the threshold of the routinely used method. Chapter 3 
explains the concept of monocyte activation during HIV infection while Chapter 4 
explores co-morbidities with HIV (specifically HIV and CVD) in relation to 
circulating monocyte activation markers and the level of effects from three activation 
markers. Improving diagnostic approaches is likely to have significant implications 
for developing more effective management strategies during chronic HIV infection 
and may also contribute to an improved understanding of other prevalent illnesses.  
The next phase of the study presented in Chapter 5 will focus on monitoring HIV in 
WA by employing a phylogenetic approach to map HIV subtypes and assess networks 
by including clinical parameters into the analysis (CD4+ T cell counts and HIV-1 
RNA levels). This will lead into the reasoning behind the formation and collaboration 
of the Australian Molecular Epidemiology Network (AMEN). This network involves 
experts in the field of HIV and epidemiology and was formed to establish an ongoing 
connection throughout Australia with the aim of assessing HIV phylogenetic 
characteristics within Australia as detailed in Chapter 6. 
The final discussion (Chapter 7) highlights the importance of developing, validating 
and implementing cost-effective assays pertaining to immune activation and HIV 
phylogeny as a way forward for routine HIV care thus allowing for improved clinical 
assessment and targeted therapeutic strategies.   
 
Figure 14: Improving HIV surveillance and monitoring in Western Australia by 
focusing on four key points throughout this citation including an analysis of HIV-1 
epidemiology and HIV-1 diversity throughout Australia. 
 
Throughout the following chapters I aim to bridge this gap through: 
1) The development of monitoring approaches and routine diagnostic assays that may 
‘reveal’ underlying systemic immune activation when current analytes like CD4+ T 
cell counts are within normal health range and HIV-1 RNA is successfully supressed, 
while immune activation persists.  
2) Surveying the HIV epidemic at an epidemiological level by investigating HIV 
subtypes, HIV transmission and network characteristics in the current era in Western 
Australia and Australia. 
This project is translational in nature, seeking to establish improved clinical 
laboratory methods for the routine assessment of immune function in ageing patients 
with HIV infection. This approach fits well with several established frameworks and 
declarations including; 1) the Western Australian HIV strategy 2015-2018; 2) the 7th 
National HIV Strategy for 2014-2017; and 3) the United Nations declaration on HIV 
and AIDS 2011, and directly addresses several priority actions identified in these 
























Box 1  WA HIV Strategy 2015–2018 
 
“Goals 
• to work towards achieving the virtual elimination of HIV transmission in 
Western Australia by 2020 
• to work towards achieving the virtual elimination of HIV transmission in 
Western Australia by 2020  
• to reduce the morbidity and mortality caused by HIV”  
 
“Prevention, training and addressing gaps 
• increase knowledge of HIV and transmission risks among priority 
populations 
• developing and implementing approaches that prepare for an ageing 
cohort of people living with HIV 
• identifying areas and regions, based on epidemiological data, where 
primary healthcare professionals may require enhanced support 
• use epidemiological data in service planning and implementation  
• work with local and national research centres on epidemiological 




Box 3  United Nations declaration on HIV and AIDS 2011  
 
“Treatment, care and support: eliminating AIDS-related illness and death 
Pledge to intensify efforts that will help to increase the life expectancy and 
quality of life of all people living with HIV. 
Commit to investing in accelerated basic research on the development of 
sustainable and affordable HIV and tuberculosis diagnostics and treatments for 
HIV and its associated co-infections and ensuring that it is based on the highest 
ethical and scientific standards.” 
 
Box 2  The7th National HIV Strategy for 2014-2017 
 
“Goals 
• work towards achieving the virtual elimination of HIV transmission in 
Australia by 2020 
• reduce the morbidity and mortality caused by HIV” 
 
“Management, care and support 
The ageing of the population of people living with HIV is an important feature 
of the changing epidemiology of HIV. Advances in HIV antiretroviral therapy 
has decreased HIV and AIDS-associated mortality and morbidity. The 
increasing numbers of people living with HIV and the ageing nature of this 
population have important implications for the healthcare system 
The effectiveness of antiretroviral therapy means there are more people with 
HIV living longer and surviving into old age. There is a growing body of 
evidence that HIV can substantially impact on people as they age; for example, 
diseases normally associated with ageing can occur at younger ages. HIV 
models of care need to facilitate the monitoring, care and support of people 
living with HIV to manage the comorbidities associated with living with HIV 
infection long-term and the natural ageing process [103].” 
 
Chapter 2: 
Determinants of residual viraemia during combination HIV 
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Determinants of residual viraemia during combination HIV
treatment: Impacts of baseline HIV RNA levels and
treatment choice
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Objectives
Effective HIV therapy reflects suppression of plasma HIV RNA levels below assay detection
thresholds, although lower levels of “residual viraemia” have also been demonstrated over
extended periods of effective antiretroviral treatment. Here we examine the determinants of HIV
RNA suppression below the standard assay threshold (40 HIV-1 RNA copies/mL) as well as factors
associated with detectable HIV RNA below this reported detection limit.
Methods
Between 2007 and 2010, 11 575 consecutive viral load (VL) tests were obtained from 1540
patients, including 356 on effective antiretroviral therapy followed since initiation (1996–2001:
n = 165; 2002–2009: n = 191). Analyses modelled the probability of an undetectable VL given
successful suppression to < 200 copies/mL, and the probability of residual viraemia given an
undetectable result.
Results
Detectable HIV RNA amplification was demonstrated in 20% of samples with a VL result < 40 copies/
mL. Longitudinal analyses from 356 patients revealed that the likelihood of achieving results < 40
copies/mL was increased with current nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy
[odds ratio (OR) 2.0; P < 0.05] and reduced with prior virological rebound (OR 0.5; P < 0.05). In
contrast, the presence of detectable HIV RNA < 40 copies/mL was strongly associated with
pretreatment HIV RNA levels among those on current protease inhibitor (PI) treatment (OR 1.5 per
log10 copies/mL increase; P = 0.02) as well as those on NNRTIs (OR 1.7; P = 0.002).
Conclusions
While HIV treatment history was associated with plasma HIV RNA levels below the detection limit,
residual viraemia results were dominantly determined by pretreatment VL. These findings support
the concept of a stable, long-lived reservoir of latently infected cells as a source of residual
viraemia despite effective HIV treatment.
Keywords: determinants of virological control, HIV, residual viraemia
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Introduction
The use of combination antiretroviral therapy (cART) reg-
imens is associated with durable virological response in
the majority of HIV-infected patients, reflected by the
laboratory assessment of an “undetectable viral load” on
monitoring blood tests. While the maintenance of viral
load levels at < 40 HIV-1 RNA copies/mL remains the
standard of care, as measured by current assays [1], there
is now increasing evidence that many patients have
“residual viraemia” with low-level viral replication below
this detection limit [2]. The long-term consequences of
persistent low-level viraemia are not known, although
there is growing interest in the chronic inflammatory
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component of HIV infection, which can be observed
among those who have residual viraemia [3,4]. For these
patients, there is no evidence that treatment intensifica-
tion with additional antiretroviral agents, [5] including
integrase inhibitor treatment [6], leads to better virologi-
cal outcomes. Previous studies have provided evidence
that better viral load outcomes are associated with lower
pre-therapy HIV RNA levels and higher CD4 T-cell count
[2,3], as well as with choice of treatment regimen [7,8],
although these data are difficult to interpret or to incor-
porate into clinical management guidelines [9].
In this study, we have investigated likely determinants
of virological response to treatment within the Western
Australian (WA) HIV Cohort study population, including
disease-specific factors (e.g. pretreatment viral load and
CD4 T-cell count [2,3]) as well as choice of antiretroviral
treatment regimen. In particular, we have assessed the
likelihood of achieving and maintaining a viral load
result where there is no detectable RNA target (“no target
detected”, as defined below) in the context of successful
suppression of HIV RNA levels to below the prescribed
assay detection limit. This cohort-based analysis has the
advantage of large sample size, single-site laboratory
evaluation using a standardized and quality-assured viral
load assay, and availability of comprehensive longitudi-
nal demographic, clinical and laboratory data for partici-
pants in the WA HIV Cohort study. An additional
advantage of this analysis is that management decisions
regarding HIV treatment could not be influenced by
knowledge of target detection in HIV RNA results below
the reported assay limit of 40 copies/mL, as this informa-
tion was not included in laboratory reports to clinicians.
Methods
The study analysed data from consecutive viral load mea-
surements collected between 2007 and 2010 from patients
attending the HIV clinic at Royal Perth Hospital. All viral
load tests were performed at the hospital Department of
Immunology, which provides a state-wide HIV laboratory
service for Western Australia, using the Cobas Ampli-
prep/Cobas TaqMan HIV-1 test (version 1: Roche Diag-
nostics, Mannheim, Germany). All assay runs were
conducted according to National Association of Testing
Authority, Australia (NATA) accreditation standards, sub-
ject to quality control procedures and an ongoing quality
assurance programme. Although plasma HIV RNA mea-
surements were determined during routine laboratory
testing, results below the prescribed assay detection limit
were simply reported to clinicians as “< 40 copies/mL”;
there was no reported differentiation between having
detectable HIV RNA levels in the range 0–40 copies/mL
and a “no target detected” result which required no
detection of target polymerase chain reaction (PCR)
amplification for > 15 cycles beyond the expected cross-
ing threshold of 32 cycles (Fig. S1).
Formal analyses were conducted on viral load measure-
ments of patients who had been followed for at least 1 year
from commencement of cART based on either a protease
inhibitor (PI) or a nonnucleoside reverse transcriptase inhi-
bitor (NNRTI), who had a CD4 count at baseline
< 1000 cells/lL, and who had a viral load measurement at
baseline > 1000 copies/mL.
Binary analyses of the viral load measurements mod-
elled two conditional probabilities: the probability of a
patient having a viral load below the assay lower limit of
40 copies/mL, given that the viral load was successfully
suppressed by treatment to at least < 200 copies/mL; and
the probability of a patient having “detectable target”
results given the achievement of a viral load < 40 copies/
mL. These analyses were undertaken within a random
effects logistic regression framework to take account of
within-subject correlation attributable to the multiple viral
load measurements per patient. The logistic regression
models the probability of an event on the log odds scale,
so in the analyses presented here the relative odds [i.e.
odds ratio (OR)] pertaining to two values of a specific vari-
able is calculated as exp (difference in predicted values).
The 95% confidence intervals (CIs) are then obtained by
the appropriate transformation of the 95% CI on the log
odds scale.
The analyses examined the impact of both treatment-
related factors (class of cART regimen, current regimen,
duration of cART, and prior viral rebound to > 400
copies/mL), clinical factors (CD4 count and viral load at
commencement of cART) and demographic factors (sex,
age and race). The demographic variables and the clinical
measurements obtained at commencement of cART were
considered as baseline variables.
Results
A schematic of the available data is presented in Fig. 1.
In total, 11 575 viral load measurements were collected
from 1540 patients [median (interquartile range (IQR)) 7
(2–12) visits per person]. Of these, 74.1% (n = 8575) were
measured at < 200 copies/mL and 64.4% (n = 7451) were
suppressed to < 40 copies/mL, with 51.4% (n = 5954)
having no target detectable. Hence, the overall proportion
of results < 40 copies/mL in which HIV RNA target
remained persistently detectable (i.e. residual viraemia)
was 20.1% (n = 1497). Of the 636 patients included in
the clinical database with demographic information avail-
able and documented treatment data during this study
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period, 607 (95.4%) received HIV therapy resulting in
viral load suppression to < 200 copies/mL over 5483
measurements in total. From these samples, viral load
results < 40 copies/mL were obtained from 87.4% of
measurements, of which 19.9% had detectable HIV RNA
target. Over half of the 581 patients having results
reported as undetectable had measurements both with
and without detectable target [n = 380 individuals;
median (IQR) 11 (8–13) visits per person]. On average,
residual viraemia was observed in 24.5% of measure-
ments from these patients.
Further longitudinal analyses were undertaken among
356 patients who had been followed since commencement
of combination antiretroviral therapy (cART) for more than
1 year and who had achieved viral suppression to < 200
copies/mL during follow-up. This data set comprised 3117
viral load measurements < 200 copies/mL with an average
of 8.76 measurements per person [standard deviation (SD)
4.4]. Within this data set, 90.4% of viral load results were
measured at < 40 copies/mL, of which 18.7% demonstrated
detectable HIV RNA target. While no HIV RNA target was
detected in any measurements for 116 patients [median
(IQR) 7 (2–11) visits per person], residual viraemia was
observed in approximately 23% of measurements [median
(IQR) 11 (8–13) visits per person] among the 212 patients
having results both with and without detectable target.
Demographics and patient summaries are provided in
Table 1, stratified according to year of cART initiation,
1996–2001 and 2002–2009, to reflect changes in pre-
scribing patterns. Of patients commencing treatment in
the years 1996–2001, 60% (99 of 165) received a PI as
their first-line cART; these patients had significantly
lower CD4 T-cell numbers at baseline (difference 110
cells/lL; P = 0.003) and were approximately 5 years
older at the time of analysis (P = 0.05) compared with
patients receiving an NNRTI (predominantly nevirapine).
In contrast, over the latter years a PI was chosen as first-
line cART for only 28% (53 of 192) of patients. Among
patients of the latter cohort, baseline viral load values
were higher among the PI recipients (P = 0.004) but
cART class differences in baseline CD4 count and age
were not observed. Plots of the observed proportions
across initial class and era of treatment are provided in
Fig. 2.
Predictors of virological response to HIV RNA levels
< 40 copies/mL
Initial univariate analyses examined the impact of each
baseline variable, in turn within each cohort, as a poten-
tial predictor of achieving viral load levels reported as
undetectable (HIV RNA < 40 copies/mL). The analyses
revealed a consistent effect of current NNRTI therapy
across both eras of treatment initiation (1996–2001, OR
2.26, P = 0.004; 2002–2009, OR 1.98, P = 0.01; Table 2).
Prior virological failure marked by a rebound of HIV
RNA > 400 copies/mL was also associated with a reduced
likelihood of achieving subsequent viral load levels < 40
copies/mL (1996–2001, OR 0.35, P = 0.001; 2002–2009,
OR 0.28, P < 0.0001). Higher pretreatment HIV viral load
Fig. 1 A schematic representation of the available data from 11 575 consecutive HIV RNA tests performed between 2007 and 2010. cART,
combination antiretroviral therapy; VL, viral load.
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levels were associated with poorer treatment response in
the later cART cohort (OR 0.52; P = 0.02) but no signifi-
cant effect was evident among the patients who com-
menced treatment in the earlier era and thus had longer
follow-up (OR 0.8; P = 0.3).
When these variables were considered together in mul-
tivariate analyses, the ability to achieve viral load levels
< 40 copies/mL remained strongly associated with current
NNRTI therapy across both treatment eras. No other vari-
able retained independent significance among those indi-
viduals who initiated treatment prior to 2002, while for
those in the latter treatment era the detrimental influence
of elevated pretreatment HIV RNA levels (OR 0.5 per
log10 copies/mL increase; P = 0.01) and prior history of
virological failure (OR 0.18; P < 0.0001) remained highly
significant. Interestingly, a longer duration of cART was
associated with an improved likelihood of achieving viral
load levels of < 40 copies/mL in the latter era (OR 1.27;
P = 0.005) but not among those who initiated treatment
prior to 2002 (OR 0.98; P = 0.8). Once current regimen
and other influencing factors were taken into account, no
Fig. 2 Observed categories of virological suppression as proportions of the HIV RNA measurements < 200 copies/mL, according to the initial
class of combination antiretroviral therapy (cART) [protease inhibitor (PI) or nonnuclesoide reverse transcriptase inhibitor (NNRTI)] and era of
treatment initiation. Pre-cART viral load (VL): low, 100040 000 copies/mL; mid, > 40 000100 000 copies/mL; high, > 100 000 copies/mL.
Table 2 Predictors of viral suppression to HIV RNA levels < 40 copies/mL among 356 individuals with viral load < 200 copies/mL and on com-
bination antiretroviral therapy (cART) for at least 1 year
cART initiated 1996–2001
(n = 165 patients; n = 1597 measurements)
cART initiated 2002–2009
(n = 191 patients; n = 1520 measurements)
Univariate Multivariate Univariate Multivariate
OR (95% CI) Pa OR (95% CI) Pb OR (95% CI) Pa OR (95% CI) Pb
Pre-Rx VL (per log10 copies/mL) 0.8 (0.52–1.25) 0.3 0.91 (0.51–1.63) 0.7 0.52 (0.31–0.88) 0.02 0.5 (0.29–0.87) 0.01
Pre-Rx CD4 count (per 100 cells/lL) 1.05 (0.91–1.21) 0.5 1.1 (0.91–1.33) 0.3 0.98 (0.84–1.15) 0.8 1.03 (0.88–1.22) 0.7
Years on cART (per year) 0.95 (0.85–1.05) 0.3 0.98 (0.82–1.18) 0.8 1.08 (0.96–1.21) 0.2 1.27 (1.07–1.5) 0.005
Current age (per year) 0.92 (0.70–1.19) 0.5 0.83 (0.58–1.18) 0.3 1.17 (0.92–1.49) 0.2 0.96 (0.74–1.26) 0.8
Male 1.52 (0.67–3.45) 0.3 1.17 (0.38–3.62) 0.8 1.17 (0.58–2.34) 0.7 0.87 (0.38–2) 0.7
Caucasian 2.36 (1.16–4.83) 0.02 2.29 (0.87–5.99) 0.09 1.16 (0.63–2.16) 0.6 1.04 (0.53–2.03) 0.9
Current NNRTI 2.26 (1.30–3.94) 0.004 2.06 (0.99–4.28) 0.05 1.98 (1.17–3.37) 0.01 1.99 (1.14–3.48) 0.02
Prior rebound in VL to > 400 copies/mL 0.35 (0.19–0.66) 0.001 0.54 (0.22–1.33) 0.2 0.28 (0.16–0.50) < 0.0001 0.18 (0.1–0.35) < 0.0001
OR, odds ratio; CI, confidence interval; Pre-Rx, pretreatment; VL, viral load; NNRTI, nonnucleoside reverse transcriptase inhibitor.
Significant values are shown in bold.
aP-value from univariate logistic regression.
bP-value from multivariate logistic regression, with adjustment for all tabled variables.
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significant additional effect of cART class at treatment
initiation was observed.
Predictors of detectable HIV RNA among patients with
viral load results < 40 copies/mL
As shown in Table 3, univariate analyses of the HIV RNA
measurements that were below the detection limit found
that detectable HIV RNA target was consistently associ-
ated with pretreatment viral load levels across both cART
eras (1996–2001, OR 1.47 per log10 copies/mL increase,
P = 0.01; 2002–2009, OR 1.96, P = 0.003). Additionally,
prior virological failure was associated with an increased
likelihood of detectable HIV RNA among patients who
had commenced treatment in the earlier cART era (OR
2.08; P = 0.001). This was particularly true when prior
viral rebound could be attributed to treatment interrup-
tion (OR 2.35; P = 0.0002) and remained significant when
analyses were restricted to only those measurements at
least 1 year subsequent to the rebound. Current NNRTI
therapy was associated with a reduced likelihood of
detectable HIV RNA only among patients of the later
cohort (OR 0.53; P = 0.008), while no significant effect of
demographic factors, time on therapy or pretreatment
CD4 levels could be detected in analyses involving either
cohort.
Results of the multivariate analysis closely mirror those
from the univariate analysis, indicating relative indepen-
dence of the contributing factors within each cohort.
Notably, the association of pretreatment viral load with
occurrence of detectable HIV RNA remained significant
for both treatment eras (1996–2001, OR 1.51 per log10
copies/mL increase, P = 0.01; 2002–2009, OR 1.96,
P = 0.004). As observed in the analyses determining pre-
dictors of viral suppression to levels < 40 copies/mL, no
additional effect of initial cART class was observed
among patients of either treatment era once the predic-
tive factors of pretreatment viral load, prior virological
failure and current regimen were taken into account.
Combined analyses
In the observed proportions of viral suppression cate-
gories (Fig. 2) and the results of combined analyses
across treatment eras (Fig. 3), we again found a consis-
tent influence of pretreatment HIV RNA levels on obtain-
ing detectable target in patients with a viral load < 40
copies/mL. The effect was observed in both treatment
groups (current PI: univariate OR 1.51 per log10 copies/
mL increase, P = 0.02; current NNRTI: OR 1.70,
P = 0.002), with no significant difference between the
treatment classes in the magnitude of this observed effect
(P > 0.4 for the interaction term). The detrimental impact
of prior virological failure was only found to be signifi-
cant among patients currently on an NNRTI (P = 0.02),
again most particularly for patients with a treatment
interruption (P = 0.008), but there appeared to be little
difference in efficacy between nevirapine and efavirenz.
While we observed an increased likelihood of detectable
HIV RNA target among patients on atazanavir compared
with other drugs of the PI class (OR 1.65; P = 0.04), the
effect diminished in analyses restricted to patients only
on ritonavir-boosted PI regimens (OR 1.46; P = 0.1).
The likelihood of achieving virological suppression to
< 40 copies/mL was particularly reduced among patients
who had experienced prior virological rebound (current
PI: OR 0.46 per log10 copies/mL increase, P = 0.02; cur-
rent NNRTI: OR 0.46, P = 0.002), while the impact of pre-
Table 3 Predictors of detectable HIV RNA among 348 individuals with HIV RNA levels < 40 copies/mL and on combination antiretroviral ther-
apy (cART) for at least 1 year
cART initiated 1996–2001
(n = 161 patients; n = 1430 measurements)
cART initiated 2002–2009
(n = 187 patients; n = 1389 measurements)
Univariate Multivariate Univariate Multivariate
OR (95% CI) Pa OR (95% CI) Pb OR (95% CI) Pa OR (95% CI) Pb
Pre–Rx VL (per log10 copies/mL) 1.47 (1.09–1.96) 0.01 1.51 (1.09–2.08) 0.01 1.96 (1.26–3.03) 0.003 1.96 (1.25–3.03) 0.004
Pre–Rx CD4 count (per 100 cells/lL) 1.00 (0.91–1.10) 1.0 1.05 (0.95–1.17) 0.3 0.96 (0.84–1.10) 0.6 0.95 (0.83–1.08) 0.4
Years on cART (per year) 0.98 (0.90–1.06) 0.6 0.93 (0.85–1.03) 0.2 1.01 (0.92–1.11) 0.9 0.96 (0.86–1.08) 0.5
Current age (per year) 1.03 (0.86–1.23) 0.8 1.10 (0.92–1.33) 0.3 1.06 (0.87–1.30) 0.5 1.02 (0.82–1.27) 0.9
Male 0.77 (0.45–1.37) 0.4 0.93 (0.50–1.70) 0.8 1.59 (0.87–2.86) 0.1 1.56 (0.81–3.03) 0.2
Caucasian 0.63 (0.38–1.05) 0.08 0.70 (0.41–1.20) 0.2 1.10 (0.65–1.85) 0.7 0.91 (0.53–1.56) 0.7
Current NNRTI 0.77 (0.52–1.14) 0.2 0.86 (0.56–1.31) 0.5 0.53 (0.34–0.85) 0.008 0.54 (0.34–0.86) 0.01
Prior rebound in VL to > 400 copies/mL 2.08 (1.35–3.23) 0.001 1.96 (1.19–3.13) 0.008 1.41 (0.81–2.43) 0.2 1.54 (0.88–2.78) 0.1
OR, odds ratio; CI, confidence interval; Pre-Rx, pretreatment; VL, viral load; NNRTI, nonnucleoside reverse transcriptase inhibitor.
Significant values are shown in bold.
aP-value from univariate logistic regression.
bP-value from multivariate logistic regression, with adjustment for all tabled variables.
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treatment viral load was evident among those currently
receiving a PI (OR 0.60; P = 0.04) but not an NNRTI
(P = 0.9). With regard to the potential impact of detect-
able HIV RNA on subsequent risk of virological failure,
we found that, among viral load measurements < 40
copies/mL, 2.7% of those with detectable residual virae-
mia were followed by a viral load above 200 copies/mL
compared with 1.2% of those where no target was
detected (OR 1.77; 95% CI 1.48–2.10; P = 0.001 with
adjustment for baseline viral load, time on therapy and
current class of regimen).
Discussion
In the analysis of viral load data obtained from a large
single-centre HIV-infected cohort, we identified disease-
and treatment-related factors associated with the likeli-
hood of observing detectable target PCR amplification in
a standard HIV RNA assay (Cobas Ampliprep/Cobas Taq-
Man HIV-1 test, version 1) below the reported detection
limit for this assay (40 copies/mL). The study included a
large majority of patients receiving effective therapy,
with HIV RNA results < 40 copies/mL demonstrated in
85–90% of those with viral load results < 200 copies/mL.
It is notable that the proportion of samples with “residual
viraemia” remained stable when comparing the overall
sample set (20.1% of 7451 results < 40 copies/mL) to the
restricted data set with comprehensive treatment history
(19.9% of 4794 results < 40 copies/mL) as well as the
longitudinal data set where viral load results could be
assessed from the commencement of combination HIV
therapy (18.7% of 2819 results < 40 copies/mL).
The principal finding of our analyses is a strong and
consistent association of pretreatment HIV viral load with
the persistence of detectable HIV RNA among patients
who would otherwise be considered to be on suppressive
HIV treatment. Strikingly, this association remained
stable with adjustment for other demographic and clinical
factors, and remained relevant for patients who had been
on therapy for many years. As noted in Fig. 2, this effect
appears to be evident at viral load ranges < 100 000
copies/mL (105 copies/mL), suggesting that consideration
of earlier treatment initiation may have long-term benefi-
cial effects on virological response. This result is consis-
tent with a recent substudy analysis of the AntiRetroviral
Therapy with TMC114 ExaMined In Naive Subjects
(ARTEMIS) trial, which also identified pretreatment viral
load as the major determinant of achieving HIV RNA
levels < 5 copies/mL among antiretroviral treatment-
na€ıve patients randomized to receive tenofovir/emtric-
itabine plus either darunavir/ritonavir or lopinavir/riton-
avir, irrespective of treatment choice [10].
We note that, while PI therapy was consistently associ-
ated with a reduced likelihood of achieving a viral load
measurement < 40 copies/mL, as noted in a meta-analysis
of 48-week efficacy data from randomized clinical trials
[9], this did not translate to a consistent reduction in the
ability to achieve a result lacking any detectable HIV
Fig. 3 Odds ratios ( 2 standard errors) from longitudinal logistic regression modelling of virological suppression rates according to class of cur-
rent therapy. cART, combination antiretroviral therapy; PI, protease inhibitor; NNRTI, nonnuclesoide reverse transcriptase inhibitor; VL, viral load.
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RNA. However, we did find evidence of an increased like-
lihood of residual viraemia associated with atazanavir
therapy, even after adjustment for any potential effects of
baseline viral load, CD4 T-cell count and demographic
variables. It is notable in this respect that ritonavir-
boosted atazanavir alone may have somewhat limited
efficacy as a treatment simplification strategy [11,12]
compared with lopinavir or darunavir [13], which sug-
gests that there may be possible differences in virological
efficacy within the HIV PI class that are not readily
explained in terms of drug resistance. In the setting of
combined antiretroviral treatment, however, it is note-
worthy that a recent clinical trial has not identified ata-
zanavir as a risk factor for achievement of viral load
results < 1 copy/mL using an ultrasensitive viral load
assay, compared with efavirenz or darunavir [14].
The impact of treatment interruptions on the likelihood
of residual viraemia is yet to be fully explored, but our
observed association of detectable HIV RNA with prior
loss of virological control, particularly when attributable
to a prior period off therapy, supports the findings of a
smaller scale study that also examined markers of persis-
tent low-level viraemia [15]. We have also noted in this
study that residual viraemia was associated with an
increased risk of progressing to higher plasma HIV RNA
levels (> 200 copies/mL), although any interpretation of
these findings is limited by the fact that medication
adherence has not been formally assessed as a potential
confounding factor. Our findings also support previous
studies indicating that residual viraemia is a true virolog-
ical entity with identifiable risk factors, rather than a pro-
duct of viral load assay error at the limits of detection.
This view is also reinforced through studies of the effects
of HIV treatment intensification (measured using ultra-
sensitive viral load assays), which have shown that resid-
ual viraemia is a stable state that appears to be unaf-
fected by the addition of an integrase inhibitor [6] or
triple-class cART regimens (i.e. NRTI/PI/NNRTI) [5]. These
findings and those of other HIV clinical trials [9,13] also
suggest that the inability of standard treatment regimens
to fully suppress plasma HIV RNA levels in some patients
is likely to reflect latent infection in long-lived cells
[3,16,17] that are minimally influenced by treatment-in-
duced reductions in viral replication [18,19].
This concept of a stable, very long-lived reservoir of
latently infected cells as a source of residual viraemia
despite effective HIV treatment is also strongly supported
by our finding that baseline plasma HIV RNA levels con-
tinue to predict virological response over extended peri-
ods of treatment – in this case 10 years and beyond. This
effect does not appear to be determined by the pretreat-
ment (nadir) CD4 T-cell count, nor is it influenced in any
detectable way by age, gender or race in this analysis.
This finding is consistent with others’ analyses of viral
load decay during treatment that have shown an eventu-
ally steady-state viral load that reflects the level of pre-
treatment viraemia and the size of the latently infected
CD4 T-cell population [16–20].
This study has several limitations, not least of which is
the determination of residual viraemia using the Cobas
Ampliprep/Cobas TaqMan HIV-1 test (version 1) assay,
rather than a dedicated ultrasensitive viral load assay. As
with any observational cohort study, it is important to
interpret findings with caution in light of potential sam-
ple biases such as variation in treatment prescribing prac-
tices. Nevertheless, this retrospective analysis has the
distinct advantage that the primary outcome measure
(detectable HIV RNA below the assay threshold of 40
copies/mL) was not known to clinicians involved in the
care of these patients, and therefore could not influence
treatment decisions during the study period. Thus, at least
one source of potential confounding has been eliminated.
Acknowledging these caveats, the association of higher
pretreatment viral load measurements with persistently
detectable HIV RNA during long-term HIV treatment is
biologically intuitive and, as noted above, is supported
by other studies. Tellingly, this effect has remained con-
sistent across various stratifications of patient groups and
over extended periods of follow-up, a result that is also
consistent with available evidence. Taken together, these
findings have some interesting implications for the
timing of HIV treatment and for the development of
management strategies aimed at optimizing HIV treat-
ment outcomes and minimizing persistent immune acti-
vation in the face of lifelong treatment. In particular, the
dominant influence of pretreatment HIV RNA level on
long-term virological outcomes – and the lack of any
discernible effect of CD4 T-cell count on these outcomes
– challenges “early” vs. “late” treatment based on CD4 T-
cell levels as the dominant topic for debate in contempo-
rary HIV management, instead arguing for a greater
appreciation of the influence of plasma HIV RNA levels
across the spectrum of HIV-induced immune deficiency.
This concept is supported by a recent meta-analysis of
HIV treatment efficacy [21], which concluded that initial
antiretroviral treatments for HIV-1 are more effective
when commenced at plasma viral loads < 100 000
copies/mL and recommended that rising viral load should
be considered an indication for starting treatment. At the
same time, there is decreasing emphasis on CD4 T-cell
levels as the basis for commencing HIV treatment follow-
ing the recent conclusion and publication of the Strategic
Timing of Antiretroviral Treatment (START) trial, which
has conclusively demonstrated the clinical benefits of
© 2015 British HIV Association HIV Medicine (2015)
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commencing HIV therapy in patients with normal CD4 T-
cell counts [22].
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Supplementary figure for Chapter 2: 
 
Fig. S1: Representative real-time polymerase chain reaction (PCR) amplification plots 
demonstrating HIV-1 amplification (lower red trendline) relative to control (upper 
blue trendline). The results show either the HIV-1 amplification being >40 copies/mL 
(A); HIV-1 amplification between 0-40 copies/mL (B) and a “target not detected” 
result (C) which showed no detection of target HIV-1 for > 15 cycles beyond the 














Summary for Chapter 2. 
In this chapter the determinants of plasma HIV-1 RNA suppression below the 
threshold (<40 copies/mL) of the routinely used method (the Cobas Taqman HIV 
system) were investigated in 11,575 consecutive tests. The data suggests that 20% of 
patients tested had residual viraemia with low-level viral replication below the 
detection limit of the standard HIV-1 RNA assay (<40copies/mL) and that the 
residual viraemia was associated with pre-treatment HIV-1 RNA levels and some 
antiretroviral therapy. These findings support the concept of a stable long-lived HIV 
reservoir of latent infected cells as a source of residual viraemia even in the context of 
successful ART, and in the context of this thesis suggest that the reporting of 
detectable HIV-1 RNA target when using assays such as the Cobas Taqman HIV 
system may have an application in routine patient monitoring. While this study has 
been able to demonstrate the prevalence of detectable HIV-1 RNA among plasma 
samples from patients receiving HIV therapy, the ultimate utility of this approach 
depends on the biological and clinical consequences of residual viraemia which is 
relatively unknown.  
To date, there is limited data available that identifies potential consequences of long 
term residual viraemia in patients on HAART or the long term clinical implications. It 
is known, however, that duration of HAART, treatment intensification or previous 
treatment failures do not significantly reduce or alter residual viraemia levels [104, 
105]. Detectable residual viraemia may increase the risk of poor virological control 
[106, 107] and potentially predict viral blips [108] that have been associated with 
immune activation [109]. Additionally, residual viraemia increased in poor 
immunological responders, particularly correlating with the activation of CD4+ and 
CD8+ T cells potentially leading to persistent immune dysfunction [110]. Monocytes 
have also been identified as a source of residual viraemia [110] implying there are at 
least two sources of residual viraemia.  
The direct role residual viraemia has on immune activation therefore requires further 
investigation especially given evidence linking HIV-1 elite controllers, who have 
residual viraemia, with the presence of increased immune activation levels [111]. It 
has also been shown that persistent production of low level circulating HIV virions 
supply antigens at low levels, which in turn, could activate monocytes [112] and 
pDCs [113], both of which have been implicated in immune activation in the setting 
of HAART. This issue will be addressed further in Chapter 4, in a large cohort-based 
study of plasma biomarkers that reflect interferon-inducible monocyte activation 
pathways. In this study we demonstrate a specific association between plasma soluble 
CD163 levels and residual viraemia, thereby providing a plausible link between 
residual viraemia and systemic inflammation. It is also notable in this study that the 
specific influence of residual viraemia was only observed in the case of soluble 
CD163, and was not demonstrated for plasma CXCL10 levels (which correlated 
closely with plasma viraemia more generally) or soluble CD14 (which was unaffected 




















Chapter 3:  
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Abstract
Objective: We investigated plasma and flow cytometric biomarkers of monocyte
status that have been associated with prognostic utility in HIV infection and other
chronic inflammatory diseases, comparing 81 HIV+ individuals with a range of
treatment outcomes to a group of 21 healthy control blood donors. Our aim is to
develop and optimise monocyte assays that combine biological relevance, clinical
utility, and ease of adoption into routine HIV laboratory practice.
Design: Cross-sectional evaluation of concurrent plasma and whole blood
samples.
Methods: A flow cytometry protocol was developed comprising single-tube CD45,
CD14, CD16, CD64, CD163, CD143 analysis with appropriately matched isotype
controls. Plasma levels of soluble CD14 (sCD14), soluble CD163 (sCD163) and
CXCL10 were measured by ELISA.
Results: HIV status was associated with significantly increased expression of
CD64, CD143 and CD163 on CD16+ monocytes, irrespective of the virological
response to HIV therapy. Plasma levels of sCD14, sCD163 and CXCL10 were also
significantly elevated in association with viremic HIV infection. Plasma sCD163 and
CXCL10 levels were restored to healthy control levels by effective antiretroviral
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therapy while sCD14 levels remained elevated despite virological suppression
(p,0.001).
Conclusions: Flow cytometric and plasma biomarkers of monocyte activation
indicate an ongoing systemic inflammatory response to HIV infection, characterised
by persistent alterations of CD16+ monocyte expression profiles and elevated
sCD14 levels, that are not corrected by antiretroviral therapy and likely to be
prognostically significant. In contrast, sCD163 and CXCL10 levels declined on
antiretroviral therapy, suggesting multiple activation pathways revealed by these
biomarkers. Incorporation of these assays into routine clinical care is feasible and
warrants further consideration, particularly in light of emerging therapeutic
strategies that specifically target innate immune activation in HIV infection.
Introduction
Monocytes are a heterogeneous cell population arising from the myeloid lineage
that provide a link between innate and adaptive immunity. They can be classified
according to cell surface expression of CD14 (a lipopolysaccharide receptor) and
CD16 (FccRIII, a low affinity Fc receptor) into three subsets known to have
different phenotype and functions. The more numerous ‘‘classical’’ CD14++/
CD16- monocytes appear to be more granulocyte-like in that they are well-
equipped for innate immune responses involving trans-endothelial migration and
phagocytosis [1], while the remaining CD16+ monocytes have been more recently
subclassified into ‘‘intermediate’’ (CD14++/CD16+) and ‘‘non-classical’’ (CD14+/
CD16++) populations that appear to have more in common with dendritic cells
and macrophages [1], in that they exhibit greater potential for HLA-restricted
antigen presentation and pro-inflammatory cytokine production [2], migrating in
response to distinct subset-specific chemokine/ligand gradients [3]. With regard
to HIV infection, there has been a great deal of interest in the potential role of
CD16+ monocytes, particularly CD14++/CD16+ intermediate monocytes, in
disease pathogenesis given that these populations (which co-express CCR5) [3]
are permissive to HIV infection [4] and are capable of transferring HIV infection
across the genital mucosal barrier [5] as well as into the central nervous system
[6]. Expansion of this intermediate monocyte population also appears to be
associated with cardiovascular events in subjects referred for elective coronary
angiography [7] and has been noted in acute coronary syndromes as well as in
chronic HIV infection [8].
Additional cell surface markers may further characterise CD16+ monocyte
function, particularly in the context of HIV infection and/or inflammation. These
include the angiotensin converting enzyme (CD143), expressed predominantly on
CD14++/CD16+ intermediate monocytes, which has been linked to mortality and
cardiovascular disease in haemodialysis patients [9]; as well as the scavenger
receptor CD163 which has been shown to be significantly elevated in the context
Monitoring Monocyte Activation during HIV Management
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of HIV infection [10, 11]. In contrast, the high affinity Fcc receptor 1 (CD64) is
principally expressed on CD14++/CD16- classical monocytes, where it may serve as
a biomarker of type I interferon activation in autoimmune diseases [12].
Monocyte CD64 expression may restrict productive HIV-1 infection by
facilitating viral phagocytosis and degradation [13].
Several plasma biomarkers of monocyte activity have also been linked to HIV
disease progression, including soluble CD14 (sCD14) which has been shown to
predict all-cause mortality in HIV patients [14], even in the setting of
undetectable plasma HIV RNA levels that would generally define effective HIV
therapy [15, 16]. Elevated levels of soluble CD163 (sCD163) have also been shown
to be associated with arterial inflammation and cardiovascular disease in HIV-
infected patients [16], although in this case sCD163 levels appear responsive to
HIV therapy [17]. Similarly, plasma levels of CXCL10 (also known as interferon
gamma-induced protein 10 [IP-10]) are induced by HIV infection [18] but are
also readily reduced by effective therapy [19].
Taken together, these data suggest that laboratory evaluation of monocyte
populations may provide important prognostic information during HIV
management that is currently ‘invisible’ through standard assessments of plasma
HIV RNA levels and CD4 T cell counts. In this study we have therefore sought to
develop and optimise methods that reveal monocyte status in a manner that
combines biological relevance, clinical utility, and ease of adoption into routine
HIV laboratory practice.
Methods
Patients attending the Royal Perth Hospital (RPH) Immunology clinic and
healthy control blood donors attending the Australian Red Cross Blood Service
(ARCBS) were recruited for this study. Informed written consent was obtained
from the patients participating in this investigation. This consent form was
reviewed and accepted by the ethics committees.Written ethics committee
approvals for this investigation were also received from Royal Perth Hospital
(EC2012/170), Murdoch University (2012/216) and the Australian Red Cross
Blood Service (11-08WA-15). After site approvals and patient consent, whole
blood was collected into EDTA anti-coagulated tubes from 81 HIV-1 positive
patients and 21 healthy controls.
Sample Collection
Plasma was collected from EDTA whole blood samples within 6 hours of
collection by centrifugal force of 2000 rpm for 20 mins. Plasma was removed and
stored at 280 C̊ until required for the enzyme-linked immunosorbent assay
(ELISA). For flow cytometry analysis, whole blood (WB) samples were kept at
room temperature and processed within 24 hours after collection.
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Whole blood flow cytometric analysis
The eight monoclonal antibodies (mAbs) utilised in this study were designed
using the BD FACSelect multicolour panel designer then purchased from BD
Biosciences, unless otherwise indicated, and stored at 4 C̊ until required.
After assessing the effect of storage time on whole blood samples, mAb
titrations and the effect of washing cell preparations (data not shown) we assessed
the above cohorts using an 8 channel multicolour flow cytometer (FACSCanto II)
for measuring monocytes and monocyte activation status using the following
conjugated antibodies; 0.5 ml APC-H7 mouse anti-human CD14 (clone MwP9),
1 ml V450 mouse anti-human CD16 (clone 3G8), 1 ml V500 mouse anti-human
CD45 (clone HI30), 1 ml PerCP-Cy5.5 mouse anti-human CD56 (clone B159),
2.5 ml PE-Cy7 mouse anti-human CD64 (clone 10.1-this was sub-aliquoted and
stored to prevent degradation from repeated exposure to light) and 5 ml APC
mouse anti-human hematopoietic progenitor cell (clone BB9), 1 ml anti-human
CD163-Alexa Fluor488 (clone 215927) and 2 ml anti-human NKG2C-phycoery-
thrin (clone 134591) from R&D systems. The appropriately matched isotype
controls were utilised for each mAb, as negative controls, and fluorescence minus
one (FMO) staining was also utilised as a control procedure.
The mAbs were pipetted into a 3DT tube (BD Falcon) followed by the addition
of 50 ml of well-mixed, reverse pipette WB. After gentle mixing the sample tubes
were incubated for 15 min at room temperature in the dark. Red blood cells were
lysed by adding 500 ml of 16 FACSLyse red cell lysis buffer (BD Biosciences),
gently mixed then incubated for a further 15 min at room temperature in the
dark. The stained cell preparation was acquired on the flow cytometer within
30 mins after incubation.
Sample acquisition was performed using 3-laser, 8-color configuration on the
FACSCanto II flow cytometer with FACSDiva 6.1.1 software (BD Biosciences).
The performance and quality control of the instrument was assessed and recorded
daily utilising CST beads (BD Biosciences).
Fluorescence compensation was required and assessed as per kit instructions
with anti-mouse Igk CompBeads (BD Biosciences) as well as the above mentioned
mAbs. Compensation values were calculated automatically and accepted when all
fluorochrome-paired values were ,30%. Voltages for forward scatter (FSC) and
side scatter (SSC) were adjusted giving a FSC voltage of 385 and a SSC voltage of
450. This enabled distinct and clear separation of the monocyte cell population
from lymphocyte and granulocyte cell populations. Sample preparation tubes
were acquired by collecting 100,000 events using the acquisition gate on the
lymphocyte cell population, ensuring at least 1000–5000 events were collected for
the monocyte population.
Analysis of monocyte subsets and activation markers
After successful acquisition the data files were saved to the BD FACS database
then exported. Data was imported into Kaluza Flow Cytometric analysis software
(version 1.1) where monocyte analysis was performed.
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Duplets were removed from the analysis by gating on the singleton cells from a
FSC-Area and FSC-Height plot. Lymphocytes and monocytes were visualised and
gated on by using forward scatter/side scatter (FSC/SSC) dot plot. Monocyte
subsets were identified by plotting CD45/FSC-A from the monocyte gate, then
plotting the CD14/CD16 fluorescence from the CD45+ gate. The three monocyte
subsets were defined by using isotype controls and FMO as cutoffs (classical
monocytes (CD14++/CD162), the intermediate monocytes (CD14++/CD16+) and
the non-classical monocytes (CD14+/CD16++). To determine the presence of
monocyte activation markers, CD64, CD163 or CD143 were plotted against SSC-
A from each monocyte subset (i.e. classical, intermediate and non classical). The
percentage of cells positive was determined from the number present in the parent
group.
Measurement of plasma sCD14, sCD163 and CXCL10 levels by
ELISA
For the quantitative determination of plasma biomarker levels, ELISAs were
utilised as per manufacturer’s recommendations unless otherwise stated. R&D
Systems, Quantikine ELISAs were used to determine sCD14, sCD163 and CXCL10
levels. Each sample was assayed in duplicate then the optical densities (OD) were
measured at an absorbance of 450 nm and 570 nm. The latter wavelength corrects
for any optical imperfections and is therefore subtracted from the 450 nm.
Standards and controls were included as per kit instructions. Log/log standard
curves were generated by averaging optical density readings from the standard
results. To determine biomarker concentrations, plasma sample OD readings were
also averaged and concentrations were determined from the log/log standard
curve.
Statistical analysis
Statistical data analysis was performed using SPSS version 21. Normality of data
distribution was assessed using the Shapiro-Wilk test. Based on these results, one
way ANOVA and Mann-Whitney tests were utilised to compare HIV+ and healthy
control groups, with appropriate correction for multiple comparisons when .2
groups were compared. Bivariate correlation and multivariate linear regression
analyses (with logarithmic data transformation to normalise distribution where
appropriate) were utilised to estimate associations between plasma biomarkers
and monocyte subsets with HIV status, HIV viral load, absolute CD4 counts,
CD4:8 ratio, gender and age.
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Results
Influence of HIV status on monocyte populations by flow cytometry
analysis
The study population included 81 individuals with HIV infection and 21 healthy
controls, covering a wide range of CD4 T cell counts and plasma HIV RNA levels
and an age range from 20-70 years (Table 1). Within the HIV group there were 48
participants with viral load results ,40 copies/mL (31 male, 17 female), 12 with
viral load levels between 40 and 400 copies/mL (11 male, 1 female), and 21 with
viral load levels .400 copies/mL (15 male, 6 female).
The identification of monocyte subsets based on CD14 and CD16 expression
was investigated in a whole blood flow cytometry assay as shown in Fig. 1. Upon
identification of the monocyte subsets, the expression of CD64, CD143 and
CD163 proteins were then assessed. For example, Fig. 1C, 1D and 1E show CD163
expression on classical, intermediate and non-classical monocytes respectively.
We initially investigated whether there was a difference in the proportion of
monocyte subsets between HIV-infected and healthy control subjects. We found
no influence of HIV status on either classical monocytes (HIV- median 78% (SE
1.4), HIV+ median 80% (SE 1.9), p50.75), intermediate monocytes (HIV median
4.2% (SE 0.5), HIV+ median 3.8% (SE 0.3), p50.18), or non classical monocytes
(HIV median 5.3% (SE 0.3), HIV+ median 4.8% (SE 0.3), p50.65) using Mann-
Whitney tests to compare groups. There was no detectable influence of gender
(p.0.05, Mann-Whitney) or correlation with age (p.0.05, Spearman’s rho) for
any monocyte subset.
Comparing participants according to HIV viral load status (21 controls, 60 with
‘suppressed’ HIV RNA levels ,400, and 21 with ‘viremic’ HIV RNA levels
.400 copies/mL), we found significantly higher levels of intermediate CD14++/
CD16+ monocytes in viremic HIV+ cases compared with suppressed HIV
(padjusted50.01), although no significant differences between viremic HIV
+ and
control groups (padjusted50.95). This was associated with a corresponding trend
on classical CD14++/CD16- monocytes, in which levels were lower among viremic
HIV+ patients compared with those with suppressed viral loads (p50.08). The
proportion of non-classical CD14+/CD16++ monocytes was similar between all
groups (p.0.45). There was no detectable association of CD4 T cell count or T
cell CD4:8 ratio with any monocyte subset (all p$0.7).
Influence of HIV status on monocyte CD64, CD163 and CD143 cell
surface expression
The expression of CD64, CD163 and CD143 proteins on all monocyte subsets was
explored using whole blood immunophenotyping as described above. As expected
and shown in Fig. 2, classical CD14++/CD16- monocytes showed the highest
overall levels of CD64 [1] and CD163 [10, 11] expression (98% and 79%
respectively), while higher overall levels of CD143 expression were observed in
CD16+ monocyte populations [9].
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Comparing HIV infected and control groups (Mann-Whitney), we found that
HIV status was associated with significantly higher CD64 expression on all three
monocyte subpopulations (Fig. 2A) with a difference of approximately 14% in
both intermediate CD14++/CD16+ monocytes (median (SE): 88% (1.2) vs 74%
(3.3), p,0.001) and non-classical CD14+/CD16++ monocytes (27% (2.3) vs 14.5%
(2.1), p,0.001).
HIV infection was also associated with higher monocyte CD163 expression for
both intermediate CD14++/CD16+ monocytes (79% (2.2) vs 65% (3.5), p50.048)
and non-classical CD14+/CD16++ monocytes (26% (1.9) vs 19% (2.1), p50.017)
(Fig. 2B). Despite low overall CD143 expression, HIV status was associated with
higher expression on CD14++/CD16+ intermediate monocytes (4.0% (0.6) vs 2.2%
(0.3), p50.01) and CD14+/CD16++ monocytes (5.5% (0.9) vs 2.0% (0.4), p50.01)
among HIV+ participants (Fig. 2C).
We then sought to examine the association of plasma HIV RNA levels with
these cell surface markers within the two CD16+ monocyte populations,
comparing the normal healthy control group, HIV+ participants with viral
suppression (viral load ,400 copies/ml) and those with higher levels of viremia
Table 1. Demographic and clinical characteristics of HIV-infected and healthy control subjects.
Category Subcategory HIV+ group Controls
Gender Males (n) 57 10
Females (n) 24 11
Total (n) 81 21
Age (years) Males mean (range) 45 (20–65) 56 (45–70)
Females mean (range) 37 (25–59) 41 (23–66)
Percentage CD4 (%) Males mean (range) 27 (5–53) NT
Females mean (range) 28 (4–48) NT
Absolute CD4 (cells/mL) Males mean (SD, range) 603 (301, 140–1369) NT
Females mean (SD, range) 611 (324, 104–1188) NT
CD4:CD8 ratio Males mean (SD, range) 0.63 (0.41, 0.07–2.36) NT
Females mean (SD, range) 0.71 (0.38, 0.07–1.48) NT
HIV viral load (copies/ml) Males mean (SD, range) 30,905 (84,837, ,40–446684) NT
Females mean (SD, range) 16,662 (43240, ,40–173780) NT
Duration of HIV (years) Males mean (SD, range) 8.6 (7.0, 1 mth–24 yrs) NT
Females mean (SD, range) 8.9 (6.9, 1 mth–24 yrs) NT
Duration of ART at time of MAM (months) Males n545, mean (SD, range) 96.3 (77, 1–240) NT
Females n522, mean (SD, range) 67.9 (57.3, 1–192) NT
Months suppressed (,400cpm) at time MAM Males n542, mean (SD, range) 49.2 (46.7, 1–184) NT
Females n518, mean (SD, range) 49.8 (43.9, 1–149) NT
Months suppressed (,40cpm) at time MAM Males n531, mean (SD, range) 30 (37.8, 2–183) NT
Females n517, mean (SD, range) 30.1 (22.3, 1–66) NT
ART naı̈ve Males (n) 12 NT
Females (n) 2 NT
NT5Not tested.
doi:10.1371/journal.pone.0115226.t001
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(HIV-1 viral load .400 copies/ml), with additional stratification by gender as
shown in Fig. 3. This analysis revealed significant between-group differences in
CD64 expression involving both intermediate monocytes (Fig. 3A, p,0.005) and
non-classical monocytes (Fig. 3B, p,0.03), indicating that although effective ART
was associated with reduced CD64 expression compared with viremic infection,
levels were not normalised to those seen in the healthy control group. No
additional influence of age or gender was detected in either of the CD16+
monocyte populations, in multivariate regression analyses (p.0.5). Similar
Fig. 1. Phenotypic identification of monocytes and monocyte subsets.Whole blood monocytes were identified by a forward scatter and side scatter plot
(A). Lymphocytes (a), monocytes (b) and the granulocytes (c) are shown. The three monocyte subsets were identified from the monocyte population (b) by
CD14 and CD16 expression (B). Classical monocytes (d-CD14++/CD16-), intermediate monocytes (e-CD14++/CD16+) and non-classical monocytes (f-
CD14+/CD16+) were gated for further analysis of activation markers. For example figures C, D and E show CD163 expression from d, e and f respectively.
doi:10.1371/journal.pone.0115226.g001
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multivariate analyses within the HIV+ group identified a marginal association of
lower CD4 T cell counts as well as higher HIV RNA levels on CD64 expression in
both intermediate monocytes (CD4 count, p50.08; HIV RNA, p50.004) and
non-classical monocytes (p50.06, p50.001 respectively).
In contrast, we found that HIV+ status was associated with elevated CD143
expression levels on both CD16+ monocyte populations, regardless of viral load
suppression (p,0.01 for all HIV+ vs. control comparisons, p.0.05 for
comparisons of suppressed vs. viremic HIV+ groups), although overall effect sizes
were small as shown in Fig. 3C and 3D. Similarly, higher levels of CD163
expression on intermediate CD14++/CD16+ monocytes were observed in the
suppressed HIV+ group compared to controls (Fig. 3E; p50.02) whilst in the
non-classical CD14+/CD16++ monocytes higher levels were observed in the
viremic HIV+ group compared to controls (Fig. 3F; p50.049), with no discernible
difference between the suppressed and viremic groups (p50.98). No significant
influence of age, gender or CD4 T cell count on CD143 or CD163 monocyte
expression in any monocyte population could be detected in regression analyses,
including within analyses restricted to the HIV+ study group (all p.0.2).
Influence of HIV status on plasma levels of sCD14, sCD163 and
CXCL10
Comparing normalised (log-transformed) levels of plasma biomarkers in the
HIV-infected and healthy control groups (ANOVA with Bonferroni correction as
appropriate for multiple comparisons), we found a highly significant difference in
plasma sCD14 levels in the HIV+ group compared to controls (Fig. 4A; p,0.001),
Fig. 2. The median cell surface expression and 95% confidence intervals are shown for CD64 (A), CD163 (B) and CD143 (C) on monocyte subsets
in HIV and control subjects. Expression on classical monocytes is significantly different between HIV and control groups for CD64 (p,0.001) but not for
CD163 or CD143. Expression of all cell surface markers on CD16+ monocytes, however, are significantly different between the HIV infected and control
groups (* p,0.05, ** p,0.01 *** p,0.001).
doi:10.1371/journal.pone.0115226.g002
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Fig. 3. HIV viral load status has different influences on monocyte cell surface expression. Expression of CD64 on intermediate (A) and non-classical
(B) monocytes, CD143 on intermediate (C) and non-classical (D) monocytes, and CD163 on intermediate (E) and non-classical (F) monocytes are shown
below. (Data presented as mean values and 95% confidence intervals; p-values derived from Kruskal-Wallis tests).
doi:10.1371/journal.pone.0115226.g003
Fig. 4. sCD14 levels are significantly elevated in HIV patients irrespective of HIV viral load status (A). In contrast sCD163 levels are only elevated in
viremic HIV patients (B) and a similar relationship is seen with CXCL10 levels (C). (Data presented as mean values and 95% confidence intervals; p-values
are derived from log transformed data and ANOVA tests were adjusted for multiple comparisons).
doi:10.1371/journal.pone.0115226.g004
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with no detectable influence of HIV suppression on sCD14 levels compared with
the viremic HIV group (p.0.9). Age and gender also had no influence in adjusted
analyses (p50.72 and p50.21 respectively). Restricting analyses to the HIV+
group, there was no evidence of an association between sCD14 and plasma HIV
RNA levels (p50.7) or CD4 T cell count or T cell CD4:8 ratio (both p.0.6).
Plasma levels of sCD163 were also elevated in the HIV group overall (p,0.05),
but in striking contrast to sCD14, we found that sCD163 was significantly
increased in viremic compared to both virally-suppressed patients (fig. 4B;
p,0.001) and healthy controls (p,0.001) whilst sCD163 levels in suppressed
patients were similar to healthy controls (p.0.9). Within the HIV+ group,
sCD163 levels were independently associated with plasma HIV RNA levels
(p,0.01) as well as T cell CD4:8 ratio (p50.003) in multivariate analysis, with no
additional effect of age (p50.3) or gender (p50.7).
Elevated CXCL10 levels were also specifically associated with viremic HIV
infection compared to both controls (Fig. 4C:p,0.001) and suppressed HIV
groups (p,0.001), with no additional effect of gender (p50.3) or age (p50.8).
CXCL10 levels were associated with plasma HIV RNA levels (p,0.001) but not
absolute CD4 T cell count (p50.1) or CD4:8 ratio (p50.5) within the HIV+
group.
We also investigated if the duration of effective HIV treatment had an influence
on these plasma biomarker levels, considering 48 patients who had achieved
virological suppression ,40 copies/mL for at least one month prior to assessment
(31 males and 17 females, with mean duration of viral suppression 30 months (SD
6.8) and 30 months (SD 5.4) respectively). Here, the duration of virological
suppression had no detectable influence on plasma levels of CXCL10 (p50.47),
sCD163 (p50.17) or sCD14 (p50.49). Similar results were obtained when
considering viral load levels ,400 copies/mL as evidence of virological
suppression (42 males and 18 females, mean duration of viral suppression
,400 copies/mL 49 months (SD 7.2) and 50 months (SD 10.3), with no evidence
of an association with CXCL10 (p50.29) or sCD14 (p50.65). There was a trend
observed for sCD163 (p50.08), although this lost significance (p50.34) after
adjustment for the influence of CD4:8 ratio (p50.008) noted earlier. No
significant effect of HIV treatment duration, or time since HIV diagnosis, was
observed for plasma biomarker levels (all p.0.3).
Correlations between flow cytometry and plasma biomarkers
Comparing plasma biomarkers in the first instance, we found that CXCL10 levels
strongly correlated with sCD163 levels in the overall dataset (r50.50, p,0.001)
and within the HIV+ group (r50.58, p,0.001), while there was no correlation
between plasma levels of sCD14 and CXCL10 (r50.08, p50.5) or sCD163
(r50.06, p50.5).
We next sought to examine correlations between plasma biomarkers and flow
cytometry expression profiles within this study population, with investigation of
significant bivariate correlations in subsequent multivariate regression analysis
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with log-transformed plasma biomarkers as the dependent variable. Here we
found that sCD14 correlated independently with non-classical monocyte CD143
expression (r50.3, p50.006), as well as with intermediate monocyte expression
levels of CD64 (r50.3, p50.001) providing a modest overall R2 value of 0.07
(p50.03). The significance of these variables was lost after inclusion of HIV status
as a covariate (b 0.34, p50.003), suggesting that HIV infection per se was the
dominant determinant of sCD14 levels. For CXCL10, we found that a
combination of sCD163 (b 0.43, p,0.001) and non-classical monocyte CD64
expression (b 0.30, p50.001) provided the best model (R2 0.37, p,0.001), with
no evidence of an additional effect of HIV status (p50.22). Soluble CD163
variability was best explained by a model including CXCL10 (b 0.47, p,0.001),
although in this case combined with non-classical monocyte CD143 expression (b
0.27, p50.002). This final model (R2 0.36, p,0.001) was also unaffected by the
addition of HIV status (p50.54). No effect of age, gender or CD4 count was
detected.
Discussion
This study was primarily concerned with the evaluation of methods relevant to
monocyte activation during HIV infection and treatment, which could be readily
adopted in routine laboratory practice. This may be particularly relevant in the
current treatment era, when the availability of effective HIV therapy (defined by
suppression of plasma HIV RNA levels and recovery of normal CD4+ T cell
counts) has brought into question the prognostic value of regular CD4 T cell
monitoring once these treatment goals have been achieved [20]. In this context,
there is an opportunity to explore novel aspects of chronic HIV infection that
currently remain ‘invisible’ in routine care despite being prognostically important
[14, 15], and which may not be influenced by what would otherwise be considered
effective therapy.
The results of our flow cytometric analyses strongly support the concept that
monocytes are phenotypically altered in the presence of HIV infection, with a
skewing of the distribution towards CD16-expressing monocytes that have been
previously associated with a range of adverse outcomes in both HIV-infected and
non-infected populations [7–9]. We also observed increased cell surface
expression of CD64, CD143 and CD163 on these CD16+ monocytes, which were
not reduced to healthy control levels despite virologically-suppressive ART. These
results suggest that chronic HIV infection promotes CD16+ monocyte activation,
overriding the ‘default’ apoptotic program that generally limits monocyte
maturation and monocyte survival (with a half-life of approximately three days)
[21]. Within this highly dynamic system, the persistence of pro-inflammatory cell
surface markers on CD16+ monocytes in the face of suppressive HIV treatment is
noteworthy.
Measurement of the plasma biomarkers sCD14, sCD163 and CXCL10 in this
cohort also revealed distinct associations with HIV disease and treatment. In these
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analyses, sCD14 levels were significantly elevated in the HIV+ group, irrespective
of viral load level, CD4 T cell counts, or demographic variables. This stability of
sCD14 levels has been previously noted over extended periods of follow-up
among patients on HIV therapy [14, 19, 22], with further evidence that sCD14
levels are established at a ‘set point’ level very early in the course of HIV infection
[23]. The fact that sCD14 levels are chronically increased with HIV infection
compared to controls in this and other studies [22, 24], and that sCD14 levels are
also strongly associated with mortality risk in the general population [25] as well
among those with HIV infection [14], suggest that variability is prognostically
important and is determined by HIV-specific factors as well as those shared
among the general population. In this respect, a recent genome wide association
study has identified heritable factors accounting for ,30% of this variation, while
sCD14 levels were also significantly associated with cardiovascular risk factors
(smoking, diabetes mellitus, fasting glucose and hypertension; all p,0.001) as well
as with C-reactive protein and IL-6 [25]. Similar associations between sCD14 and
cardiovascular risk factors have also been discovered in a study of HIV-infected
patients [26].
In contrast, we found that both CXCL10 and sCD163 levels were elevated in
association with viremic HIV infection – with significant linear correlations
between plasma HIV RNA levels and these variables – but that suppressive ART
restored plasma levels to healthy control values. In the case of CXCL10 this is in
keeping with previous studies [18, 19], as well as observations in acute HIV-1
infection that plasma CXCL10 levels provide a very early predictive measure of
set-point viral load, CD4 T cell activation and disease progression [27] most likely
through direct stimulation of monocyte and plasmacytoid dendritic cell CXCL10
production via toll-like receptor ligation [18]. Similar evidence has been provided
for a correlation between plasma HIV RNA levels and sCD163 [17], and the
interrelationship between sCD163 and CXCL10 identified in this study has also
been noted in rheumatoid arthritis [28] – suggesting common activation
pathways for these molecules.
In terms of the utility of these assays in a routine HIV laboratory setting, our
data indicate that virological suppression (a known variable in HIV care) would
be anticipated to have a favourable influence on plasma CXCL10 and sCD163
levels – potentially limiting the independent value of these tests in routine
management. In contrast, many of the observed effects of HIV infection on CD16+
monocyte surface expression profiles (CD64, CD143 and CD163) and plasma
sCD14 levels were not corrected by HIV treatment, nor were they associated with
other variables considered in these analyses (gender, age, CD4 T cell count). Given
available evidence that these monocyte biomarkers have prognostic significance in
the general population as well as among those with HIV infection – including
when standard CD4 T cell monitoring approaches carry limited prognostic value
in the setting of ‘successful’ therapy [20, 29] – we would suggest that consideration
of their inclusion in routine care is warranted. This is particularly relevant in light
of emerging HIV treatment strategies that seek to reduce systemic immune
activation (including sCD14 levels), either through modifying antiretroviral
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therapy [30, 31], or introducing adjunctive therapies such as statins [32], low-dose
corticosteroids [33], or IL-7 treatment [34]. In these circumstances the ability to
assess who will benefit from these treatment strategies, and then to monitor
treatment response, will be critically important.
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27. Liovat AS, Rey-Cuillé MA, Lécuroux C, Jacquelin B, Girault I, et al. (2012) Acute plasma biomarkers
of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One 7:e46143.
28. Jude C, Dejica D, Samasca G, Balacescu L, Balacescu O (2013) Soluble CD163 serum levels are
elevated and correlated with IL-12 and CXCL10 in patients with long-standing rheumatoid arthritis.
Rheumatol Int 33: 1031–7.
29. Sax PE (2013) Editorial commentary: can we break the habit of routine CD4 monitoring in HIV care? Clin
Infect Dis 56: 1344–6.
Monitoring Monocyte Activation during HIV Management
PLOS ONE | DOI:10.1371/journal.pone.0115226 December 29, 2014 15 / 16
30. Lake J, McComsey G, Hulgan T, Wanke C, Mangili A, et al. (2014) Switch to raltegravir decreases
soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat
Accumulation Trial. HIV Med Feb 10. In press.
31. Romero-Sánchez MC, Machmach K, Gonzalez-Serna A, Genebat M, Pulido I, et al. (2012) Effect of
maraviroc on HIV disease progression-related biomarkers. Antimicrob Agents Chemother 56: 5858–64.
32. Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, et al. (2014) Rosuvastatin treatment
reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis
58: 588–95.
33. Kasang C1, Ulmer A, Donhauser N, Schmidt B, Stich A, et al. (2012) HIV patients treated with low-
dose prednisolone exhibit lower immune activation than untreated patients. BMC Infect Dis 12: 14.
34. Sereti I, Estes JD, Thompson WL, Morcock DR, Fischl MA, et al. (2014) Decreases in colonic and
systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog 10:e1003890.
Monitoring Monocyte Activation during HIV Management
PLOS ONE | DOI:10.1371/journal.pone.0115226 December 29, 2014 16 / 16
Supplementary information for Chapter 3: The method development and 
validation of the flow cytometry monocyte activation marker panel. 
3.1 Background 
This supplementary component of Chapter 3 presents the development and 
optimisation of the eight colour flow cytometry method used for assessing monocyte 
cell populations in HIV infected individuals and a healthy control population. The 
process of assay development features: 1) instrumental setup and validation controls 
including compensation and brightness assessments, 2) staining and gating controls 
including isotype control (IC) determination and fluorescence minus one (FMO) 
staining controls, and 3) biological/experimental controls including normal or 
untreated samples. Through this process, the FMO controls help identify gating 
boundaries when using multi-channel panels, isotype controls help identify staining 
issues, and unstained controls show the background or auto-fluorescence of the 
system. 
3.2 Fluorochrome selection for the eight colour monocyte activation marker 
(MAM) assay 
Designing an eight colour flow cytometry assay has its challenges, although this 
process has been simplified by the development of commercial product websites. In 
this case, the design of the eight colour MAM panel, shown throughout Chapter 3, 
was selected utilising the BD multicolour panel designer 
(https://www.bdbiosciences.com/paneldesigner/). This simplified the process of 
matching antigen density to fluorochrome brightness, by selecting the antigen with the 
highest density to be matched to the fluorochrome with the lowest intensity (Figure 
S1). The panel of fluorochromes available for consideration for the work up of the 
MAM panel are highlighted in Table S1 (blue) along with the final MAM panel 
selection (shown in light blue and turquoise). Primary, secondary and tertiary antigens 
are classified according to how well they have been characterised and their level of 
expression (i.e. CD45; well characterised and easily classified positive or negative 
while CD143 poorly classified and expressed at low levels).  
Additionally, the fluorochrome present on tandem dye conjugates (i.e. PE-Cy7) 
degrade with exposure to light and temperature therefore to avoid this occurring, the 
 
 
tandem conjugates used throughout the MAM assays were stored in small volumes at 
4°C until required.   
 
Figure S1: Monocyte activation marker panel matching procedure. Antigen density 
(left panel; primary, secondary and tertiary antigens) are matched to fluor intensity 
(right panel; bright, moderate or dim). 
3.3 Instrument set up  
The FACSCanto II instrument used for the eight colour monocyte expression assay 
was monitored daily within the Royal Perth Hospital Haematology department. Daily 
maintenance of the instrument involved running the BD Cytometer Setup Beads 
(CST) to monitor the 3 laser/eight colour settings. Optimisation of photomultiplier 
tube (PMT) voltages occurred monthly to obtain maximum resolution between 
negative and positive populations of a fluorescence channel.  
3.4 Compensation evaluation 
Colour compensation analysis was performed at the beginning of the assay 
optimisation then repeated every six months or when the instrument was calibrated. 
Compensation was used to reduce the fluorescence spill-over (optical background) 
from laser channels as the more colours used resulted in more spill-over which in turn 
 
 
resulted in higher background. The compensation set up was performed using the 
BD™ CompBeads Set as per manufacturer’s instructions. Voltages were adjusted 
specifically for V450 with V500; PE with PerCP-CY5.5; and PerCP-CY5.5 with 
PECY7 to ensure precise compensation with minimal spill-over. Once established the 
compensation profile was stored for future use. 
Table S1: The antibody-fluorochrome pairs were selected by using the BD 
multicolour panel designer (https://www.bdbiosciences.com/paneldesigner/). The 
final selection of the monocyte activation marker panel, used in the evaluation, are 
shown in light blue and turquoise (grey = not available, royal blue = available but not 
considered). 
 
3.5 Establishing monocyte activation marker parameters 
Once the assay compensation was established, each antibody was tested against a 
donor HIV negative control, using the manufacturer’s instructions, to identify whether 
all antibodies worked efficiently. The corresponding ICs were also tested. Initially 
tests were carried out using two protocols. One protocol (wash protocol - Figure S2-
A) required a centrifugation wash step (after cell staining) followed by a red cell lysis 
step while a second protocol (no wash protocol - Figure S2-B) was used without a 
centrifugation wash step after the cells were stained. The results from this experiment 
demonstrated that a centrifugation wash step changed the size of some monocytes. 
Figure S2 below clearly shows two monocyte populations, one larger forward scatter 
 
 
than the other (Figure S2A: T vs F) with “T” expressing more inflammatory 
monocytes (intermediate; 10.7% vs 3.9% and non classical monocytes; 13% vs 1.5%), 
while the no wash protocol only identified one monocyte population (Figure S2B: F) 
and expressed monocytes at levels previously described. Since it is highly important 
to reflect the in vivo biological activity of monocytes without artificially activating the 
monocytes with washing in vitro, the “no wash protocol” was used throughout 
evaluation as described below. 
I. Add the appropriate volume of antibody to a tube (as identified from 
titration experiments) 
II. Add 50ul of well mixed whole blood and gently vortex 
III. Incubate for 15 minutes (at room temperature, in the dark)  
IV. Add 500ul of FACSLyse red cell lysis buffer and gently vortex 
V. Incubate for 15 minutes (in the dark, at room temperature)  
VI. Process the samples immediately on the Canto instrument. 
Assessing the correct number of events is important because monocytes comprise 
only 2-12% of the lymphocyte population therefore approximately 5000 monocytes 
(events) were collected. 
After establishing the optimal conditions for each antibody, the next step of the assay 
workup assessed how well the “pooled” antibody mix worked. The probability of 
spill-over occurring increases when “pooling” antibodies, therefore it is important to 
define the best concentration of antibody to use throughout testing without 
compromising brightness and sensitivity. A titration optimisation step was therefore 
performed on 50ul of whole blood from healthy control samples. The antibodies were 
evaluated neat (N), and diluted (N/2, N/5, N/10, N/25, N/50) using flow buffer. To 
ensure that the intensity of the antibody was not compromised, the most appropriate 
dilution was determined by selecting the dilution preceding the limiting dilution 
factor. Once the most appropriate concentration of antibody was determined, all 
antibodies were pooled and reassessed as per the method above.  
The next step was to perform a titration of the whole blood and to test the samples 
over 76hrs to ensure there was adequate number of cells collected without 
compromising cellular integrity and intensity of the fluorochromes. Whole blood 
samples stored at room temperature or at 4°C were used to evaluate the effect of 
storage temperature on monocyte subsets at times 4hrs, 28hrs, 52hrs and 76hrs after 
 
 
collection. The final volume of whole blood used in the experiments was 50ul and 
samples were deemed satisfactory for use for up to 52hrs at room temperature or 
76hrs of storage at 4°C (Figure S3). 
 
\ 
Figure S2: The effect of “washing” monocyte cell populations. Two monocyte cell 
populations were identified when employing the “wash protocol” (A: F and T) while 
only one monocyte cell population (B: F) was identified with the “no wash protocol”. 
  
3.6 Gating strategy to identify MAM expression levels 
An important part of the assay optimisation was to ensure that the gating strategy was 
robust. Isotype antibody controls were used to identify staining problems for single 
antibody use, while FMO staining was used to identify gating boundaries for the 8 
colour multi-channel MAM panel. As shown in Figure 1 in Chapter 3, forward-light 
scatter (FSC) and side-light scatter (SSC) area plots were used to set the gate around 
the monocyte population. The monocyte population was further identified based on 
CD45 fluorescence. From here CD14 vs CD16 expression was plotted to determine 
 
 
the classical, intermediate and non classical monocyte populations. Furthermore, 
within each monocyte subpopulation, CD64, CD163 and CD143 expression was 
identified. Of importance, the gating strategy for identifying positive cell populations 
from FMO and isotype controls should be determined for each individual sample. An 
example displaying the gating strategy for CD14 and CD16 is shown below (Figure 
S4). 
 
Figure S3: The effect of temperature and time on monocyte subsets. The average 
percentage of monocyte subsets (classical, intermediate and non classical) taken from 
2 healthy donors after storing whole blood at room temperature or at 4°C. 
 
3.7    Safety guidelines utilised for the MAM whole blood phenotyping assay  
Another important aspect to consider when developing, optimising and utilising 
infectious whole blood in the eight colour flow cytometry MAM method, is safety 
procedures. Throughout this study universal safety precautions and the Royal Perth 
Hospital health and safety principles and practices were followed to reduce the risk of 
exposure to hazardous materials and eliminate sample contamination. These practices 
follow the accreditation standards maintained by the Department of Immunology to 





Figure S4: The gating strategy for CD14 (A) and CD16 (B) monocytes.  Fluorescent 
minus one (FMO) controls, unstained controls and samples stained with 8 














Summary for Chapter 3.  
In Chapter 3 “Elevated plasma soluble CD14 and skewed CD16+ monocyte 
distribution persist despite normalisation of soluble CD163 and CXCL10 by effective 
HIV therapy: a changing paradigm for routine HIV laboratory monitoring?”, the 
influence of HIV infection and its treatment on monocyte activation was explored. 
Cell surface expression markers on monocytes were evaluated by flow cytometry and 
circulating soluble plasma biomarkers were analysed using commercial ELISA 
assays, among patients with HIV infection as well as healthy control samples. The 
results showed ongoing systemic immune activation in response to HIV infection, 
characterised by persistent alterations of CD16+ monocyte expression profiles and 
elevated soluble CD14 levels that were not corrected by antiretroviral therapy and 
thus likely to be of prognostic significance. The elevated soluble CD14 result is an 
interesting one given that this marker has been associated with increased mortality 
risk in patients with HIV infection; however, its role in HIV infection especially 
involving co-morbidities is still poorly understood and warrants further investigation. 
For this reason, Chapter 4 will explore potential roles of the three soluble markers of 
monocyte activation evaluated in Chapter 3 (sCD14, sCD163 and CXCL10) during 
chronic HIV infection in 475 persons where cardiovascular risk assessments, lipid 
profiles and HIV treatment information were collected in 2010. The major aim being 
to identify therapies (HAART, statins and lipid lowering treatments) that may reduce 
monocyte activation in HIV patients to normal healthy levels, while adding evidence 
that each of these ‘biomarkers’ reflects distinct biological pathways that influence 
monocyte activation. Taken together these research findings may be useful in 
reducing immune dysfunction during chronic HIV infection and limiting age related 
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We investigate the associations of three established plasma biomarkers in the context of
HIV and treatment-related variables including a comprehensive cardiovascular disease risk
assessment, within a large ambulatory HIV cohort. Patients were recruited in 2010 to form
the Royal Perth Hospital HIV/CVD risk cohort. Plasma sCD14, sCD163 and CXCL10 levels
were measured in 475 consecutive patients with documented CVD risk (age, ethnicity, gen-
der, smoking, blood pressure, BMI, fasting metabolic profile) and HIV treatment history
including immunological/virological outcomes. The biomarkers assessed showed distinct
associations with virological response: CXCL10 strongly correlated with HIV-1 RNA
(p<0.001), sCD163 was significantly reduced among ‘aviraemic’ patients only (p = 0.02),
while sCD14 was unaffected by virological status under 10,000 copies/mL (p>0.2). Associa-
tions between higher sCD163 and protease inhibitor therapy (p = 0.05) and lower sCD14
with integrase inhibitor therapy (p = 0.02) were observed. Levels of sCD163 were also asso-
ciated with CVD risk factors (age, ethnicity, HDL, BMI), with a favourable influence of Fra-
mingham score <10% (p = 0.04). Soluble CD14 levels were higher among smokers (p =
0.002), with no effect of other CVD risk factors, except age (p = 0.045). Our findings confirm
CXCL10, sCD163 and sCD14 have distinct associations with different aspects of HIV infec-
tion and treatment. Levels of CXCL10 correlated with routinely monitored variables,
sCD163 levels reflect a deeper level of virological suppression and influence of CVD risk
factors, while sCD14 levels were not associated with routinely monitored variables, with evi-
dence of specific effects of smoking and integrase inhibitor therapy warranting further
investigation.
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Introduction
In spite of the evident success of highly active antiretroviral therapy (HAART) in suppressing
plasma levels of HIV-1 RNA, preventing progressive immune deficiency and ultimately
improving patient survival [1], there is increasing evidence that immune activation persists in
the face of effective HIV treatment [2,3]. This immune phenotype, which is characterized by
prominent monocyte activation [2–4], heightens age related changes [5] and has been associ-
ated with increased prevalence and earlier onset of a range of non-infectious co-morbidities
among HIV-infected individuals including cardiovascular and liver disease, type II diabetes
mellitus and cognitive decline [2–4,6]. The prognostic significance of several innate immune
‘biomarkers’ such as interleukin-6, C-reactive protein and particularly soluble CD14 (sCD14)
[7] as strong predictors of mortality in the setting of treated HIV infection, has also now been
established [2–4].
We have previously described an ongoing systemic inflammatory response to HIV infection
among 81 HIV+ individuals with a range of treatment outcomes compared to 21 healthy con-
trol blood donors [8]. Here, untreated HIV infection was characterised by elevated levels of
pro-inflammatory CD16+ monocytes as well as elevated plasma levels of monocyte-derived,
interferon-inducible proteins (sCD14, soluble CD163 and CXCL10). Treatment-associated
suppression of plasma HIV-1 RNA levels (i.e.<40 copies/mL) was associated with levels of
sCD163 and CXCL10 that were similar to healthy controls, while sCD14 levels remained signif-
icantly elevated despite what would otherwise be considered successful HIV treatment [8].
This observation of stable elevated sCD14 levels has also been made by others [9,10], highlight-
ing that plasma ‘biomarkers’ of systemic immune activation have distinct relationships with
HIV infection and its treatment.
In this study we have sought to investigate these plasma ‘biomarkers’ further, utilising a
larger study population and incorporating analysis of cardiovascular disease risk factors, noting
that sCD14 has been positively correlated with smoking, diabetes, fasting glucose and hyper-
tension (all p<0.001), as well as all-cause mortality, in a large US cohort study of older adults
[11]. We were also interested to explore the influence of detectable plasma HIV-1 RNA below
the standard viral load assay threshold of 40 copies/mL on these biomarkers, having previously
demonstrated in a study of>11,000 viral load results that ‘residual viraemia’ could be identi-
fied in 20% of samples measured at<40 copies/mL and was strongly predicted by the level of
plasma viraemia prior to HIV treatment–even after 10–15 years of suppressive HIV therapy
[12].
Our principal aim was to investigate the potential utility of incorporating one or more of
these plasma biomarkers into routine HIV management, through an improved understanding
of their relationships to known laboratory and clinical variables. This is informed by a growing
awareness that monitoring CD4+ T cell counts has limited ongoing utility once normal levels
have been achieved [13], while other markers of immune function may have more prognostic
value [7] as well as providing insights into disease pathogenesis [14] and informing new thera-
peutic strategies beyond the current antiretroviral treatment paradigm [15].
Materials and Methods
Patient cohort
Patients residing in Western Australia and attending the Royal Perth Hospital (RPH) Immu-
nology clinic in 2010 were recruited for this study. Informed written consent was obtained
from the patients participating in this investigation. This consent form was reviewed and
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accepted by the ethics committees. Written ethics committee approvals for this investigation
were received from Royal Perth Hospital (EC2012/170) and Murdoch University (2012/216).
Plasma collection process
Plasma samples were collected on the day of CVD risk assessment. Plasma was collected from
EDTA whole blood samples within 6 hours of collection by centrifugal force of 1000g for 20
mins. Plasma was removed and stored at -80°C until required for the plasma HIV-1 RNA viral
load and enzyme-linked immunosorbent assays (ELISA).
Cardiovascular disease risk assessments and HIV laboratory testing
Data on cardiovascular disease risk factors were obtained by physical examination and blood
tests assessed at the time of visit. Serum levels of total cholesterol, high density lipoprotein
(HDL), low density lipoprotein (LDL) and triglycerides were measured and the total:HDL ratio
was subsequently calculated.
HIV-1 RNA levels were measured using the Roche Cobas ultrasensitive ampliprep assay V1
(Roche). CD4+ T cell counts, CD4+ T cell percentage and CD4:8 ratios were measured from
sample acquisitions performed on the FACSCanto II flow cytometer with FACSDiva 6.1.1 soft-
ware (BD Biosciences).
Physical examinations included records for age (at sample collection), gender, ethnicity,
height (cm), weight (kg) and blood pressure monitoring (FsysBP, FDiaBP). Smoking was self-
reported and recorded as either being a smoker, a non-smoker or an ex-smoker (within 1
year). Clinical notes were accessed to record whether patients were using ART (protease inhibi-
tor, NRTI, NNRTI and Integrase inhibitor), ACE inhibitors or statin therapy at the time of
assessment. Body mass index (BMI) was calculated using height and weight measurements
overseen by a dietitian, whilst the Framingham score (mean 5-year CVD risk score) was deter-
mined using the National Heart Foundation absolute CVD risk algorithm.
Measurement of plasma sCD14, sCD163 and CXCL10 levels
For the quantitative determination of plasma biomarker levels, ELISAs were utilised, without
modification, as previously described [7]. In-house control samples (sCD14 = 400,000 ρg/μl;
sCD163 = 250 ηg/μl; CXCL10 = 125 ρg/μl) were included in each assay. The mean concentra-
tion values (SD) for the assay controls over all runs were 444,080 ρg/μl (17310), 251 ηg/μl
(16.7) and 120.8 ρg/μl (5.76) for sCD14, sCD163 and CXCL10 respectively. The mean R value
from all ELISAs was 0.993, 0.997 and 0.998 for sCD14, sCD163 and CXCL10 respectively.
Statistical analysis
Statistical data analysis was performed using SPSS version 21. Data distribution was assessed
for normality, with transformation of variables as required. Plasma biomarker data required
logarithmic transformation while absolute CD4+ cell count, CD4:8 ratio and total cholesterol
levels were square rooted. One way ANOVA analysis was utilised to compare variants within
the HIV cohort with appropriate correction for multiple comparisons when>2 groups were
compared. Univariate correlation and multivariate linear regression analyses were utilised to
estimate associations between plasma biomarkers and HIV clinical parameters (viral load sta-
tus, HIV-1 RNA viral load level, absolute CD4+ T cell count, CD4:8 ratio), treatment choice,
CVD risk factors (blood pressure and cholesterol variables, smoking, BMI and Framingham
score), gender, age and ethnicity. Statistical significance required a p-value of<0.05.
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Results
The study population included 474 consecutive patients who attended the Royal Perth Hospital
(RPH) Immunology clinic in 2010 who consented to a cardiovascular risk assessment including
smoking history, standardised measurements of blood pressure and weight as well as collection
of a fasting metabolic profile. Patient characteristics, demographics and clinical details for this
study are shown in Table 1.
The overall study population comprised 78.5% males, 68.8% Caucasians, with a mean age of
45 years (range 21–81 years, SD 12.3 years). The overall mean CD4+ T cell count was 567 cells/
μL (range 3–2205 cells/μL, SD 319 cells/μL) and mean plasma HIV-1 RNA level was 2.4 log10-
copies/mL (lcpm) or 251 copies/mL (cpm). Three hundred and sixty-five patients were on
Table 1. Demographics and patient characteristics from 474 HIV positive patients who underwent
CVD risk assessments in 2010.
Characteristic Value
Age at time of assessment, mean years (range) 45 (21–81)
Male sex (n, %) 372 (78.5)
Ethnicity
- Caucasian (n, %) 326 (68.8)
- Indigenous Australian (n, %) 24 (5.1)
- African (n, %) 57 (12.1)
- Asian (n, %) 66 (14.0)
Current Smoker (n, %) 168 (35.4)
HIV Clinical Parameters at time of assessment
- Plasma HIV RNA viral load (lcpm) 2.4 (1.6–6.0)
- Aviraemia (n, %) 211 (44.5)
- Residual viraemia <1.6 lcpm (n, %) 60 (12.7)
- HIV RNA viral load 1.6-3 lcpm (n, %) 75 (15.8)
- HIV RNA viral load 3–4 lcpm (n, %) 49 (10.3)
- HIV RNA viral load4 lcpm (n, %) 79 (16.7)
- CD4%, mean % (range, SD) 26.1 (1–62, 11)
- Absolute CD4 T cell count, mean (range, SD) 567 (3–2205, 319)
- CD4:8 ratio, mean (range, SD) 0.65 (0.01–3.1, 0.4)
HIV therapy at the time of assessment (n) 365
- NNRTI (n, %) 215 (45.4)
- NRTI (n, %) 348 (73.4)
- HIV Protease Inhibitor (n, %) 161 (34)
- Integrase (n, %) 17 (3.6)
Framingham score (mean, range) 6.67 (0–42)
BMI, kg/m2 (mean, SD) 25 (4.8)
Statin therapy, n (%) 72 (15.2)
Diabetic, n (%) 25 (5.3)
ACE inhibitor, n (%) 54 (11.4)
sCD14 (log ρg/μl), mean (SD error, range) 6.24 (0.007, 5.65–6.62)
sCD163 (log ηg/μl), mean (SD error, range) 2.89 (0.009, 2.22–3.42)
CXCL10 (log ρg/μl), mean (SD error, range) 2.05 (0.018, 1.13–3.22)
lcpm = log copies per mL, SD error = standard error; n = number, BMI; body mass index; ACE = angiotensin
converting-enzyme inhibitor; NRTI = Nucleoside Reverse Transcriptase; NNRTI = Non Nucleoside/
Nucleotide Reverse Transcriptase.
doi:10.1371/journal.pone.0158169.t001
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antiretroviral therapy (77%), with undetectable HIV-1 RNA viral load (<40 cpm) noted for
271 patients; 57.2% of the overall cohort, and 74.2% of those on HIV therapy. Within this sub-
set, target HIV-1 amplification could be detected on the Cobas HIV-1 ampliprep system below
the assay threshold of 40 cpm, reflecting ‘residual viraemia’ in 60 cases (22.1% of results
reported as<40 cpm).
With regard to cardiovascular risk factors, the mean 5-year CVD risk score (Framingham
score) in the study population was 6.6% (SD 6.7; range 0–42), including 325 patients (71.0%)
in the low risk category (estimated 5-yr CVD risk<10%), 90 patients (19.7%) deemed at mod-
erate risk (5-yr CVD risk 10–15%), and 43 patients within the high risk group (n = 23 (5.0%)
with CVD risk 15–20%, and n = 20 (4.4%) with CVD risk>20%). The study group included
168 current smokers (35.4%) and 25 diabetics (5.3%). The average BMI of the study group was
25.0 kg/m2 (SD 4.8). Statin therapy was used in 15.2% while ACE inhibitors were used in
11.4% of participants.
Plasma biomarker levels were approximately normally distributed following logarithmic
transformation, with mean log values and corresponding plasma concentrations for sCD14,
sCD163 and CXCL10 of 6.24 [1,737,800 ρg/μl], 2.89 [776 ηg/μl] and 2.05 [112.2 ρg/μl] respec-
tively (Table 1).
Correlations between HIV-1 clinical parameters, CVD risk and
circulating plasma biomarkers
Spearman rank correlations were used to explore associations between circulating soluble
plasma biomarkers and HIV clinical and CVD risk parameters. Investigating the influence of
HIV clinical parameters (HIV-1 RNA, CD4+ T cell count and CD4:8 ratio), we observed strong
positive correlations between plasma HIV-1 RNA levels and both CXCL10 and sCD163
(p<0.001, r = 0.5: Fig 1A and 1B) and strong negative correlations for CD4+ T cell (p<0.001,
r = -0.36) and CD4:8 ratio (p<0.001, r = -0.37) while we could not find any significant correla-
tions between HIV clinical parameters and sCD14 (p>0.1, Fig 1C).
With respect to CVD risk, we demonstrated a strong and significant negative correlation for
sCD163 and CXCL10 and total cholesterol levels (data not shown; p<0.001, r = -0.23), LDL-c
(p<0.01, r = -0.18) and HDL-c (p0.001, r = -0.18), however these parameters did not corre-
late with sCD14 levels (p>0.6). There were no significant correlations between the plasma bio-
markers and total:HDL cholesterol ratio (p>0.1), blood pressure parameters (p>0.2),
Fig 1. Differing correlation outcomes between the three plasma biomarkers and HIV-1 RNA levels. A significant correlation was recognised between
HIV-1 RNA levels with CXCL10 (A) and sCD163 (B) while there was no significance with sCD14 (C).
doi:10.1371/journal.pone.0158169.g001
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Framingham score (p>0.15) or BMI (p>0.07). Analysis with the Tukey post-hoc test revealed
lower sCD14 levels in non-smokers compared to smokers (Fig 2A: p = 0.004). Furthermore,
there was a significant positive correlation for sCD14 and sCD163 levels with smoking (data
not shown; p = 0.002, r = 0.14; p = 0.03, r = 0.1 respectively) but not CXCL10 (p = 0.07).
We also demonstrated correlations between the three plasma biomarkers assessed. Circulat-
ing sCD163 had a strong positive correlation with CXCL10 levels (p<0.001, r = 0.41, S1A Fig)
and sCD14 levels (p<0.001, r = 0.17, S1B Fig) however sCD14 did not significantly correlate
with CXCL10 (p = 0.07, r = 0.07 S1C Fig). We did not identify any correlations for age
(p>0.09) or gender (p>0.4) with circulating plasma biomarkers. Univariate analysis of the
plasma biomarkers with ethnicity suggests higher levels of CXCL10 and sCD163 in Indigenous
Australians (S2A and S2B Fig) and lower levels of sCD14in Africans (S2C Fig).
Multivariate regression analysis reveals distinct biomarker associations
Multivariate regression analysis was then undertaken with each plasma biomarker in isolation
(Model 1) as well as considering the influence of all three biomarkers in adjusted analyses
(Model 2).
CXCL10. In unadjusted analyses for Model 1 (S1 Table), CXCL10 levels were strongly
associated with higher HIV-1 RNA viral load (p<0.0001) and lower CD4+ T cell counts
(p = 0.0001) as well as lower CD4:8 ratio (p = 0.008). Participants on NRTI therapy had lower
CXCL10 (p = 0.0002) whilst being an Asian (p = 0.05) or African male had favourable effect on
CXCL10 levels (p = 0.0001, β>0.2). Framingham score and BMI were not associated with
CXCL10 levels, however patients on an ACE inhibitor had significantly higher levels of
CXCL10 than patients not on an ACE inhibitor (p = 0.045, β = 0.1). Lower total cholesterol lev-
els were also associated with elevated CXCL10 levels (p = 0.02, β = -0.37).
As shown in Table 2 (Model 2), the inclusion of all plasma biomarkers did not abrogate the
significant associations of CXCL10 with HIV clinical parameters (CD4+ T cell counts
Fig 2. There was a significantly strong correlation between sCD14 and smoking where HIV-1 smokers have higher sCD14 levels than HIV-1 non-
smokers while patients on an integrase inhibitor had significantly lower sCD14 levels than patients on an alternative treatment.
doi:10.1371/journal.pone.0158169.g002
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(p = 0.0005) and CD4:8 ratio (p = 0.012) and HIV-1 RNA viral load (p<0.0001), ethnicity
(p = 0.001), NRTI therapy (p<0.001) or with sCD163 (p<0.0001). It did however nullify the
significant association with ACE inhibitor treatment and cholesterol levels. Interestingly, the
adjusted multivariate regression analysis confirmed an interaction between gender and ethnic-
ity (Table 2) which attributed to significantly lower CXCL10 levels in Asian (p = 0.001, β =
-0.15) and African males (p<0.001, β = -0.22).
sCD163. In unadjusted analysis plasma levels of sCD163 were significantly reduced
among ‘aviraemic’ patients only (p = 0.02, β = 0.06) and otherwise remained stably elevated
across all levels of virological suppression (Model 1; S1 Table). Higher levels were associated
with lower CD4+ T cell counts (p = 0.01, β = -0.004), as previously noted for CXCL10. Several
CVD risk factors were associated with sCD163, namely age (p = 0.001, β = 0.003), ethnicity
(p = 0.01, β = 0.1), HDL (p = 0.048, β = -0.05) and BMI (p = 0.009, β = 0.005), with a favourable
influence of Framingham score<10% (p = 0.04, β = 0.06). Additionally, the level of circulating
sCD163 was increased when the choice of HIV treatment was a PI (p = 0.05, β = 0.04) but
decreased if participants were on NRTIs (p = 0.04, β = -0.06).
Including all the biomarkers in the regression analysis for sCD163 (Model 2; Table 2)
showed a positive association with both CXCL10 (p<0.0001) and sCD14 (p = 0.003). Interest-
ingly sCD163 remained significantly associated with ‘aviraemic’ status only (p = 0.02) and with
several CVD risk factors including age (p = 0.03), ethnicity (p = 0.01), BMI (p = 0.02), Fra-
mingham score<10% (p<0.05). Univariate associations with CD4+ T cell counts and choice of
therapy were abrogated in adjusted analyses. Of interest, the adjusted multivariate regression
analysis confirmed that sCD163 levels were significantly higher among indigenous cases
(p = 0.012, β = 0.11).
Table 2. Model 2—Multivariate regression results showing significant associations of plasma biomarker with HIV clinical parameters, CVD risk
age, gender, ethnicity and smoking after adjusting for CXCL10, sCD163 and sCD14.
Biomarker CXCL10 sCD163 sCD14
Variable β std error p β std error p β std error p
Age at 2010 - - - 0.002 0.001 0.03 0.001 0.0006 0.08
Gender - - - - - - 0.031 0.018 0.08
Ethnicity -0.15 0.046 0.001 0.107 0.042 0.012 -0.058 0.022 0.009
Gender:Ethnicity -0.224 0.063 0.0004 - - - - - -
Smoking - - - - - - 0.043 0.015 0.004
Residual viraemia - - - 0.058 0.026 0.025 - - -
VL5 0.28 0.058 <0.0001 - - - 0.07 0.023 0.002
SQR CD4:8 -0.202 0.080 0.012 - - - - - -
SQR CD4 -0.01 0.003 0.0005 - - - -0.002 0.001 0.07
NRTI -0.156 0.046 0.0007 - - - - - -
NNRTI - - - - - - 0.052 0.018 0.004
PI - - - - - - 0.041 0.018 0.026
Integrase - - - - - - -0.078 0.037 0.037
HDL - - - -0.04 0.023 0.09 - - -
BMI - - - 0.004 0.002 0.017 - - -
Framingham score - - - 0.05 0.025 0.049 - - -
CXCL10 - - - 0.18 0.026 <0.0001 -0.023 0.022 0.3
sCD163 0.51 0.079 <0.0001 - - - 0.13 0.039 0.0009
sCD14 -0.06 0.096 0.53 0.16 0.056 0.003 - - -
“-“p = >0.01; std = standard error.
doi:10.1371/journal.pone.0158169.t002
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sCD14. Analysing the determinants of sCD14 levels in Model 1 (S1 Table) revealed no sig-
nificant influence of virological status under 10,000 cpm (p = 0.8: data not shown) although
sCD14 levels were incrementally higher when HIV-1 RNA levels were>10,000 cpm
(p = 0.003, β = 0.06). Soluble CD14 levels were higher among smokers (p = 0.002, β = 0.05),
lower in Africans (p = 0.009, β = -0.06) with no effect of other CVD risk factors or overall Fra-
mingham score, apart from age (p = 0.04, β = 0.001). Interestingly, lower sCD14 levels were
associated with use of integrase inhibitor therapy (p = 0.02, β = -0.09; also Fig 2B).
After adjusting for soluble biomarkers in Model 2 (Table 2), sCD14 levels remained strongly
associated with sCD163 (p<0.001), HIV-1 RNA level>10,000 copies/mL(p = 0.002), smoking
(p = 0.004), ethnicity (p = 0.009) and choice of HIV treatment–with a beneficial effect of inte-
grase inhibitor therapy (p = 0.037). In this analysis, the univariate association with age was
abrogated (p = 0.08). Interestingly, the adjusted multivariate regression analysis confirmed that
sCD14 levels were significantly lower for African cases (p = 0.009, β = -0.06).
Discussion
This study confirms our previous finding that CXCL10, sCD163 and sCD14 have distinct
although overlapping associations with different aspects of HIV infection and treatment [8], as
well as cardiovascular disease risk factors and demographic variables (Fig 3). These relation-
ships are in keeping with an increasingly refined understanding of these plasma biomarkers
and their place within the immune environment. For example, CXCL10 was initially identified
as an interferon-gamma-induced protein (also named interferon inducible protein-10) and a
ligand for CXCR3 [16,17], although in the context of HIV infection there is evidence that the
strong relationship between plasma viraemia and CXCL10 [5, 8–10,18] is likely to be mediated
via IFN-α-induced toll-like receptors 7 and 8 [18]. Circulating plasma virions therefore provide
the major stimulus for CXCL10 secretion from monocytes and monocyte-derived dendritic
cells [18], which in turn inhibits IFN-γ signalling and adaptive immune responses [19]. In this
respect, CXCL10 appears to have its most important prognostic role in early HIV infection,
where elevated levels independently predict disease progression rate [20] even among HIV-
controllers with low levels of viraemia [21], and are also associated with risk of transmitting or
acquiring HIV infection [22]. In this setting, the potential utility of CXCL10 measurement in
clinical practice is likely to diminish in light of recent evidence that early treatment of HIV
infection is beneficial irrespective of baseline CD4+ T cell count or plasma viral load [1].
Soluble CD163 provides an interesting contrast in that elevated plasma levels are associated
with a range of cardiovascular risk factors (age, HDL cholesterol, body mass index), and per-
haps most importantly with the overall Framingham cardiovascular risk score. This is in keep-
ing with a number of studies that have identified associations between sCD163 and
cardiovascular inflammation and atherosclerotic plaque formation in the setting of HIV infec-
tion [14,23–25] as well as in the general population [23,26,27]. This association appears to be
underpinned by the role of activated monocyte-derived macrophages within atherosclerotic
vessels [28] as well as in adipose tissue [29,30] in producing sCD163. This pathway involves
tumor necrosis factor-alpha (TNF-α) and ADAM-17 [30,31], thus providing a link between
inflammation and atherosclerotic risk factors including oxidised lipids that may be particularly
relevant in HIV infection [32,33] but are rarely measured in routine care.
We previously found that sCD163 levels were elevated in the setting of untreated HIV infec-
tion, while levels among those on suppressive antiretroviral therapy were comparable to
healthy controls [8]. Here we extend this observation, noting that sCD163 levels were signifi-
cantly reduced only among those patients with no detectable plasma HIV-1 RNA, and
remained relatively elevated in the 60 cases with residual viraemia (22.1% of results reported as
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<40 cpm). This is consistent with previous studies that have identified the TNF-α pathway as a
sensor of low-level viraemia [34,35], although to our knowledge sCD163 has not been previ-
ously studied in this context. Given previous evidence that persistent low-level viraemia
Fig 3. CXCL10, soluble CD14 and soluble CD163 have distinct although overlapping associations with
cardiovascular disease risk factors, HIV treatment, ethnicity and age (A) along with different aspects of HIV infection
(B).
doi:10.1371/journal.pone.0158169.g003
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originates largely from a reservoir of long-lived, latently-infected CD4+ T cells [36,37], it is
interesting to note that ADAM-17 and TNF-α (the major stimuli for sCD163 shedding [31])
are implicated in the replication of quiescent CD4+ T lymphocytes initiated by exosomes from
HIV Nef-expressing cells [38].
These findings suggest that measuring soluble CD163 in routine HIV care has the potential
to capture important prognostic information regarding cardiovascular risk [14,23–25] and
other co-morbid conditions [39] as well as HIV treatment responses beyond the detection
threshold of routine viral load measurements.
The measurement of soluble CD14 in this study population confirmed previous observa-
tions by ourselves [8] and others [9,10,40,41] that levels remain elevated irrespective of the
level of plasma HIV suppression. In contrast to the broad influence of cardiovascular risk fac-
tors on sCD14 levels in the general population [11], we did not observe any influence of indi-
vidual risk factors or the overall Framingham score–suggesting that HIV infection itself
provided an overriding stimulus. We did however observe a significant influence of cigarette
smoking, which was not examined specifically in the population-based study but has been
identified previously in the setting of HIV infection [42]. Moreover, we identified a favourable
effect of integrase inhibitor-based HIV treatment on sCD14 levels in this study, despite the
small number of patients receiving this regimen in 2010 (n = 17). This effect has also been
observed by others [43,44] although not universally [40,45], and at this stage an underlying
mechanism has not been identified although an association between sCD14 and integrated
HIV DNA has been observed in one study [46]. This warrants further study, along with the
impact of smoking, particularly given the established mortality risk associated with elevated
sCD14 levels [7] as well as the ongoing strong influence of smoking on mortality among HIV+
individuals [47,48].
The major strength of this analysis is the statistical power associated with a large sample
pool with complete HIV treatment history and full CVD risk assessments. Limitations include
the lack of subclinical measurements of vascular disease, so that we were unable to confirm pre-
vious findings of associations between sCD14 or sCD163 and cardiovascular disease or mortal-
ity. This study lacked an HIV negative control group, however, we have previously provided
evidence of significantly lower sCD14 in an HIV negative population compared to treated and
untreated HIV groups, while sCD163 and CXCL10 were reduced to levels seen in HIV unin-
fected controls when treated with antiretroviral therapy [8].
In summary, this study supports growing evidence that monitoring plasma immune activa-
tion markers has prognostic significance throughout the course of HIV management. We pro-
vide further evidence that these biomarkers, although linked through common associations
with monocyte activation and interferon signalling, reveal distinct aspects of the inflammatory
response and indeed of the HIV replication cycle. We found that levels of CXCL10 correlated
with routinely monitored variables particularly with plasma viraemia levels, while cell-associ-
ated virus appears to be the major stimulus for sCD163 levels, reflecting a deeper level of viro-
logical suppression. Levels of sCD163 also appear to capture the influence of a broad range of
CVD risk factors, potentially revealing insights into the inflammatory component of cardiovas-
cular disease that may be particularly relevant in the setting of HIV infection. Lastly, while lev-
els of sCD14 are not associated with routinely monitored variables, this study suggests
integrated virus is associated with sCD14, and that cessation of smoking along with the use of
integrase inhibitor therapy could significantly reduce levels of this monocyte activation marker,
in turn potentially decreasing mortality risk during HIV infection. With the ongoing identifica-
tion of pathways leading towards monocyte activation, targeting these sources (i.e.ADAM17,
IFN-α, TNF-α) could lead to useful therapeutic strategies to reduce immune activation, which
has been shown to be associated with the development of age-related disease and mortality in a
Plasma Biomarkers, HIV Treatment and CVD Risk
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treated HIV setting. Further research into these mechanisms is warranted, underpinned by the
evolution of new HIV monitoring strategies that reflect the underlying chronic inflammatory
disease burden and provide insights into pathogenesis and response to treatment.
Supporting Information
S1 Fig. Correlations between plasma biomarkers show strong correlation between sCD163
and CXCL10 (A) and sCD163 and sCD14 (B) while there was no correlation between sCD14
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Chapter 4 supplementary Table and Figures. 
Supplementary Table S1: Model 1- Multivariate regression analyses results. 
CXCL10, sCD163 and sCD14 plasma biomarkers showed significant associations 
with HIV clinical parameters, CVD risk age, gender, ethnicity and smoking. 
Biomarker CXCL10 sCD163 sCD14 
Variable β std 
 
p β std 
 
p β std 
 
p 
Age at 2010 - - - 0.003 0.001 0.001 0.001 0.0006 0.044 
Gender - - - - - - 0.035 0.018 0.057 
Ethnicity -0.18 0.047 0.0002 0.116 0.045 0.011 -0.058 0.022 0.009 
Gender:Ethnicity -0.26 0.065 0.0001 - - - - - - 
Smoking - - - - - - 0.046 0.015 0.002 
Residual viraemia - - - 0.062 0.027 0.022 - - - 
VL3 0.08 0.043 0.056 - - - - - - 
VL4 0.12 0.063 0.054 0.082 0.037 0.028 - - - 
VL5 0.29 0.060 <0.0001 - - - 0.064 0.022 0.003 
SQR CD4:8 -0.22 0.083 0.0085 - - - - - - 
SQR CD4 -0.01 0.003 0.0001 -0.004 0.001 0.011 -0.002 0.001 0.051 
NRTI -0.18 0.048 0.0002 -0.059 0.028 0.039 - - - 
NNRTI - - - - - - 0.047 0.018 0.008 
PI - - - 0.038 0.019 0.052 0.042 0.018 0.021 
Integrase - - - - - - -0.088 0.038 0.019 
Cholesterol (log) -0.37 0.158 0.02 - - - - - - 
HDL - - - -0.049 0.025 0.048 - - - 
BMI 0.006 0.003 0.078 0.005 0.002 0.009 - - - 
Framingham score - - - 0.056 0.027 0.038 - - - 
ACE Inhibitor 0.099 0.049 0.045 - - - - - - 
CVD= cardiovascular disease; VL= Viral load; residual viraemia= 0<VL≤1.6; VL3= 
1.6<VL≤3: VL4= 3<VL≤4; VL5= 4<VL≤6; SQR= squared; BMI= body mass index; 
NRTI= nucleoside reverse transcriptase inhibitor; NNRTI= non nucleoside reverse 
transcriptase inhibitor; PI= protease inhibitor; HDL= high density lipoprotein; ACE= 





Supplementary Figure S1: Correlations between plasma biomarkers. Strong 
correlation between sCD163 and CXCL10 (A) and sCD163 and sCD14 (B) were 







Supplementary Figure S2: Plasma biomarker marker levels correlate with ethnicity. 
CXCL10 was significantly lower in Asian but higher in Indigenous Australians (A), 
sCD163 was significantly higher in Indigenous Australians (B) while sCD14 was 





Summary for Chapter 4. 
Throughout Chapter 4 the aim was to explore potential roles and associations between 
the plasma biomarkers representing monocyte activation, CXCL10, sCD163 and 
sCD14 with the choice of HIV-1 treatment regimen, HIV-1 treatment response and 
cardiovascular disease risk factors during chronic HIV infection in 475 persons within 
the Royal Perth Hospital HIV cohort. The results reveal distinct and sometimes 
overlapping associations with different aspects of HIV infection and CVD risk factors 
to provide an increased understanding on the role these biomarkers have with respect 
to immune activation.  
We have shown that CXCL10, sCD163 and sCD14 have distinct associations with 
different aspects of HIV infection and treatment, with several novel findings that have 
potential implications for clinical management and disease monitoring. For example, 
results show CXCL10 levels correlate strongly with the level of plasma viraemia, 
while elevated levels of sCD163 levels persist even among those with residual 
viraemia (i.e. detectable HIV-1 RNA with a viral load <40 copies/mL) but are 
reduced when there is no detectable HIV-1 RNA. Soluble CD163 levels are also 
influenced by a range of CVD risk factors, potentially reflecting the intersection of 
traditional and HIV-specific risk factors for atherosclerosis.   
We have also found that sCD14 levels remain elevated despite HIV therapy, with no 
evidence that virological suppression at any level has a beneficial effect. This 
highlights a potentially important gap in the current approach to monitoring HIV 
infection over time, noting that sCD14 levels have been shown to predict overall 
mortality in the general population as well as those with HIV infection. In this regard, 
we have demonstrated specific effects of smoking and integrase inhibitor therapy that 
warrant further study. 
The results presented in Chapter 4 builds on a growing level of interest in the role of 
innate immune activation during long-term HIV management, with strong evidence 
that deleterious systemic inflammation persists despite successful virological 
suppression and CD4+ T cell recovery. Looking into the future, incorporating 
biomarkers into routine care can now be seen as a powerful tool to optimise clinical 
practice and improve individualised treatment and patient care, without the need for 
extra patient bleeds as the biomarkers can be tested from the same plasma sample as 
the HIV-1 RNA test or HIV-1 genotyping assay. 
A collective summary for Chapters 2, 3 and 4.  
The main conclusions derived from the observations presented in Chapters 2, 3 and 4 
include:  
1) The routine method used at RPH for detecting plasma HIV-1 RNA (Cobas 
Ampliprep/Cobas TaqMan HIV-1 test) performed well at amplifying and identifying 
residual viraemia in previously reported “undetectable” (<40cpm) patients. 
Remarkably, 80% of HIV patients in the RPH cohort had plasma HIV-1 RNA levels 
<40 copies/mL and in 20% of these, residual viraemia was detectable below this 
threshold. This residual viraemia was strongly associated with pre-treatment HIV-1 
RNA levels, suggesting earlier treatment based primarily on the level of viraemia may 
be beneficial.  
2) The distribution of monocyte subsets is altered with HIV infection with an 
increased proportion of CD16+ monocytes (inflammatory and patrolling monocytes) 
that are not normalised with HAART.  
3) The large HIV/CVD cohort studied in Chapter 4 showed high levels of CXCL10 in 
untreated HIV infection, with strong correlations between plasma HIV-1 RNA levels 
and CXCL10 levels suggesting it is the circulating HIV-1 virus that stimulates the 
production of CXCL10 potentially through pDC and monocytes by directly 
stimulating TLR pathways (TLR7/8). In contrast, we noted that sCD163 levels were 
only influenced by HIV treatment when there was no detectable HIV-1 RNA (ie. 
beyond the reportable assay threshold of 40 cpm). The level of sCD163 detected was 
also associated with CVD risk factors including an overall Framingham risk score, 
suggesting that this biomarker may reflect the inflammatory component of 
atherosclerosis risk in this population. Finally, we found that sCD14 levels remain 
significantly elevated in the setting of HIV infection, irrespective of HIV-1 RNA 
levels, although our results and others suggest that integrase inhibitor therapy may be 
associated with beneficial effects on sCD14 (though not restoring them to normal 
levels). Smoking was also found to have a negative impact on circulating sCD14 
levels, which is a noteworthy observation given the high prevalence of smoking 
among patients with HIV infection [114] and its impact on mortality in this setting 
[115]. 
These results can inform further research aimed at understanding mechanisms driving 
immune activation, inflammation and residual viraemia, along with elucidating the 
biological roles of these biomarkers. These issues will be explored briefly below, to 
highlight possible future pathways to study. 
4.1. Impact plasma biomarkers have on HIV replication, associations with 
HIV treatment choice and response to HAART 
An overall representation of the effect HIV-1 replication has on plasma biomarker 
levels, pre and post HAART, is represented in Figure 1.  
The interferon inducible protein-10 (CXCL10) was shown to strongly correlate with 
HIV-1 RNA levels, as treatment with HAART reduced circulating levels of CXCL10 
to levels comparable with healthy controls. Plasma HIV-1 particles are therefore a 
major stimulus for CXCL10 secretion from monocytes and pDC [95], which in turn  
inhibits IFN-γ signalling, thus regulating overall immune responses including the 
inhibition of the adaptive immune responses [116]. The pathways involved in HIV-1 
induced CXCL10 production include signalling through the TLR7/8 pathway, as it 
has been previously shown that blocking TLR7/9 effectively blocks CXCL10 
production [95]. These toll-like receptors are expressed intracellularly on endosomes 
in response to CpGDNA (TLR9) or ssRNA (TLR7). Both TLR7/8 and TLR9 trigger 
MyD88 dependant immune activation of monocytes and pDCs [117] by promoting 
IFN-α production.  
Once HAART is administered and maintained, HIV viral replication is diminished 
along with CXCL10 levels, CXCL10 functions by binding to CXCR3 (receptor 3) to 
activate the GPCR and MAPK pathways via adenylated cyclases. This leads to a 
number of effects including chemokine activity, actin reorganisation which enables 
effective antiviral response, cell migration and immunity and inflammation. Both 
immune cells and non immune cells produce CXCL10 in response to inflammation 
[118, 119] helping recruit effector cells (monocytes, T lymphocytes and NK cells) to 
the site of inflammation to promote antiviral responses [120]. During early HIV 
infection CXCL10 levels were shown to be associated with rapid disease progression 
[121] and it has been shown that HIV-1 Tat can synergise with IFN-γ to increase the 
production of CXCL10 in monocytes via the MAPK pathway [122]. This could be 
important when exploring the relationship between immune activation and risk of 
HIV-1 transmission among serodiscordant couples. Mechanisms identified during 
early HIV-1 infection may explain why HIV-1 transmission was significantly 
associated with elevated CXCL10 levels in HIV-1 seroconverting partners [123], 
suggesting it may have a role in viral entry [124]. Additionally, a study on CXCL10 
levels in the genital mucosa of high risk seronegative women showed remarkably low 
levels of CXCL10, potentially promoting protection [125]. For these reasons, 
exploring pathways and mechanisms relating to the HIV-1 induced CXCL10 requires 
further investigation.  
In chapter 3 we identified increased sCD163 levels in untreated HIV patients and 
decreased levels, similar to those seen in healthy controls, in a treated HIV setting. In 
Chapter 4 we have added to this outcome by comparing patients with an “aviraemic” 
status with patients who had detectable HIV-1 RNA below the reported assay 
threshold of 40 copies/mL (residual viraemia),  and to those with HIV-1 RNA >40 
copies/mL. Our results showed sCD163 was significantly reduced among aviraemic 
patients only and remained elevated in patients with residual viraemia. Surprisingly, 
sCD14 levels, which are associated with increased risk of mortality, remained 
elevated regardless of the level of HIV suppression, but were significantly reduced 
among patients receiving integrase inhibitor treatment. The mechanism for this has 
yet to be determined although, as suggested in Chapter 4 and in Figure 1, an 
association between sCD14 and integrated HIV DNA has been reported [126] along 
with increased levels of 2-LTR episomes as discussed below, all of which warrant 
future investigations. 
 
Figure 1: The effect HIV-1 and HAART has on plasma biomarkers. CXCL10, 
sCD163 and sCD14 were elevated in the presence of untreated HIV infection (A) 
however under HAART, 3 levels of effects were observed at different stages of HIV-1 
replication. CXCL10 and sCD163 are reduced while only integrase inhibitors reduced 
sCD14 but not to normal levels. 
4.2 Implications of persistent residual viraemia 
With the introduction of HAART many HIV patients have successfully controlled 
HIV-1 viraemia to below the detection level of routine diagnostic methods. Despite 
this success some patients have persistent HIV-1 residual or low level viraemia and 
the relationship between residual viraemia and immune activation requires ongoing 
investigation. It is known that the duration of HAART or some treatment 
intensification drugs do not significantly reduce or alter residual viraemia levels [104, 
105]. Detectable residual viraemia has been linked to increased risk of poor 
virological control [106, 107, 127] and potentially predicts viral blips [108] that have 
been associated with immune activation [109]. Residual viraemia is increased in poor 
immunological responders, correlating with the activation of CD4+ and CD8+ T cells 
potentially reflecting persistent immune dysfunction [110]. The relationship between 
residual viraemia and latently infected cells has been investigated with conflicting 
results. Genetic similarities between reactivated latent HIV-1 compared to residual 
viraemia during ART have been observed [128] while other studies show genetic 
differences between residual viraemia sequences and the heterogeneous forms of 
reactivated virus [129,130] leading to suggestions that residual viraemia does not 
commonly originate from CD4+ T cells. To support this, monocytes have also been 
identified as a source of residual viraemia [110] confirming there are at least two 
cellular sources of residual viraemia. The results presented in this dissertation indicate 
that residual viraemia was associated with increased levels of sCD163 (monocyte 
activation), although at this stage it is unknown if latently-infected monocytes and/or 
T lymphocytes provide the stimulus for sCD163 secretion. As discussed below and 
shown in Figure 2, mechanisms have been described that provide plausible links 
between cell-associated HIV proteins (Nef in particular) and the release of sCD163 
from its membrane-bound precursor.   
4.3 Cardiovascular disease risk factors and associations with plasma 
biomarkers 
The biomarker assessments outlined in Chapter 4 resulted in very interesting 
associations with CVD risk factors, including the most striking association between 
sCD163 and Framingham score as well as age, high density lipoprotein, cholesterol 
and body mass index. Together the results suggest a role for inflammatory pathways 
associated with atherosclerotic plaque formation seen both in the HIV [68, 92, 131] 
and healthy populations [92,132,133]. The associations appear to be related to the role 
that activated monocyte-derived macrophages play within the atherosclerotic vessels 
in producing sCD163 [134]. The link between inflammation and atherosclerotic risk 
factors may lie with pathways involving TNF alpha and a disintegrin and 
metalloproteinase (ADAM17). A possible scenario is presented in Figure 2 showing 
the potential role Nef particles play in stimulating and activating ADAM17 to cleave 
membrane bound CD163 to free soluble CD163 [135]. This occurs through the co-
expression of the Nef signaling block (A) that activates Erk1/2. Erk1/2 is the pivotal 
kinase activating ADAM17 (B), and it also requires the interaction of ADAM17 with 
Eed and paxillin (C). Together the complete “Nef signalling complex” of 
Nef/Eed/paxillin leads to the activation of ADAM17 (D). Activated ADAM17 cleaves 
membrane bound CD163 at the “ARG-SER-SER-SER-ARG” site to release it as 
soluble CD163 (E) [136]. The “Nef signaling complex” can also induce the secretion 
of ADAM17 via extracellular vesicles (F) and also activates to release TNF. This 
process requires activated ADAM17 to cleave pro-TNF to release mature TNF (G). 
The mature TNF binds to the TNF receptors to promote the reactivation of HIV-1 and 
also induces CXCL10 production via the NFkB activation pathway (H).  
Monocyte ADAM17 facilitates endothelial migration by accelerating the rate of 
diapedesis [137] by cleaving Mac-1 therefore regulatory mechanisms of diapedesis, 
may be important for the development of therapy to decrease CVD risk and for 
atherosclerosis; all of which warrants further investigation. 
Another potential key driver of immune activation in HIV, particularly with respect to 
CVD risk factors, is coinfection with CMV. In an HIV setting CMV infection has 
been shown to be associated with higher CD8 T-cell counts, lower CD4/CD8 ratio 
and increased inflammation [138] while a recent study indicated CMV/HIV 
coinfection (based on CMV IgG positivity at baseline) was associated with increased 
risk of SNAEs particularly cardiovascular events [139]. These results are interesting 
though the exact mechanisms were not identified and the plasma biomarkers sCD14 
and sCD163 were not assessed.  
 
 
4.4 Clinical relevance of plasma biomarkers and monocyte subsets during 
HIV infection 
While the primary concern in Chapter 3 was to evaluate methods relevant to 
monocyte activation during HIV infection and treatment by focussing on flow 
cytometry and ELISA-based methods, the focus for Chapter 4 involved identifying 
the role plasma biomarkers play in CVD disease risk in an HIV setting. The results 
from both chapters have helped further define the potential clinical relevance and 
prognostic role of each biomarker in routine laboratory practice, and the potential 
value of these assays in identifying those who may benefit from alternative treatment 
strategies and monitoring the treatment response. These analytes are currently 
”invisible” in existing routine laboratory practices and HIV management, but may 
assume increasing importance in the current era of HIV management where patients 





Figure 2: The potential role Nef particles play in stimulating and activating 
ADAM17. Nef particles activates ADAM17 to 1) cleave membrane bound CD163 to 
its free soluble CD163 form; and 2) release TNF, which promotes the reactivation of 
HIV and the release of CXCL10. Adapted from Lee and Etzerodt [135, 136]. 
 
The results presented here indicate that CXCL10 is useful in predicting HIV disease 
progression rate (due to strong positive correlations with HIV-1 RNA levels [140]) 
however implementing CXCL10 assays into clinical practice may provide little 
additional clinical value particularly in light of recent studies indicating early 
treatment of HIV is beneficial regardless of HIV-1 RNA levels or CD4+ T cell counts 
[141]. In a non-HIV setting CXCL10 levels have been shown to be increased in 
patients with coronary artery disease (CAD) when compared to control cases, 
although in keeping with the results presented in Chapter 4, CXCL10 did not however 
have predictive power for CAD risk [142, 143].  
There is, however, the potential to include sCD163 into routine monitoring as it 
captures important information pertaining to 1) treatment responses beyond those that 
are currently reported in laboratory practices, 2) cardiovascular disease risk within the 
HIV setting and 3) the potential to capture prognostic information relating to other co-
morbidities [144].  
The inflammatory marker, sCD14, can help predict mortality even after accounting 
for HIV-1 RNA levels [28] therefore monitoring systemic immune activation, 
particularly sCD14 levels, during HIV management could offer important prognostic 
information that could ultimately  improve standard of care and improve treatment 
strategies beyond the current paradigm of achieving undetectable plasma HIV-1 RNA 
levels and normal CD4+ T cell counts – noting that both of these outcomes have little 
influence on sCD14 levels. Finally, the elevated level of CD16+ monocytes 
(intermediate and non-classical monocyte) regardless of HIV-1 RNA levels is worth 
monitoring routinely especially as effective HIV therapy has brought in to question 
the prognostic value of regular (quarterly) CD4+ T cell count monitoring once HIV-1 
RNA is successfully suppressed to <40cpm [101]. Activation of CD16+ monocytes 
may be important mediators and markers of CVD risk [86], neurocognitive disorders 
[145] and breast cancers [146]. Monitoring monocyte subsets during clinical practice 
could therefore be important in identifying patients with high inflammatory responses 
and immune activation and further clarify the role monocytes play in disease 
progression though more work is required in this area particularly in larger cohorts.   
Additional laboratory tests could be employed to assist in patient care by monitoring 
ongoing HIV viral replication. In HAART patients, linear HIV-1 cDNA integrates 
into host DNA which promotes HIV replication. This coincides with increased levels 
of immune activation. With raltegravir intensification however, particularly for those 
on a protease inhibitor, linear HIV-1 cDNA integration reduces, unintegrated 
episomal cDNA levels (2-LTR circles) increase, and markers of immune activation 
are normalised [147]. These results suggest active replication exists and this could 
reflect the overall burden of cell associated HIV during HAART which drives 
immune activation. Quantitative PCR methods could be utilised in a laboratory setting 
to measure 2-LTR circles to monitor HAART efficacy and to detect the level of 
ongoing replication (Figure 3). 
  
Figure 3: The impact of raltegravir intensification on HIV-1 2-LTR circles in 
HAART-suppressed subjects. Raltegravir blocks integration to promote episome 
formation by blocking the integration of linear viral cDNA (A), and subsequently, the 
DNA is circularized by host DNA repair enzymes to form episomes containing two 
copies of the viral long terminal repeat (2-LTR circles) or undergoes recombination to 
form a 1-LTR circle. Therefore, an increase in episomal cDNA occurs when active 
replication is inhibited by raltegravir. A lower level of 2LTR is present when HIV 
DNA integrased into the hosts DNA (B). Adapted from Buzon M [147]. 
 
An overall representation of HIV pathogenesis and its relationship with plasma 
biomarker levels while on HAART is shown in Figure 4. As described in the 
introduction to this dissertation, monocyte activation is established in the early phase 
of HIV infection (innate immune response) and is depicted by the increase in plasma 
biomarkers including sCD163, CXCL10 and sCD14 and an increase in CD16+ 
monocytes. We have shown that by reducing plasma HIV-1 RNA levels with HAART 
we can reliably reduce CXCL10 levels, and in the case of sCD163 levels this 
beneficial effect requires a deeper level of virological suppression without detectable 
residual viraemia. In contrast, sCD14 levels remain unaffected by virological 
suppression, although preliminary evidence of the beneficial effects of integrase 
inhibitor treatment suggest that HIV integration may be an important factor. Taken 
together these research findings indicate that reducing immune dysfunction during 
chronic HIV infection may have a role in limiting age-related illnesses during HIV 
infection, and that monitoring monocyte-derived inflammatory markers is feasible and 
should be considered in routine management. 
 
 
Figure 4: HIV pathogenesis is altered by antiretroviral therapy, as are plasma 
biomarkers and monocyte activation associated with immune activation.  
4.5 Type 1, 2 and 3 Interferon responses during HIV infection 
Interferons (IFN) are regulators of the innate immune responses induced to provide 
protection against early HIV infection as well as offering additional immune 
responses during acute and chronic immune activation. There are three types of IFNs 
including human Type I IFNs (IFN-α has 13 known subgroups, IFN-β, IFN-ω, IFN-κ, 
IFN-ε) Type II (IFN-γ) and Type III (IFN-λ). Most cells within the human body can 
produce IFN however pDCs are powerful producers of Type I and III IFNs in 
response to DNA or RNA viruses [148]. Type III IFNs primarily act on epithelial 
cells and prevent viral invasion through mucosal areas [149]. The primary producers 
of IFN-γ are CD4+ and CD8+ T cells along with NK cells which provide antiviral 
responses to HIV and to other pathogens.  
The induction of IFNs in combating HIV infection involves many pathways as shown 
in Figure 5. Adaptors (TRIF, MyD88, MAVS and STING), kinases (TBK1, IKKs) 
and transcription factors (IRF3, IRF7), along with NFκB, bind to IFN promoters to 
facilitate the transcription of IFN genes and the process is dependant on the level of 
HIV-1 proviral DNA synthesis present. Once produced, IFNs act on cells by binding 
to cell surface receptors (Type 1-IFNAR1 and IFNAR2; Type II- IFNGR1and 
IFNGR2 and Type III (IFN-λ3- IFNLR1 and IL10R2). The binding of IFNs to the 
receptors triggers intracellular signalling pathways leading to the transcription of IFN 
stimulated genes (ISGs; Figure 6). There are over 2,000 ISGs, many of which are 
responsible for the antiviral control and immunomodulation during infection. Some of 
the antiviral restriction factors induced by IFNs include APOBEC3G/3F, SAMHD1, 
tetherin and TRIM5 (Table 1) however HIV can counteract many aspects of the IFN 
response including inhibiting IRF and NFκB functions and inhibiting antiviral 
restriction factors (i.e.APOBEC3G, SAMHD1 and tetherin) through the action of HIV 
accessory proteins Vif [150], Vpx [151] and Vpu [152] respectively. HIV can also 
block IFN induction in DC and macrophages by the dysregulation of TANK-binding 
kinase 1 (TBK1). Here, HIV-1 accessory proteins, Vpr and Vif, blocks the IFN 
induced signalling pathway by inhibiting phosphorylation of TBK1 [153]. 
It is interesting to note that some high risk cohorts, including sex workers, MSM and 
discordant couples, remain HIV free potentially due to the significantly higher level 
of APOBEC3G shown in PBMCs and cervical tissue of HIV-exposed seronegative 
groups [154, 155] suggesting potent restriction factors could offer a barrier against 
HIV infection during early exposure. Another potential barrier against HIV infection 
is the inhibition of the hosts’ cytoplasmic exonuclease TREX1. When TREX1 is 
inhibited, HIV infection of cells triggers Type I IFN expression and secretion via the 
STING/TBK1/IRF3 dependent pathway [156] (Figure 5). Avoiding this process 
promotes HIV integration into host DNA and ultimately HIV replication. For this 
reason the inhibition of TREX1 during early HIV infection may offer an important 
immune based therapy, however improved understanding of how TREX1 pathways 
function is required, especially since the accumulation of DNA due to TREX1 
mutations has shown to be associated with systemic lupus erythematosus (SLE) [157]. 
 





APOBEC3G Restricts HIV replication by editing C to U nucleotides in HIV 
DNA, introducing stop codons, inhibiting reverse transcriptase 
and therefore integration 
TRIM5 Blocks the un-coating of invading HIV virions 
Tetherin Blocks the release of HIV enveloped virus 
SAMHD1 Inhibits replication in myloid cells 
 
 
It is reasonable to envisage there may be competition between recognising and 
masking HIV-1 cDNA by cytoplasmic receptors and celluar factors respectively and 
TREX1 function to clear HIV [158]. An interesting line of future studies would be the 
analysis of TREX1 gene sequences between high risk-uninfected subjects and HIV-
infected subjects, looking for sequence differences associated with HIV infection, 
DNA integration and residual viraemia. 
During acute HIV infection a cytokine storm erupts, including the rapid release of 
IFN-α from pDCs and a slow release of IFN-γ from T cells and NK cells. This early 
induction of IFNs is thought to aid in HIV control however, it could potentially be 
detrimental as the increased immune activation may lead to the influx of 
monocytes/macrophages and T cells providing an environment to promote HIV 
replication which coincides with the increase in HIV-1 RNA levels [159, 160] thus 
highlighting both protective and infection-promoting mechanisms that involve IFN 
signalling. High levels of IFNs have been noted once HIV replication has been 
established and throughout disease progression, which may lead to damaging effects 
during ongoing HIV infection, therefore striking a balance between the role IFNs play 
during early and late HIV infection requires ongoing research.  
 
 
Figure 5: HIV infection can induce Type I, II and III IFNs. These processes are 
facilitated through alternative pathways and depend on the level of proviral DNA 
synthesis.  
 
In summary, the complex relationship between HIV sensing by the innate immune 
system, through the induction of antiviral response factors and immune surveillance 
factors, that provide an antiviral environment and the rapidly mutating capabilities of 
HIV to promote viral invasion [158] requires further understanding to help guide 
therapeutic strategies. 
4.6 Therapeutic strategies to reduce systemic immune activation 
A significant barrier faced when searching for ways to improve the long term 
outcome for people living with HIV is the persistence of immune dysfunction that 
drives cellular activation while on effective HAART. It is well established that 
inflammation and immune activation exist during HIV infection, whether it is early in 
the acute phase of HIV infection, in untreated or treated settings when HIV-1 RNA 
levels are below the detectable limits of commercial assays, in long term non-
progressors or in elite controllers [161]. In all cases inflammation and immune 
activation does not always normalise with HAART and studies have shown a direct 




Figure 6: The secondary response pathways induced from Type I, II and III IFNs. The 
antiviral responses and immune surveillance factors are dependant on the type of IFN 
stimulation. 
 
Although challenging, treatment with HAART in the first 10-20 days after HIV-1 
transmission tends to reverse mucosal and systemic inflammation [162, 163]. As this 
is challenging, targeting the mediators of immune activation could be pursued as an 
alternative strategy to reduce immune activation and mortality within the HIV cohort. 
As described in the introduction, microbial translocation plays a role in establishing 
HIV infection during early exposure. A recent study focused on the effect of a 
polyherbal formulation had on immune activation [164]. Although LPS levels were 
not altered, the sCD14 levels were significantly reduced indicating sCD14 as a marker 
of monocyte activation that is not restricted to activation by LPS. A number of 
alternative studies investigated the supplementation of HAART with probiotics. The 
results showed some reduction in immune activation and inflammation [165, 166]. 
The “PROOV IT” trial is ongoing however it investigates the use of probiotics to 
reduce inflammation and enhance gut health in an HIV setting [167]. Although 
immune activation has shown to be reduced in these circumstances the exact 
mechanisms are yet to be identified and therefore require further investigation. 
Several other studies have delved into defining mechanisms and drugs to target and 
reduce immune activation. Determining outcomes for patients already on HAART 
and who undergo treatment intensification with the integrase inhibitor raltegravir or 
with maraviroc have been studied [168, 169]. Intensification with raltegravir showed 
a decrease in T cell activation and HIV viraemia however in this study immune 
activation persisted [168]. This suggests low level viraemia may be the key player in 
promoting immune dysfunction (immune activation) in T cells potentially triggering 
the activation of monocytes and pDCs. Residual viraemia has also been highlighted as 
a possible barrier to producing an effective HIV cure [170]. The intensification of 
HIV treatment with maraviroc (a CCR5 antagonist) in a small group of patients 
experiencing HIV associated neurocognitive disorders (HAND) showed promising 
results particularly with a significant decrease in the proportion of circulating 
intermediate monocyte (inflammatory) and non-classical monocyte (patrolling) 
subsets, a reduction in monocyte HIV DNA level and significant reduction in sCD163 
levels while improving neuropsycological performance [169]. The results presented in 
Chapters 3 and 4, showed a decrease in sCD14 (a monocyte activation marker) when 
an integrase inhibitor was used, indicating immune activation pathways may be 
blocked when inhibiting integration of HIV viral ssDNA into the host genome, while 
sCD163 was significantly associated with residual viraemia and CVD risk factors 
therefore providing a potential basis for examining the effects of maraviroc 
intensification therapy. 
The use of aspirin has been studied to determine its effect on immune activation and 
inflammation [171]. This study found low dose aspirin may be a potential intervention 
for the HIV-infected population as it reduces platelet/endothelial activation (by 
decreasing p-Selectin, in-turn minimising activation of integrins - which is required 
for ADAM17 activation), immune activation and inflammation. One week of aspirin 
treatment successfully enhanced TNF-α levels released from monocytes while 
decreasing but not normalising activated CD4+ and CD8+ T cells along with sCD14, 
IL-6, d-dimer and hsCRP levels; however only CD8 T cells reached levels observed 
in uninfected controls. Interestingly activated platelets secreting p-Selectin also 
activate monocytes and DCs to produce inflammatory cytokines and chemokines 
[172]. Overall, aspirin may have a place in effectively reducing immune activation 
and inflammation, although further studies are needed on a large scale to expand on 
potential mechanisms and pathways. 
The role played by IFNs during early HIV infection also offers an interesting insight 
into HIV protection particularly given high risk groups exposed to HIV produce high 
levels of IFNs to avoid infection [148, 149]. IFN treatment (IFN-α2b) has been used 
in acutely infected HIV patients to stimulate a primary anti-HIV antibody response 
[173] while IFN inhibitors have been tried in chronic HIV patients. An asymptomatic 
HIV study group was vaccinated against IFN-α and showed reduced levels of 
circulating IFN-α and HIV events. Another study looked at ways to reduce immune 
activation and IFN-α level in HIV chronically infected patients by using chloroquine, 
an endosomal TLR inhibitor [174, 175]. In vitro studies with chloroquine 
demonstrated reduced T cell activation in HIV untreated patients [176] while in ART 
treated patients with CD4+ T cells <200 copies/ml chloroquine decreased immune 
activation by reducing TLR4 expression on CD14 monocytes, reducing activated 
CD4+ T cells and inflammatory responses along with a reduction in IFN-α producing 
pDCs [177]. Interestingly the effect of chloroquine in an alternative study, in HAART 
naive patients with CD4+ T cell >400 copies/ml, showed T cell activation did not 
reduce, T cell numbers depleted while HIV viral replication increased [178] indicating 
that during early HIV infection, inhibiting IFN responses provides a platform for HIV 
establishment. Another strategy looked to suppress HIV replication through the use of 
pegylated (peg) interferon alfa-2a [179]. Despite the small number of virologically 
suppressed subjects on HAART with CD4+ T cells counts >450 copies/ml, results 
suggest, after the discontinuation of HAART, a reduction in viral replication and 
levels of integrated DNA was observed, although residual viraemia levels increased. 
Further work is therefore required on larger cohorts especially given the side effects 
observed in some patients. Finally, the use of Type III IFN-λ3 before and during HIV 
infection has revealed strong antiviral effects by inducing the TLR3 pathway along 
with adaptors MyD88 and TRIF resulting in increased antiviral factors decreasing 
viral replication [180] (Figure 7). Although IFN-λ3 is broadly expressed on many cell 
types, the expression pattern of IFN-λ3 receptors is more cell specific [181] therefore, 
when used as a therapeutic option, it may have fewer side effects over other IFNs 
hence making it more attractive to use.  
A recent study has investigated the effects of combined IL-21 treatment (which 
promotes maintenance and functionality of Th17 cells critical for mucosal immunity) 
with ART compared with ART only, looking at both inflammatory markers and viral 
persistence in SIV infected macaques. Those treated with IL-21 and ART showed 
improved restoration of intestinal Th17 and Th22 cells, reduction in immune 
activation in the blood and mucosa along with reduced SIV RNA in plasma and 
CD4+ T cells harbouring replication-competent virus [182]. This study highlights the 
link between immune activation and residual viraemia and shows an effective way of 
reducing both and maintaining levels after ART is halted, however it did not examine 
the effect on monocyte activation. Future exploration in humans could provide a key 
in utilising IL-21 as an immune based therapy. 
Overall, the challenges faced in future immune based therapy to treat HIV infection is 
to tip the balance in favour of optimising the beneficial antiviral IFN effect while 
minimising HIV-inducing effects of IFN that promote replication, which may involve 
different treatment approaches for different stages of HIV disease. High risk patients 
may benefit from slow release pre exposure IFN therapy while inhibiting IFN during 
chronic infection may be beneficial, however both scenarios require ongoing research 
efforts, particularly to avoid side effects associated with IFN therapy. Including 
therapy to reduce platelet and endothelial activation could also hold benefit in 
reducing immune activation and inflammation, along with consideration of ART 
intensification. 
 
Figure 7: IFN-λ3 inhibits HIV-1 infection of macrophages through JAK/STAT 
pathway. Primary and secondary response pathways show: upregulation of TLR3, 
TRIF and MyD88 adaptors, IRF7 along with STAT1 and STAT2 resulting in the 
upregulation of antiviral factors (indicated by yellow arrows). IFN-λ3 receptors are 
expressed on only a few cell types making IFN-λ3 a good candidate for therapy with 
less side effects and inhibiting HIV replication.   
4.7 Importance of early treatment to reduce immune activation 
It is now well established that HIV infection (treated and untreated) is associated with 
chronic inflammation and immune activation. Activated monocyte/macrophages 
(soluble CD14) and high levels of a number of pro-inflammatory cytokines (IL-6, 
CRP) are hallmarks associated with chronic immune activation. Effective HAART 
decreases levels of most of these biomarkers, however levels in many patients on 
HAART remain higher than those observed in age-matched uninfected adults [26, 
28]. Chronic inflammation during both untreated and treated disease is strongly 
associated with risk of non-AIDS defining morbidity and all-cause mortality [26, 28]. 
HIV replication contributes to this inflammatory state, therefore earlier use of ART to 
lessen this process may be beneficial.  
The results reported from a two armed randomised study involving untreated HIV 
adults with a CD4+ count of >500 cells/µl highlight the importance of immediate 
initiation of ART. A higher proportion of patients achieved HIV-1 RNA levels <200 
copies/ml and quicker recovery of CD4+ T cell counts when immediate ART was 
administered upon diagnosis when compared to deferred ART arm, as would be 
expected, although the clinical benefits of HIV treatment in terms of morbidity and 
mortality were not associated with these parameters [141]. In the SMART study, the 
risk of cardiovascular events was greater in participants randomized to the treatment 
interruption arm (based on CD4+ T cell counts) than for patients who received 
continuous ART [65]. Treatment initiation also resulted in improvements in 
biomarkers associated with CVD, including markers of immune dysfunction 
(monocyte activation [sCD14 and sCD163]), T cell activation, T cell senescence), 
inflammation (IL-6, CRP), hyper-coagulation (D-dimers) and endothelial dysfunction. 
Supporting the recommendation for patients to immediately start ART regardless of 
CD4 T cell count also comes from studies showing ART reduces the risk of HIV 
transmission [182] including perinatal transmissions [184]. Early treatment, however, 
relies on the common barrier of early diagnosis. Early diagnosis within transmission 
networks will be addressed in Chapter 5.  
To conclude, the implementation of two major advances in the combination ART era 
has improved HIV outcomes, one being the use of combination therapy and the other 
being the use of HIV-1 RNA detection assays to monitor HIV replication. Twenty 
years on from these achievements, there is now strong evidence supporting the need 
for alternative monitoring strategies that can identify ongoing immune activation and 
guide the development of novel therapeutic strategies capable of improving long-term 
health outcomes for those living with HIV infection. We have shown throughout the 
chapters and in a large HIV/CVD cohort that immune activation remains present and 
can be reliably measured in a routine laboratory setting. Moreover, distinct 
differences between the plasma biomarkers that we have assessed in terms of their 
associations with HIV treatment response as well as other clinical and demographic 
variables, highlights gaps in our current understanding of HIV pathogenesis 
mechanisms, as well as opportunities for improved approaches to treatment and 





























Preamble to Chapters 5 and 6: HIV-1 epidemiology in Western Australia and 
Australia: An overview into HIV-1 diversity and HIV-1 phylogenetic analysis 
techniques 
At the end of 2013 an estimated 35,300 people had been diagnosed with HIV in 
Australia, including 26,800 people currently living with HIV and 90.7% of whom 
were males [3]. It is also estimated that 14% of HIV infections remain undiagnosed 
[3]. Although the numbers are low when compared to the overall world-wide HIV-1 
epidemic, the number of new diagnoses in Australia has steadily increased since 1999 
against the current world trends [2] (specifically in the last 5 years). New HIV 
infections diagnosed in Australia since 1984 are depicted in Figure 1. In the early 
years of the HIV epidemic in Australia, HIV diagnoses were high, peaking in 1987 
then followed by a decline to a nadir in 1999 which follows the introduction of 
antiretroviral therapy (1991) and of durably effective combination treatment regimens 
in 1996. The majority of HIV infections have been diagnosed in New South Wales 
(51.7%) followed by Victoria (22.7), Queensland (13%), Western Australia (6.1%), 
South Australia (4.1%) and other states (2.4%) [3]. The spread of HIV-1 within 
Australia has, historically, been driven by sexual contact within the MSM population 
(74.7%) and dominated by HIV-1 B-subtype [6]. 
HIV transmission through heterosexual contact has been historically low in Australia 
with only 13.9% of infections reported to be from heterosexual contact. Between 2004 
and 2013, there were 372 children born to women with HIV in Australia. This has 
increased from 9.7 per 100,000 births in 2004-05 to 17.5 in 2012-2013. Among these 
births, 13 children (3.4%) have been diagnosed with HIV infection [3]. This rate is 
remarkably low when compared to the world-wide mother to child transmission rate 
(between 30-45% when not on ART and depends on the duration of breastfeeding; 
and high (30% in central African countries) [2]. 
The historical association between HIV-1 subtype and geographical location (C-
subtype in sub-Saharan Africa and India, CRF01_AE in south east Asia) is well 
established, however in recent times there has been a shift in global diversity patterns. 
Many countries have changed from a predominantly B subtype cohort to one with 
increasing non-B subtypes [5, 12, 185-188]. Although the number of HIV infections 
diagnosed in Western Australia is low compared to other states, this state’s 
demographic profile has been characterized by a high percentage of migrants settling 
into Western Australia from sub-Saharan Africa, with short term visitors coming into 
Australia from countries where HIV notifications are high and with the increased 
travel of Australian residents to countries where HIV notifications are also high (as 
discussed in Chapter 1). In this setting, an improved understanding of the HIV 
epidemic at an epidemiological level is a valuable tool for the development of rational 
prevention and diagnostic strategies.  
 
Figure 1: New HIV infections diagnosed, per year, since 1984. From the Kirby 
institute report [3]. Antiretroviral therapy was introduced in 1991 after which the 
number of diagnoses declined to a nadir in 1999. There has been a steady increase of 
newly diagnosed HIV infections in Australia since 1999, going against the current 
world-wide trend.  
Chapter 5 presents a focus on monitoring the HIV epidemic within Western Australia 
through our investigation of the link between HIV-1 clinical parameters (CD4+ T cell 
counts and HIV-1 RNA levels), HIV-1 viral subtypes and HIV-1 sequence relatedness 
with an aim to uncover the contribution of travel and migration, as well as local 
transmission networks, towards the recent evolution of the HIV epidemic in Western 
Australia. This approach has also been applied to Australia as a whole, through the 
formation of the Australian Molecular Epidemiology Network (AMEN), which 
represents a collaborative network of HIV-1 sequencing laboratories involving all 
Australian states. This network involves experts in the field of HIV and epidemiology 
and was formed to establish an ongoing connection throughout Australia with the aim 
of assessing HIV phylogenetic characteristics, on a larger scale, as detailed in Chapter 
6. 
The HIV phylogenetic approach employed in both the Western Australian and 
Australian analyses is widely accepted [188]. The BioEdit program [189] was used to 
align sequences and Molecular Evolutionary Genetics Analysis Version 6 (MEGA 
V6) Phylogenetic tool [190] was utilised to construct the phylogenetic tree used to 
infer clustering and network patterns. This statistical analysis approach determines 
HIV-1 sequence similarities by inferring maximum likelihood trees with 100 
“bootstrap” runs while the substitution model (general time reversible, GTR) was 
used to estimate evolutionary distance. The “bootstrap” percent infers how reliable it 
is that HIV-1 sequences will cluster together, statistically, in 100 repeated and 
consecutive analyses (Figure 2A). The substitution model used in the phylogenetic 
analysis determined the genetic similarity of the sequences. In keeping with previous 
analyses [188], the phylogenetic trees were searched for patterns that defined 
transmission clusters according to the following conservative approach (Figure 2B);  
1) paired transmission where two sequences only cluster together according to the 
criteria where the bootstrap value (BS) was ≥ 98% and the genetic distance (GD) was 
≤ 1.5% and  
2) a “network” where more than two sequences had a BS value of ≥ 98% and a GD ≤ 
1.5%.  
The stability of sequence clustering within both cohorts was also assessed by the 
removal of drug resistance sites while determining whether there was intrusion of 
“geographically distant HIV-1 subtype B sequences” within a pair or network was 
performed only in the Western Australian analysis. This approach provides a 
conservative estimate of HIV-1 sequence clusters, limiting the likelihood of false 
assignment of sequences into a pair or network where they do not belong. 
There are several challenges faced when performing HIV-1 phylodynamics.  Since 
HIV-1 is a genetically variable and rapidly mutating virus and because of the 
influence of host factors, phylogenetic analysis is most suited to sequences obtained 
during early HIV infection. For this reason baseline or the earliest obtained HIV-1 
sequences will be used throughout the analysis. The substitution model estimates 
evolutionary distance and therefore the sequence quality and the length of sequence 
impacts final clustering results. The quality of sequence was assessed and confirmed 
in the Bioedit alignment step in the analysis before the phylogenetic tree construction 
step.  
Finally, a recent report from UNAIDS proposed an ambitious 2020 target of 90% of 
people living with HIV knowing their status, 90% of people diagnosed with HIV on 
treatment, and 90% of people on treatment with suppressed HIV-1 RNA. Achieving 
this target within Australia can be facilitated by knowledge gained through the 
surveillance of HIV-1 subtype diversity and sequence network characteristics within 
Australia. The analyses and results obtained in Chapters 5 and 6 will potentially assist 
in updating world-wide HIV epidemiology and provide insight into the design of 
prevention strategies and clinical monitoring techniques in Australia. 
Figure 2: The concept behind the phylogenetic analysis approach. A). A schematic 
showing the criteria to provide evidence of phylogenetic clustering including 
“bootstrap” and “genetic distance” definitions. B). A possible phylogenetic tree result 
showing a pair of similar sequences (A+B) with GD=0.5% and BS=99%, a single 
sequence (C) genetically removed from the others (GD=3%) and a network of four 
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Abstract
We examined baseline HIV-1 protease and reverse transcriptase sequences and HIV clinical parameters from
1,021 consecutive patients (814 male, 207 female) through the Royal Perth Hospital HIV service to investigate
HIV-1 subtype diversity and local phylogenetic networks from 2000 to 2014. HIV-1 subtype B virus sequences
were demonstrated in 619 (61%) of cases, with increasing non-B HIV-1 subtypes from 23.2% (2000–2003) to
48% (2008–2011) and 43% (2012–2014) ( p < 0.001), including the CRF01_AE subtype [6.6% (2000–2003) to
21.5% (2008–2011)] and HIV-1 C subtype [9.5% (2000–2003) to 20.2% (2008–2011)]. More HIV-1 B subtypes
were assigned to phylogenetic clusters compared to non-B subtypes (34% vs. 18%; p < 0.001), with larger
clusters identified (cluster size >2: 135/211; 64% vs. 13/69; 19%; p = 0.001), including one cluster of 53 HIV-1
B subtype sequences that evolved from 2008 to 2014. Non-B subtype HIV-1 was associated with lower baseline
CD4 T cell count ( p = 0.005) but not plasma HIV-1 RNA levels ( p = 0.31), suggesting relatively delayed
diagnosis. Baseline viral load was strongly associated with calendar time [mean 18,620 copies/ml in 2000–2003;
75,858 copies/ml in 2012–2014 ( p < 0.001)], and was also associated with larger phylogenetic clusters (size >2)
in adjusted analyses ( p = 0.03). This study identifies a number of temporal trends over the past 15 years,
including an increasing prevalence of non-B subtype HIV-1 that highlights the growing influence of migration
and travel on the Australian HIV-1 epidemic and the associated increased role of heterosexual HIV-1 trans-
mission in this context. At the same time, these data indicate that local transmission within predominantly male
networks remains a challenging issue for HIV-1 prevention.
Introduction
The dynamic nature of the global HIV-1 pandemicis indicated by social and behavioral factors that influ-
ence the risk of transmission, as well as by biological factors
that influence host–viral interactions. In Australia, as in many
developed countries, early implementation of free diagnostic
and treatment services as well as public health strategies in-
cluding needle-sharing programs and promotion of safe sex
practices have contributed to a low overall national HIV-1
prevalence of *158 per 100,000, with *26,800 people
currently living with HIV in Australia.1 Despite this laudable
history the number of new diagnoses in Australia has steadily
increased over the past 13 years with a 26% increase in the
population rate since 2003, including 1,236 new cases in
2014 representing a 10% increase over the numbers diag-
nosed in 2011.1 This is set against an overall downward
global trend in new HIV diagnoses, most notably in sub-
Saharan Africa and also evident in the Asia Pacific region.2
In this context, we have utilized routinely generated HIV-1
partial pol sequences to characterize the changes in HIV-1
genetic diversity from 2000 to 2014 to determine whether
local transmission pairs or networks are increasing and to
identify changing epidemiological patterns within Western
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Australia that could reveal the relative contributions of
overseas travel and migration as well as local risk factors.
This investigation is predicated on known characteristics of
HIV-1 genetic diversity including historical associations
between geographic location and distinct HIV-1 subtypes
(A, B, C, D, F, G, H, J, and K) of which the B and C subtypes
account for approximately 60% of HIV-1 infections.3
The C subtype is prevalent in sub-Saharan Africa and Asia,
A is dominant in east Africa, while the B subtype accounts for
the majority of infections within white populations that are
typically also characterized by transmission via male-to-male
sexual contact as previously documented in 2002 for the
Western Australian HIV population.4 Genetic diversification
of HIV-1 is also promoted by high rates of recombination
events5 that generate stable circulating recombinant forms
(CRFs), which together account for 20% of global HIV-1
infections, as well as unique recombinant forms (URFs).3
While these recombinant forms are increasing in number
within the Los Alamos National Laboratory repository (there
are currently 72 HIV-1 CRFs compared with 10 in 2003), it is
also relevant to this study that CRF01_AE is the dominant
viral subtype in southeast Asia, while CRF02_AG originates
in west and central-west Africa.3 More recent reports support
the idea that some HIV subtypes may have differing bio-
logical outcomes, including clinical implications relating to
disease progression,6 transmissibility,7 and susceptibility to
HIV therapy.8
In addition to identifying likely geographic origins of
local HIV-1 infections, this investigation of viral sequence
variation also allows for the estimation of transmission
networks,9 in which there is sufficient viral sequence simi-
larity relative to other local sequences to suggest a common
source. This methodology has been applied in previous
studies of domestic and international transmission networks
at a global scale,10 as well as in studies within Europe,11,12
the United Kingdom,13 the United States,14 and eastern
Australia.15 These studies have highlighted the complex
interplay between travel, migration, and domestic factors
that contributes toward new HIV-1 infections, changing
global epidemiological profiles, and growing viral diversity.
We were particularly interested in this aspect of phyloge-
netic analysis, given Western Australia’s role as a mineral
and energy resource economy with close links to Asia and
Africa and a relatively mobile local population, and to
identify clinical parameters (CD4 T cell counts or HIV
RNA levels) potentially linked to HIV diversity, transmis-
sion pairs, or networks.
Materials and Methods
Study population
This study was conducted within the Department of
Clinical Immunology at Royal Perth Hospital, which is the
sole provider for diagnostic HIV laboratory services (in-
cluding HIV-1 RNA quantitation, lymphocyte subsets, and
HIV-1 sequencing for drug resistance testing) in Western
Australia. Data collection and analyses were conducted on all
plasma samples genotyped between the years 2000 and 2014
(n = 1,021). In cases in which multiple sequences were per-
formed during the study period, the earliest sequence was
drawn on to represent the baseline sequence for the analysis.
The sequences were then stratified into four periods of state
department of health notifications (2000–2003, 2004–2007,
2008–2011, and 2012–2014). Written ethics committee ap-
provals for this investigation were also received from the
Royal Perth Hospital (EC2012/170, REG-14/112) and Mur-
doch University (2012/216). All viral HIV-1 sequences and
clinical parameters were collated and linked through the
routine HIV laboratory service at Royal Perth Hospital. This
information was subsequently deidentified by assigning a
unique anonymized assessment number used throughout the
study. To determine the effectiveness of identifying highly
related sequences we applied 173 HIV B subtype sequences
from a geographically distinct cohort,16 included multiple
time point sequences from patients within the Western
Australian cohort (n = 30) and removed drug-resistant sites as
previously reported.12
Sample collection, sample processing,
and clinical assessments
Data collected at the time of HIV-1 sequence analysis in-
cluded gender and age at notification, ‘‘earliest’’ plasma
HIV-1 RNA level, and ‘‘earliest’’ CD4 T cell count where the
patients’ first HIV-1 RNA result and CD4 T cell count were
defined as the ‘‘earliest’’ one. From 2000 all HIV-1 viral load
tests were performed using the Cobas Ampliprep/Cobas
TaqMan HIV-1 test (version 1 and version 2 implemented in
2010) with a lower detection limit of 1.6 log10 copies/ml.
CD4 T cell counts were performed using a BD FACSCanto
(II) Flow cytometer instrument. All assay runs were con-
ducted according to NATA accreditation standards, subject
to quality control procedures and RCPA or alternative quality
assurance programs.
For HIV-1 sequencing the protease (PR) gene (amino acid
positions 1–99 in HXB2) and the reverse transcriptase (RT)
gene (amino acid positions 100–235 in HXB2) were ampli-
fied by separating the plasma samples from EDTA whole
blood within 6 h of collection by centrifugation at 2,000 rpm
for 20 min and then storing at -20C (24 h) or -80C (>24 h).
Viral RNA was extracted from plasma as per the manufac-
turer’s instructions using the QIAGEN QIAamp Viral load
RNA Mina Spin kit (Cat. #52906) and converted into cDNA
using Oligo d(T) 20mer primers and RNAse Out Ribonu-
clease Inhibitor (Invitrogen, Cat. #18418-020), Superscript
III reverse transcriptase (Invitrogen, Cat. #18408-085). Two
sets of primers were utilized in the first round cDNA am-
plification to account for potential primer site polymorphisms
(Supplementary Table S1; Supplementary Data are available
online at www.liebertpub.com/aid). PCR products were
electrophoresed on 1% Ultrapure Agarose gel (Invitrogen,
Cat. #15510-027). Purification of positive PCR products for
DNA sequencing was performed using the MioBio Ultra
Clean purification kit (Geneworks: MB-12500-250). Se-
quencing was performed using the ABI Prism Big Dye ter-
minator chemistry (ABI Cat. #4337457) using M13F and
M13R universal primers, purified using CleanSEQ beads
(Agencourt Cat. #AG000135), and electrophoresis was per-
formed on the ABI 3730xl instrument. Analysis of PR and RT
sequences was performed by using the ASSIGN editing
program (Conexio Genomics). We obtained drug resistance
profiles by submitting the fasta files to a calibrated population
resistance tool linked to the Stanford HIV database (http://
hivdb.stanford.edu/).
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The HIV-1 phylogenetic analysis approach
and definition of clusters
Phylogenetic analysis was performed utilizing an approach
previously published.12 In brief, the BioEdit tool17 and Mole-
cular Evolutionary Genetics Analysis Version 6 (MEGA V6)
Phylogenetic tool18 were utilized to construct the phylogenetic
tree used to infer clustering patterns. In keeping with previous
analyses, we defined transmission clusters according to the
following conservative approach: (1) paired transmission where
two sequences only group together according to the criteria in
which the bootstrap (BS) value was ‡98% and the genetic
distance (GD) was £1.5%; (2) a ‘‘network’’ in which more than
two sequences had a BS value of ‡98% and a GD value of
£1.5%; (3) cluster stability after removal of drug resistance
sites; and (4) no intrusion of ‘‘geographically distant HIV-1
subtype B sequences’’ within a pair or network. This conser-
vative criteria approach limits the likelihood of falsifying a
sequence into a pair or network in which they do not belong.
Statistical analysis
Statistical data analysis of demographic and clinical data was
performed using Statistical Package for the Social Sciences
version 21.0 (SPSS v21: Armonk, NY: IBM Corp.). Data dis-
tribution was assessed for normality with some variables re-
quiring log or square root transformation based on their
distributional profiles. Statistical analysis utilized ANOVA
and post hoc tests with correction for multivariate regres-
sion comparisons for multivariable analyses. Results were
considered statistically significant when p-values were <0.05.
Results
Demographic and clinical features of the 1,021 study
participants, who provided sequence data between 2000 and
2014, including 814 males (80%) and 207 females (20%), are
described in Table 1. Overall, 619 (61%) of the HIV-1 pa-
tients were infected with subtype B virus while 402 (39%)
were infected with non-B viruses including A, C, D F, G,
CRF01_AE, and CRF02_AG subtypes and other inter-
subtype recombinant forms. Females were more likely to be
infected with non-B subtype viruses compared with males
(70% vs. 31.6%, p < 0.001) and were on average 6 years
younger than males (33 years of age for females with both B
subtype and non-B subtype HIV-1 infection, compared with
39 years for both B and non-B subtype males; gender dif-
ference p = 0.0007; viral subtype difference p = 0.52).
HIV-1 subtype trends between 2000 and 2014
As shown in Fig. 1, there has been a substantial increase in
the proportion of non-B HIV-1 subtypes rising from 23.2% in
2000–2003 to 43% in the period 2012–2014 ( p < 0.001) with
a peak in 2008–2011 (47.7%). This was associated with an
increase in HIV-1 subtype diversity with a notable increase of
the CRF01_AE subtype from 6.6% in 2000–2003 to 17.1% in
2004–2007, followed by a smaller increment to 21.5% in the
2008–2011 notification period, staying stable through 2012–
2014 at 20.4%. There has also been a marked increase of
HIV-1 C subtype infections over time, from 9.5% in 2000–
2003 and 2004–2007 to 20.2% in 2008–2011 and then finally
to 15.2% in 2012–2014. Infections with a CRF02_AG sub-
type were <4% throughout the study eras.
Analyzing these results in terms of gender (Fig. 2), there
has been a clear increase in the number of cases of non-B
subtype HIV-1 from 2000 to 2012 in both males and females
(Fig. 2A and B respectively) while the proportion of B sub-
type infections has decreased from 2000–2003 to 2012–2014
among both males (83% to 64%) and females (53% to 22%).
As expected, the proportion of males acquiring HIV-1 B
subtype infection has remained consistently high throughout
the study period (with a 1.5-fold increase over time: Fig. 2C)
while non-B subtypes increased at a higher rate (4-fold),
largely accounted for by CRF01-AE cases followed by HIV-
1 C subtype infections. Among females there was a signifi-
cant contribution of HIV-1 C subtype infections, with a 4-
fold increase from nine infections (28%) in 2000–2003 to a
peak of 36 infections (47%) in 2008–2011, while CRF01_AE
subtype infections increased from two (6%) in 2000–2003 to
19 in 2008–2011 (29%: Fig. 2D).
Table 1. Patient Characteristics and Clinical Parameters at Time of HIV Notification (n = 1,021)
Subtype B Non-B Intersubtype recombinants
Patient (n) 619 364 38
Gender**
Male 557 232 25
Female 62 132 13
Age (years)
Male 38.8 (12–76) 39.6 (1–74) 38.4 (4–68)
Female 33.1 (1–74) 32.7 (1–68) 38.2 (21–59)
Viral load (log10 copies/ml)
Male 4.57 (1.6–7)* 4.76 (1.6–7)* 4.79 (2.6–6.63)
Female 4.33 (1.6–6.23) 4.40 (1.6–7) 4.51 (2–6.13)
CD4 T cell count (cells/ll)
Male 445 (3–1792)** 362 (2–1710)** 379 (84–1302)
Female 436 (6–1020) 357 (6–2024) 374 (77–736)
CD4:CD8 ratio
Male 0.46 (0.01–2.57) 0.41 (0.01–1.92) 0.36 (0.07–0.73)
Female 0.50 (0.04–2.6)* 0.39 (0.02–1.21)* 0.53 (0.12–1.77)
*p < 0.05, **p < 0.001.
HIV SEQUENCE DIVERSITY AND TRANSMISSION IN WA 3
Phylogenetic analysis of subepidemic
transmission networks
We then undertook phylogenetic analysis of the 1,021
available HIV-1 pol sequences to investigate clusters of
highly related sequences likely to reflect linkage through
transmission networks. A radial representation of the phylo-
genetic analysis for all HIV-1 B (n = 619) and non-B subtypes
(n = 402: including intersubtype recombinants) from 2000 to
2014 is shown in Fig. 3, following maximum likelihood tree
construction utilizing MEGA v6. All phylogenetic clusters,
defined in this analysis by a bootstrap value ‡98% and genetic
distance £1.5%, are also represented in Table 2.
For the HIV-1 B subtype phylogenetic analysis (Fig. 3A)
paired transmissions, networks with more than two patients,
the subepidemic network of 53 patients and the subepidemic
FIG. 1. The HIV-1 subtype diversity distribution and proportions identified in Western Australia during 2000–2014,
represented according to four notification eras and an overall proportion.
FIG. 2. The proportion of males (A) and females (B) within HIV-1 B-subtype, non-B subtype, and recombinants represented
by the HIV notification era and the number of HIV sequences assessed by specific HIV-1 subtypes for males (C) and females (D).
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network of 12 patients are defined by the ‘‘diamonds’’,
‘‘circles’’, ‘‘star’’ and ‘‘cross’’ respectively. For the non-B
analysis (Fig. 3B) intersubtype recombinant forms are rep-
resented by the ‘‘suns’’.
Of the 619 HIV-1 B subtype sequences analyzed, 56
clusters were identified incorporating 211 (34%) individuals
(Table 2). Among the 402 non-B sequences, 69 (18%) fell
into one of 32 clusters. Non-B subtype phylogenetic clusters
were characterized by a larger proportion of pairs (28/32
clusters; 87.5%) compared to B subtype clusters (38/56
clusters; 68%: p < 0.05). Conversely, more individuals with B
subtype HIV-1 infection were identified within larger net-
works (cluster size >2) than non-B-infected patients (135/
211; 64% vs. 13/69; 18.8%; p = 0.001).
Including gender in this analysis (Supplementary Table
S2), we found 53 male only clusters (60.2%), 31 male and
female clusters (35.2%), and four clusters represented by
females only (4.6%). The majority of B subtype clusters were
composed of males only (45/56, 80.4%) while the majority of
C subtype clusters included males and females (11/15, 73%).
Within the CRF01_AE subtype we noted both male-only
clusters (6/15, 33%) as well as a larger proportion of female
and male clusters (8/15, 53%). Larger phylogenetic clusters
of males (cluster size ‡3) were identified predominantly
within the B subtype (15/56 clusters: 26.8%), while only
two male-only clusters with ‡3 subjects were identified
within non-B subtypes (CRF01_AE, 13%). These findings
are consistent with HIV-1 B subtype transmission within
networks of men who have sex with men (MSM), while the
HIV-1 C subtype was predominantly associated with het-
erosexual transmission. For CRF01_AE clusters the mode of
transmission was either MSM or heterosexual contact.
The largest subepidemic network was represented by a
group of patients with B subtype infections. This network
was established in 2008 with three patients and evolved to
53 patients by 2014 (Fig. 4), including one female and 52
males, with a median age of 40 years (range = 19–61 years).
This network is defined by the presence of a minor non-
nucleoside reverse transcriptase inhibitor (NNRTI) drug re-
sistance mutation K101Q (present in all sequences) and the
FIG. 3. A radial representation from the phylogenetic analysis performed on HIV-1 partial pol sequences (protease and
reverse transcriptase) for all HIV-1 B (A) and non-B (B) subtype samples genotyped during 2000–2014 [diamonds = pairs
(n = 66, 132 patients), star = a cluster of 53 patients, cross = a cluster of 12 patients, circles = clusters > 2 (n = 22, 82 patients),
suns = intersubtype recombinants and singletons].







with ‡3 subjects (n, %)
Number of clusters
2008–2014 (n, %)
B 56 (64) 38 (68) 18 (32) 30 (54)
CRF01_AE 15 (17) 12 (80) 3 (20) 12 (80)
C 15 (17) 14 (93) 1 (7) 10 (67)
Others 2 (2) 2 (100) 0 (0) 0 (0)
Total 88 66 (75) 22 (25) 52 (59)
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minor PR drug resistance mutation, L10F, which emerged
during the end of 2011 into 2012 in 6/53 patients. Interest-
ingly, the network of 53 patients is characterized by a higher
baseline viral load (Fig. 5A: p = 0.01) and CD4 count (Fig.
5B: p = 0.001) than ungrouped patients. This network ex-
panded in 2014 (12 new cases) despite high proportions of
early diagnoses (25% with acute HIV-1 serology) and treat-
ment uptake (76% with viral load <40 copies/ml by 2014),
although three patients (two notified in 2013 and one in 2014)
had a CD4 T cell count <55 cells/ll and HIV-1 viral load
>750,000 copies/ml at the time of notification, indicating
delayed HIV-1 diagnosis.
A second large subepidemic, involving males only,
emerged in 2008 as two similar sequences, increasing to four
patients by 2010 and then to 12 cases by 2014 (median age:
31.5 years, range: 20–67 years). The minor PR drug resis-
tance mutations L33I and A71T are seen in all sequences for
the subepidemic network with 12 patients. We have identified
only four smaller networks within the non-B subtypes
(CRF01_AE and C subtype; three to five patients/network)
established after 2010.
To investigate temporal patterns for the formation of clus-
ters overall, we determined the notification date of the second
sequence into the cluster. This revealed a more recent evolu-
tion of clusters within the CRF01_AE HIV-1 subtype (80% of
clusters since the beginning of 2008) compared to C subtype
(67%) and B subtype clusters (54%). To explore any potential
bias associated with HIV-1 drug resistance profiles we re-
moved drug resistance sites from all sequences. We addi-
tionally included sequences from the Swiss HIV cohort study
(n = 173) to determine if geographically and temporally distant
sequences would cluster with local sequences. Both ap-
proaches did not significantly alter the results of the underlying
clustering analysis. Finally, we also included a number of
multiple time point sequences from 30 patients. The samples
with the same identifier clustered within the conserved criteria
approach of BS ‡98% and GD £1.5% (data not shown).
HIV-1 intersubtype recombinants
Of the 1,021 samples analyzed in this study 38 (3.4%) were
intersubtype recombinants (Supplementary Table S3). Of
these 18 (47.4%) have been identified during the period
2011–2014. Of all recombination events present in our co-
hort, half of them (19/38) are intersubtype recombinants
between non-B HIV-1 subtypes. The main HIV-1 recombi-
nant forms represented in the Western Australian cohort were
A/CRF01_AE (6/38; 15.8%) and D/B (5/38; 13.1%). Three
patients with an A/CRF01_AE subtype clustered tightly to-
gether (BS 100%, GD <1.0%).
Influence of HIV-1 subtype and phylogenetic clusters
on viral load and CD4 T cell count at diagnosis
When we assessed CD4 T cell counts and plasma HIV-1
RNA levels for C and CRF01_AE subtypes within each no-
tification period we found an association with reduced CD4 T
cell counts (Fig. 5C, p < 0.001) and CD4:CD8 ratios at noti-
fication ( p = 0.02) compared to HIV-1 B subtypes. In con-
trast, HIV-1 subtype was not associated with differences in
plasma HIV-1 RNA levels ( p = 0.31).
We also observed a progressive increase in the plasma
HIV-1 RNA level at diagnosis over calendar time, increasing
from 18,620 copies/ml in 2000–2003 to 75,858 copies/ml in
2012–2014 (Fig. 5D: p < 0.001). This was not associated with
any evidence of a trend in CD4 T cell count ( p = 0.1) or the
CD4:CD8 ratios ( p = 0.2) over time. Examining these results
in terms of gender and HIV-1 subtype, we found no signifi-
cant associations between baseline viral load and HIV-1
subtype or age in females ( p > 0.1), although males with non-
B HIV-1 subtype were found to have significantly higher
baseline viral load results than males with B subtype (57,550
copies/ml vs. 37,150 copies/ml: p = 0.028) regardless of age.
Overall multivariate regression analysis revealed that base-
line plasma HIV-1 RNA levels were positively associated with
calendar time ( p < 0.001; b 0.20), male gender ( p = 0.003;
b 0.23), age ( p = 0.04; b 0.01), membership of a phylogenetic
cluster of size >2 ( p = 0.03; b 0.06), and lower CD4 T cell
count ( p < 0.001; b -0.01). In contrast, a higher baseline CD4
T cell count was associated with HIV-1 B subtype ( p = 0.005;
b -0.09), lower HIV viral load ( p < 0.001; b -0.31), and
younger age ( p < 0.001; b -0.12) as well as membership of a
cluster of size >2 ( p < 0.001; b 0.12) (Fig. 6).
Discussion
This study has identified increasing genetic diversity of
HIV-1 in Western Australia over the past 15 years, with
significant increases in HIV-1 non-B subtype sequences over
the study period, although HIV-1 B subtypes remain mar-
ginally dominant. These findings correspond to previous
studies that have noted increasing heterosexually acquired
HIV notifications in the Western Australia cohort including a
50% increase in HIV notifications among heterosexual wo-
men since 2006.19 The relative increase of HIV-1 C and
CRF01-AE subtypes in the Western Australian HIV cohort
has also been observed in other Australian studies.15,20 These
non-B subtypes are known to be from regions where HIV-1 is
highly prevalent and corresponds with the increased migra-
tion from sub-Saharan African regions (subtype C) and
overseas travel to Southeast Asia (subtype CRF01_AE).
The phylogenetic analysis performed in this study, based
on a previously described approach,12 provides a conserva-
tive estimate of likely transmission networks within the
FIG. 4. A large WA cluster (n = 53) showing clinical dy-
namics over time including indeterminate 4 Western blot,
HIV-1 RNA <40, and CD4 T cell counts <350.
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FIG. 6. Multivariate re-
gression results showing sig-
nificant associations of HIV
clinical parameters (HIV-1
RNA and CD4 T cell counts)
with notification era, age,
cluster group, gender, and HIV
subtype.
FIG. 5. Dynamics of the earliest HIV-1 RNA (A, D) and earliest CD4 T cell count (B, C) for sequences within a cluster
group (A, B) or defined by HIV subtype (C, D).
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Western Australian cohort. The results reveal more pairs and
large networks within the B subtype analysis, which remain
largely confined to male groups. In contrast, phylogenetic
clusters within the C subtype analysis predominantly con-
sisted of female/male pairs, while in the CRF01_AE analysis
there were both male-only groups as well as female/male
groups. Larger transmission networks are largely confined to
the HIV-1 B subtype, and show significant associations with
higher HIV RNA levels and higher CD4 T cell counts at the
time of diagnosis but not with age or gender. These findings
suggest that larger networks are expanding despite early di-
agnosis (many in the acute phase of infection) and high
treatment uptake, in keeping with a U.S. study in which large
cluster size was associated with higher CD4 counts (>350
cells/ll) and HIV RNA levels (>10,000 copies/ml). This U.S.
study also reflects the network patterns identified here, in
which a small number of large networks exists along with
small defined networks and pairs.14
These data suggest that local HIV-1 transmission is still
dominated by B subtype viral strains, mostly within male
networks. The introduction of increasing non-B subtypes into
Western Australia, in keeping with increasing immigration
and overseas travel, does not appear to be associated with a
noticeable rise in local transmission of non-B HIV-1, apart
from an emerging pattern of onward transmission of
CRF01_AE within male networks. We were also interested to
observe a pronounced temporal trend in viral load measure-
ments at the time of diagnosis in this study, irrespective of
HIV-1 subtype. A similar trend has been identified in a meta-
analysis of >30,000 individuals spanning the years 1984–
2010,21 raising the possibility that HIV-1 replicative capacity
(‘viral fitness’) is increasing over time, and that higher viral
load levels represent a virological risk factor for membership
of larger transmission clusters.
While the HIV-1 subtype does not influence viral load
measurements in this study, we did note that baseline CD4 T
cell counts were lower among those with non-B HIV-1 sub-
types, including both C and CRF01_AE subtypes, with a
mean difference of *80 cells/ll in both males and females
compared to those with B-subtype HIV-1. It is conceivable
that this reflects the increased virulence of non-B HIV sub-
types with greater loss of CD4 T cells as a consequence.
For example, CXCR4 tropism, which has been associated
with rapid disease progression,22,23 is associated with the
CRF01_AE subtype23,24; however, in contrast, C subtype
HIV-1 has a lower CXCR4 virus than B subtype25 with a
slower CD4 T cell decline in patients with a C subtype26
unless failing HIV therapy.27 In the context of this study, a
more likely explanation is that diagnosis of HIV-1 is delayed
among those with non-B HIV-1 infection in Western Aus-
tralia, due in part to the fact that HIV-1 screening is not un-
dertaken among migrants entering Australia with temporary
visas, and diagnosis is therefore often delayed until a per-
manent visa application is undertaken or until medical care is
required for symptomatic disease or pregnancy.28 In this re-
gard, a study involving the provision of HIV treatment to
Medicare-ineligible migrants in Australia has also noted re-
duced CD4 T cell counts within this population compared to
the overall Australian HIV Observational Database.29
This study has the advantage of full assessment of baseline
HIV-1 pol sequencing performed within the Royal Perth
Hospital laboratory between the years 2000 and 2014, in-
cluding 1,021 HIV-positive individuals. With regard to
phylogenetic analysis and the classification of HIV-1 trans-
mission networks, we acknowledge that this approach has
limitations associated with viral divergence over time as well
as uncertainty regarding the appropriate bootstrap values and
genetic distance thresholds that are utilized to define clusters.
We therefore applied relatively stringent clustering criteria
(bootstrap value ‡98%, genetic distance £1.5%) in order to
provide a conservative estimate of phylogenetic clusters as
utilized in other studies.9,10,12 We also undertook sensitivity
analyses including the incorporation of a group of sequences
from a geographically distinct B subtype cohort, and removal
of drug resistance sites from all sequences to remove any
potential bias associated with HIV-1 drug resistance profiles.
These approaches did not alter the results of the underlying
clustering analysis.
Overall, this study identifies a number of temporal trends
that are relevant to the evolution of the Australian HIV-1 ep-
idemic over the past 15 years. We have identified an increasing
prevalence of HIV-1 non-B subtypes over this period, from
23% in 2000–2003 to more than 40% from 2012 onward. This
reflects an increased ‘‘importation’’ of HIV-1, particularly
from sub-Saharan African and southeast Asian countries, in-
cluding migrants28,29 as well as Australians who have travelled
to these destinations for business and tourism.30,31 These
findings are not unique to Western Australia, and it is notable
that similar observations have been made in Victoria15 and
South Australia.20 These data also provide reassurance that
onward transmission of non-B subtype HIV-1 within local
networks remains uncommon, despite evidence for delayed
diagnosis of HIV-1 in this population. On the other hand, we
have observed the evolution of large local transmission net-
works of B-subtype HIV-1 despite relatively high rates of early
diagnosis and treatment within local networks. The observa-
tion of increasing baseline viral load measurements over cal-
endar time suggests that viral factors may be influencing this
trend, within an overall framework that argues for a range of
preventive measures beyond ‘‘test and treat’’ approaches to
reduce HIV-1 transmission within Australia.32
The overall findings of this study highlight the cooperative
approach that is required to effectively prevent new HIV
cases in Australia, involving an increased appreciation of the
role played by travel and immigration (and immigration
policy), and the associated increased role of heterosexual
HIV-1 transmission in this context. At the same time, these
data indicate that local transmission within MSM networks
remains a challenging issue for HIV-1 prevention.
Sequence Data
The sequences used in this study have been deposited into
GenBank under the following accession identifications:
Western Australian sequences KT228338–KT229359.
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Additional supplementary data for the manuscript in Chapter 5. 
Supplementary Table S1: HIV-1 Protease and Reverse Transcriptase primer sequences. 
1st Round PR-RT amplification primers:   
PR2056- 5’TGAAAAAGTGTACTGAGAGACAGGR 
RT3.2Outer- 5’CAGGAAACAGCTATGACCACTTCTGTATGTCATTGACAGTCC 
Alternative 1st Round PR and RT amplification primers:  
PR5A- 5’TGTAAAACGACGGCCAGTCAGAGCCAACAGCCCCACCA 
PR3A- 5’CAGGAAACAGCTATGACCTTTCCCCACTAACTTCTGTATGTCATTGA 
RT5'Outer- 5’CCATTAGCCCTATTGAGACTGTACCAG  
RT3.2Outer- 5’ CAGGAAACAGCTATGACCACTTCTGTATGTCATTGACAGTCC 
Second round RT primers:  
RT5'Inner94-M13F- 5’TGTAAAACGACGGCCAGTTAAAGCCAGGAATGGATGGCCC  
RT3'Inner94-M13R- 5’CAGGAAACAGCTATGACCGATGGAGTTCATAACCCATCC  









Supplementary Table S2: The distribution of HIV-1 clusters according to subtype, cluster 











Total # of 
clusters 
B 2 30 7 1 38 
13 
5 
3-5 12 1 0 
>6 3 2 0 
CRF01_AE 2 4 7 1 12 
3 
0 
3-5 2 1 0 
>6 0 0 0 
C  2 2 10 2 14 
1 
0 
3-5 0 1 0 
>6 0 0 0 
Others 2 0 2 0 2 
0 
0 
3-5 0 0 0 
>6 0 0 0 






Supplementary Table S3: HIV-1 inter-subtype recombinants identified 2000-2014 (n=38) 






B CRF01_AE C A CRF02_AG D K F 
B  3 3   5  3 
CRF01_AE 2   6 1 1   
C 2   1   3  
A  3   2  1  
G     1    














Summary for Chapter 5: 
The identification of extensive HIV-1 diversity within the Western Australian HIV cohort, 
along with the recent evolution of increased numbers of clusters and large networks has 
highlighted several challenges in HIV-1 prevention, including delayed diagnosis among HIV-
1 non-B-subtypes, namely migrants and overseas visitors. Although HIV-1 B subtype 
remains the dominant viral strain, this study highlights the more recent evolution of clustering 
pairs within the C and CRF01_AE subtypes since 2008, which are highly prevalent in sub-
Saharan Africa and south east Asia respectively, reflecting a role of overseas travel to these 
areas and the importation of HIV-1 into Western Australia through heterosexual and MSM 
contact. We have also identified a substantial increase in baseline HIV-1 RNA over time, 
including higher viral load levels within a large B subtype transmission cluster (identified 
through stringent phylogenetic analysis) that continues to expand despite frequent early 
diagnosis and high treatment uptake.  
HIV infection in Western Australia was once thought of as predominantly affecting young 
gay men. This analysis clearly shows a shift from this perception as indicated from the wide 
age range at the time of HIV diagnosis within the Western Australian cohort, from infants to 
76 year olds regardless of subtype groups (Figure 1). HIV-1 B subtype infection is still the 
predominant subtype among men while women are more likely to be infected with a non-B 
subtype. This also reflects an ageing Western Australian HIV cohort which is approaching a 
median age of 50 years. As indicated in Chapters 3 and 4, there are a number of important 
patient care considerations, namely the impact of age related comorbidities - particularly 
CVD, adding to the complication of HIV management.  
As stated in the preamble, by the end of 2013, 13 children within Australia had been infected 
with HIV through perinatal transmissions [3]. The age distribution plots below represent a 
high proportion of children, who reside in Western Australia, are infected with non-B 
subtypes, suggesting a link between imported HIV-1 viruses potentially through migration. 
Overall, the results shown in Chapter 5 identify a number of temporal trends that are relevant 
to the evolution of the Western Australian HIV-1 epidemic over the past 15 years. For this 
reason, in Chapter 6, HIV-1 subtype diversity and phylogenetic network characteristics 
within B and non-B subtypes will be investigated within an Australian HIV cohort. Keeping 
in line with Chapter 5, baseline HIV-1 partial pol sequences will be phylogenetically mapped 
using techniques outlined in Chapter 5 with the aim of highlighting any new challenges in 
HIV-1 prevention that may inform strategies to treat HIV and to end HIV-1 transmissions in 
Australia and potentially world-wide.  
 
 
Figure 1: The age distribution plots for patients in the Western Australian HIV cohort. This is 
stratified by HIV-1 non-B subtypes, including inter-subtype recombinants (A) and HIV-1 B 
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Introduction: Rates of new HIV-1 diagnoses are increasing in Australia, with evidence of an 
increasing proportion of non-B subtypes reflecting a growing impact of migration and travel. 
This present study aims to define HIV-1 subtype diversity patterns and investigate HIV-1 
transmission networks within Australia.  
Methods: The Australian Molecular Epidemiology Network (AMEN) HIV collaborating 
sites in Western Australia, South Australia, Victoria, Queensland and western Sydney, 
provided baseline HIV-1 partial pol sequence, age and gender information for a total of 4,873 
patients during 2005-2012. HIV-1 phylogenetic analyses utilised MEGA V6, with a stringent 
classification of transmission clusters (bootstrap ≥98%, genetic distance ≤1.5%). 
Results: HIV-1 B subtype represented 74.5% of 4,873 sequences (WA 59%, SA 68.4%, w-
Syd 73.8%, Vic 75.6%, Qld 82.1%), with similar proportion of clusters compared to non-B 
subtypes (23% vs 24.5% of sequences, p=0. 3), significantly more larger cluster size within B 
subtype (45.0% with >2 sequences vs 24.0% of non-B clusters, p=0.021) and more male-only 
groups (88%). HIV-1 subtype C networks (38 groups) included more female/male clusters 
(74%) and a smaller proportion of groups >2 (16%), while CRF01_AE networks (44 groups) 
included 59.1% male-only clusters, with groups >2 accounting for 22.7%. Factors associated 
with being in a cluster of any size include; being sequenced in a current time era and being 
younger (p<0.001), being male (p=0.023) and having a B subtype (p=0.02). Being in a larger 
cluster (>3) is associated with being sequenced in a current time era (p=0.05) and being male 
(p=0.008). 
Conclusion: This nationwide study of HIV-1, involving 4,873 patient sequences, highlights 
the increased diversity of HIV-1 subtypes within the Australian epidemic, as well as 
differences in transmission networks that are associated with these HIV-1 subtypes. These 
findings provide epidemiological insights not readily available using standard surveillance 
methods and can inform the development of effective strategies for prevention of new HIV-1 





HIV-1 is a genetic variable and rapidly mutating virus, with ongoing high rates of mutation 
and recombination associated with an error-prone and non-proofreading reverse transcriptase 
activity [1]. There are four distinct HIV-1 groups (M, N, O and P) of which the M group 
accounts for 90% of infections. Within the M group there are nine phylogenetically distinct 
subtypes (A-D, F-H, J and K) along with an increasing number of inter subtype recombinant 
forms, with 72 identified to date. The main HIV-1 subtypes have distinct geographical 
associations that can provide useful epidemiological information [2], although there is 
growing evidence of increasing subtype and inter-subtype HIV-1 genetic diversity in regions 
previously characterised by specific HIV-1 subtypes [3-6]. Globally, HIV-1 subtype C 
infection has the highest prevalence with strong associations with sub-Saharan Africa and 
India, followed by A subtype (east Africa) and B subtype (western Europe, United States and 
Australia); these jointly account for 70% of HIV infections [2,7]. Other major subtypes (F, H, 
J and K) have remained stable at low levels, accounting for around 1% of infections 
worldwide, whilst HIV-1 D-subtype has decreased over time [2]. Circulating recombinant 
forms of HIV-1 account for 20% of infections worldwide and have increased in proportion by 
17% during 2000-2007, although unique recombinant forms (URFs) have diminished by 
3.1% over time [2].   
Although HIV-1 subtype diversity is known to exist in Africa, where HIV infection has been 
long established [2,8,9], there is recent evidence of migration of previously geographically-
restricted HIV-1 subtypes to broader regions of the world [2,4-6,10,11]. This increasing HIV-
1 diversity may have important clinical implications given that HIV-1 subtypes have been 
associated with differences in disease progression [12-14], transmissibility [15,16] 
susceptibility to antiretroviral therapy [12, 17], HIV-1-specific immune responses relevant to 
in vivo infection and vaccine design [18], as well as risk of age-related diseases [19]. 
Importantly, increased HIV-1 subtype diversity including inter-subtype recombinant forms 
pose a challenge in HIV diagnostic laboratories, particularly pertaining to HIV-1 RNA assays 
where the accuracy of results may be influenced by sequence variation among non-B HIV-1 
subtypes [20]. 
Australia has a history of strong public health and clinical management strategies that have 
contributed to a low national HIV-1 prevalence of ~158 per 100,000, with ~26,800 people 
currently living with HIV [21]. Despite this, the number of new diagnoses in Australia has 
steadily increased over the past 13 years with a 26% increase in the population rate since 
2003, including 1,236 new cases in 2014 representing a 10% increase over the numbers 
diagnosed in 2011 [21]. This is set against an overall downward global trend in new HIV-1 
diagnoses, most notably in sub-Saharan Africa and also evident in the Asia Pacific region 
[22]. 
The HIV epidemic in Australia has previously been characterised by a high prevalence of   
HIV-1 B subtype in all risk categories [23-25]. Recently however, there has been a reported 
increase of migration by travellers [26] to and from areas where known HIV-1 diversity has 
been established or from areas where HIV-1 infections are increasing or highly prevalent 
[22,27,28] and among risk categories other than men who have sex with men (MSM) [27]. 
Given the ongoing rise in new HIV infections in Australia, investigating the distribution of 
HIV-1 subtypes in Australia may provide valuable information that can inform prevention 
strategies, while also ensuring that laboratory monitoring is appropriate for the local 
epidemic. This concept is supported by recent epidemiological studies of HIV-1 sequences 
that have shown marked increases in the prevalence of HIV-1 non-B subtypes and circulating 
recombinant forms (CRFs) [3,4,10]. 
Sequence analysis of the HIV-1 pol region remains the gold standard for drug resistant 
mutation classification due the class of antiretroviral therapies used to treat HIV-1, however, 
the same sequence can be utilised for HIV-1 subtype determination as well as phylogenetic 
analysis. Phylogenetic analysis of HIV-1 can be used to monitor sequence similarities, follow 
the introduction of new subtypes, and has increasingly been utilised to characterise 
transmission clusters and networks in order to trace the mobility of HIV-1 globally [29-31] 
including over time analyses [32-34] and within different risk groups [35,36]. This 
methodology has been applied at a global scale to study transmission networks [29] and to 
investigate the role travel plays in the spread of HIV-1 within Europe [6, 33], the United 
States [32] and the United Kingdom [35]. These approaches are useful to gain a better 
understanding of sequence dynamics which is proving essential for real time HIV-1 
surveillance and potentially suitable to prevent further HIV infections. 
In order to provide a national population-based platform for these analyses, we have 
established a collaborative network of all Australian HIV-1 sequencing laboratories, which 
together provide accredited HIV-1 sequencing for clinical management throughout all 
Australian states and territories. This network has been identified as the Australian Molecular 
Epidemiology Network (AMEN). In this study, we have performed a retrospective analysis of 
predominantly baseline (pre-treatment) HIV-1 sequences to determine the subtype 
distribution and phylogenetic structure of HIV-1 within Australia during the period 2005-
2012, with the aim of supporting rational, evidence-based approaches to prevent, treat and 
monitor HIV-1 infection within Australia and its linked transmission networks. 
MATERIALS AND METHODS 
Sample population and dataset collation: This study was conducted within the framework 
of the Australian Molecular Epidemiology Network (AMEN). The AMEN is a collaborative 
network formed to include HIV laboratory services across Australia (Western Australia, 
South Australia, Victoria, Queensland and New South Wales: represented in this study by 
western Sydney). Samples notified in the Northern Territory and in Tasmania were also 
represented in the dataset as sequencing was conducted through Victoria. State and national 
ethics and governance frameworks were established to include assessment of de-identified 
HIV-1 sequences where a unique identification number was assigned, along with the 
notification of each state, the year the sequence was performed, the gender and the age of the 
patient at the time of sequence. Data collection and analysis was performed on base line HIV-
1 plasma RNA samples analysed throughout Australia from 2005-2012 with the exception of 
Queensland where sequences from 2007-2012 were provided. In the case where multiple 
sequences were identified, the earliest sequence was determined to be the base line sequence 
for the analysis. A total of 4,873 sequences were assessed and stratified over 4 time eras 
based on the year of sequence (2005-2006, 2007-2008, 2009-2010 and 2011-2012).   
HIV-1 subtype determination: Protease (PR, positions 1-99 in HXB2) and reverse 
transcriptase (RT, positions 20-240 in HXB2) sequences were amplified according to each 
state using in-house techniques (Western Australia [37], South Australia [38], Victoria [39], 
and western Sydney) or commercially available methods (Queensland; Viroseq HIV-1 
Genotyping System, Abbott Celera). The HIV-1 subtype determinations were assigned by 
each state by submitting the fasta files to the calibrated population resistance tool linked to 
the Stanford calibrated HIV database (http://hivdb.stanford.edu/) with the exception of 
Victoria who submitted to the Los Alamos database (http://www.hiv.lanl.gov). For the 
assessment of inter-subtype recombination sequences, all sequences were submitted to four 
alternative phylogenetic analysis tools including COMET, SCUEAL, pgHMM and REGA. A 
consensus was assigned when 3 or more tools (including Stanford) obtained the same HIV-1 
subtype result.  
All laboratories sequence assays were monitored for quality according to the National 
Association of Testing Authority (NATA), Australia accreditation standards and subjected to 
quality control procedures and the Royal College of Pathologists of Australasia (RCPA) or 
alternative quality assurance programs. 
HIV-1 phylogeny approach: Sequence alignments and processing: Data collation and 
analysis was performed on all de-identified samples at one site (Western Australia). This 
process involved utilising the BioEdit tool [40], for sequence alignments and assessing 
sequences quality, while the Molecular Evolutionary Genetics Analysis Version 6 (MEGA 
V6) phylogenetic tool [41], was used to construct the phylogenetic tree and infer clustering 
patterns of similar sequences as previously described [33]. 
Characterisation of sequence similarities pertaining to clusters: In keeping with previous 
analyses we removed drug resistance sites then defined clustering patterns of similar 
sequences according to the following conservative approach: (1) paired sequences where two 
sequences group together according to the criteria where the bootstrap (BS) value was ≥ 98% 
and the genetic distance (GD) was ≤ 1.5%; and (2) a “cluster or network” where more than 
two sequences had a BS value of ≥ 98% and a GD ≤ 1.5%. 
Statistical analysis: Statistical data analysis of demographic was performed using Statistical 
Package for the Social Sciences version 21.0 (SPSS v21: Armonk, NY: IBM Corp). Data 
distribution was assessed for normality then subjected to statistical analysis using T tests, 
ANOVA and post hoc tests with correction for multiple comparisons in multivariable 
analyses. Results were considered statistically significant when P-values <0.05. 
RESULTS 
Data distribution within the AMEN HIV-1 cohort: The baseline HIV-1 sequence 
contribution from each Australian state from 2005-2012, and the corresponding subtype 
diversity for 4,873 sequences are shown in Table 1. Samples submitted by Victoria (n=1,668, 
34%) and Queensland (n=1,579, 32%) account for 66% of the total samples for the study 
while Western Australia (15.5%), Western New South Wales (11%) and South Australia 
(7.5%) account for 44% of the sequences. Overall, 3631 (74.5%) of HIV-1 patients were 
infected with subtype B virus while 1,242 (25.5%) were infected with non-B viruses 
including A, C, D F, G, CRF01_AE, CRF02_AG subtypes and other inter-subtype 
recombinant forms. Males were more likely to be infected with HIV-1 (n=4,203, 86%) than 
females (n=648, 13%), as described in Table 2 however females were more likely to be 
infected with non-B subtype viruses compared with males (females: 436/648, 67% versus 
males: 796/4,203 19%, p<0.0001). Females with a non-B subtype were on average six years 
younger than non-B males (females: 32.5 years vs males: 38.5 years) and 3.8 years younger 
than females with a B subtype (gender difference p< 0.001; viral subtype difference 
p=0<0.001) while females with a B subtype were approximately three younger than males 
with a B subtype (females: 36.3 years vs males 39.2 years, gender difference p< 0.001). 
HIV-1 subtype diversity distributions from 2005-2012: As shown in Figure 1, a substantial 
increase in the proportion of HIV-1 non-B subtypes has been demonstrated within each state 
over time, with Western Australia having higher baseline non-B sequences in the earliest time 
era (32.3% in 2005-2006), rising to approximately 48% in the period 2011-2012. 
Interestingly, the substantial increase in HIV-1 non-B subtypes observed in South Australia, 
western Sydney and Queensland occurred during 2009-2010 while Victoria showed a steady 
increase from 2007-2012. Overall Queensland had the lowest proportion of non-B subtypes 
in the study (21%) while Western Australia had the most (48%). 
 
Figure 1: HIV-1 subtype distribution in Australia over time. Four eras, 2005-2006, 2007-
2008, 2009-2010 and 2011-2012 show the changing subtype distribution for 4,873 sequences.
Table 1: Contribution toward the AMEN epidemiological and diversity study, by state, showing HIV-1 subtype characteristics and baseline 
sequence information. 
State Method Year 
Sequence 























































Total   4873 3631 484 475 88 21 128 46  
 
Each state was represented by a range of HIV-1 subtypes including B, C, D, CRF01_AE, 
CRF02_AG subtypes and other inter-subtype recombinant forms as shown in Figure 2. There 
are proportionally more C (15.1%) and CRF01_AE (19.2%) subtype sequences in Western 
Australia, more B subtypes (82%) sequences in Queensland and more CRF02_AG (5.7%) 
subtype sequences in South Australia than other states while inter subtype recombinant forms 
are represented in all states (discussed below).  
 
Figure 2: The distribution and proportion of HIV-1 subtypes present in each Australian state. 
The pie graphs represent the proportions while the table shows the proportion for each state 
per HIV-1 subtype. 
 
Phylogenetic analysis: Overall we identified 1,135/4,873 sequences (23%) that were 
classified within a phylogenetic cluster, with no differences in the proportion of B versus 
non-B subtype sequences in a phylogenetic cluster (B subtype 829/3,631 (23%); non-B 
subtype 306/1,242 (24.5%), p=0.3). The phylogenetic trees based on HIV-1 partial pol 
sequences of B subtypes and non-B subtypes are represented in Figure 3A and 3B 
respectively. From the total number of pairs and clusters with more than two sequences 
(n=419) there were 286 paired sequences, 115 clusters with 3-5 sequences,  17 clusters with 
6-13 sequences and one outlying cluster consisting of 29 related sequences.  
Table 2: Demographics for HIV-1 B subtype, non-B subtypes and sequences in a network including age, gender, AMEN centre and sequencing 
era.  
Characteristic All sequences B subtype Non-B 
subtype 
Sequences in a 
network (%) 
Sequences not in a 
network (%) 
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Figure 3: The phylogenetic tree constructions based on HIV-1 pol sequences for (A) HIV-1 B 
and (B) non-B subtypes assessed in the AMEN study. Each branch colour represents a state 
(Western Australia (black), South Australia (red), Victoria (blue), western Sydney (green) 
and Queensland (maroon). 
 
Analysing these results further in terms of subtype distribution, we found proportionally more 
pairs (two similar sequences) within the C subtype analysis (77%; Figure 4A) compared to 
those within the CRF01_AE or B subtype analysis (64%; Figure 4B and 47%; Figure 4C), 
along with significantly more non-B pairs than non-B larger clusters (>2 similar sequences: 
94 vs 29, p=0.003) and significantly more larger clusters with a B subtype than a non-B 
subtype (45% vs 24% p=0.021). 
At a national level, the dynamics of gender distribution within clusters are remarkably 
different between HIV-1 B, CRF01_AE and C subtypes (Figure 5A, Anova: p<0.001). We 
show, as expected, a higher proportion of B subtype sequence clusters include only males 
(88%) compared to CRF01_AE and C subtype (53% and 17% respectively). Significantly 
more C subtype clusters include both males and females (74%) compared to CRF01_AE 
(39%) and B subtype clusters (11%).  
The analysis of B and non-B subtype clusters according to gender can be further assessed by 
a “state by state” approach. Within the HIV-1 B subtype (Figure 5B), most states have high 
proportions of male-only clusters (>84%), with Victoria registering the highest proportion 
(95%), however South Australia and western Sydney have lower proportions of male-only B 
subtype clusters (64% and 68% respectively) due to higher proportions of male/female 
clusters (36% and 18% respectively).  
 
Figure 4: Differences in the distribution and proportions of pairs and larger cluster size for 
HIV-1 subtypes; HIV-1 C subtype (A), CRF01_AE subtype (B) and B subtype (C) (excludes 
singletons). 
When assessing the non-B cluster dynamics, surprisingly, Victoria has a larger proportion of 
male only non-B clusters (63%) followed by Queensland (44%) than other states (Figure 5C). 
Conversely, western Sydney, Western Australia and South Australia experienced the highest 
proportion of non-B males clustering with females (73%, 67% and 65% respectively) 
followed by Queensland and Victoria (49% and 32% respectively). More non-B female only 
clusters were represented in South Australia (13%) than in any other state. 
Analysis of large sub-epidemic HIV-1 clusters: In the large sub-epidemic cluster analysis 
we found five distinct clusters with more than nine similar sequences represented per cluster. 
The largest sub-epidemic cluster was represented by sequences within HIV-1 B subtype 
analysis. This cluster was initially established in 2008 by three similar sequences then 
evolved to 29 patients by 2012. All sequences were from males, including 27 sequences from 
Western Australia and two from Victoria, with a median age of 47.5 years (range 23-70). The 
overall mean genetic difference for this cluster was 0.3% (range, 0.2%-1.2%) with a 
bootstrap value of 99%. Other B subtype clusters include two clusters of 10 sequences, one 
cluster of 11 sequences (all male only clusters and all from Victoria) and one male/female 
cluster of ten sequences which included sequences from three states (Western Australia, 
South Australia and Victoria), with 80% of the sequences notified in South Australia. 
 
Figure 5: Gender distribution within clusters according to HIV-1 subtypes (A) and for 
clusters in each state with B subtype (B) or a non-B subtype (C). 
Factors influencing large HIV-1 networks of similar sequences: We employed a 
multivariate regression analysis to show factors associated with being in a cluster of two or 
more similar sequences and furthermore, factors associated with being in a large cluster (>3 
sequences), with both analyses excluding children <18 years of age. 
The analyses identifying factors with being in a cluster (regardless of size) are presented in 
Figure 6A and show, overall at a national level, associations with being younger (β -0.003; 
p<0.001), having a sequence performed during later era (β 0.05; p<0.001), being male (β -
0.01; p=0.023) and having a B subtype (β -0.05; p=0.021) however no associations with 
Australian states were found (β 0.01 p=0.4). Differences within each state revealed age was 
associated with being in a cluster for sequences from Western Australia, western Sydney and 
Queensland, while being sequenced in the current era was a significant factor for being in a 
cluster for all states besides western Sydney. Being male was a significant factor for being in 
a cluster in Victoria while, interestingly, having a non-B sequence was associated with being 
in a cluster in Queensland but not in a large cluster size (>2). 
When we assessed factors associated with being in a larger cluster only (>3 sequences in a 
cluster) compared with smaller clusters of two or three sequences (Figure 6B), we found a 
weak association with having a sequence performed during later era (β 0.03; p=0.05) and a 
strong association with being male (β -0.12; p=0.008). In Western Australia, having an HIV-1 
B sequence (β -0.34; p<0.001) and being sequenced in a current era (β 0.09; p=0.004) were 
associated with larger cluster size. Age was associated with large cluster size in western 
Sydney (β -0.01; p=0.04) and Queensland (β 0.006; p=0.01) while being male was a 
significant factor in Victoria (β -0.4; p<0.001). There were no factors associated with large 
cluster size in South Australia. 
 
Figure 6: Multivariate regression analysis reveals factors associated with a sequence being 
classified into (A) a cluster regardless of cluster size or as a singleton or (B) only sequences 
in larger networks where the sequence size equals 2-3 or >3. All results are for >18yo 
(Coefficient and significance are shown). 
 
Phylogenetic clusters within and between Australian states: Monitoring sequence 
similarities within and across state boundaries was assessed within both the HIV-1 B and 
non-B subtype analysis (data not shown). Sequences from Victoria were more likely to 
cluster with sequences from other states regardless of being a B or non-B subtype (72/190 
sequences (38%) and 18/52 sequences (35%) respectively), followed by Western Australia (B 
subtype 49/190, 26%) and Queensland (non-B subtype 13/52, 25%). Overall we showed the 
least migration of non-B sequences from Western Australia and South Australia and B 
sequences from South Australia and western Sydney. 
Analysis of HIV-1 inter-subtype recombination sequences: Inter-subtype recombination 
sequences were identified from partial pol sequences using the Stanford HIV database tool 
for all states as shown in Figure 2. The highest proportions were observed in sequences from 
Western Australia (3.2%) followed by Victoria (2.9%). By applying 4 alternative 
phylogenetic subtype assigning tools (COMET, SCUEAL, jpHMM and REGA) to the 128 
inter-subtype recombinants and five pure subtypes identified using Stanford and the large 
branch of divergent sequences (n=69) highlighted in Figure 3A, a consensus subtype was 
generated (Table 3). The results show we identified 45.5% (92/202) of the sequences 
differing to the results generated from Stanford while for 41% (83/202), no consensus was 
reached when applying the alternative tools. Only 13.5 % (27 sequences) generated the same 
results as Stanford. 
The divergent branch of B subtype sequences (generated via Stanford tool) had disparate 
results when compared the consensus results including 39/69 (56.5%) having a C, 
CRF01_AE or A subtype, 25/69 (36.2) did not reach consensus and 5 were assigned as an 
inter-subtype recombination. 
DISCUSSION 
The outcomes of this study highlight an HIV-1 epidemic in Australia that is characterised by 
an increasing prevalence of non-B HIV-1 infections as well as increasing overall HIV-1 
subtype diversity. The dominant non-B subtypes, C and CRF01_AE, identified here reflect 
the main subtypes represented among the sub Saharan African and south east Asian 
populations, with phylogenetic analysis indicating that these non-B HIV-1 subtypes are more 
likely to involve heterosexual HIV-1 transmission networks. Similar proportions of HIV-1 C 
subtype infections among males and females in this study is consistent with the distribution 
of heterosexual transmissions documented in the sub Saharan Africa region [42] while the 
increase proportions of females and males infected with CRF01_AE subtype correspond to 
patterns of heterosexual and increasing MSM transmissions and injecting drug use (IDU) 
present in south east Asia [43].   
Although in the overall analysis we identified 25.5% of non-B subtypes, which is lower than 
observed in North America [4], Europe [6] and Belgium [44], the impact of time on the 
change of non-B HIV-1 subtype proportions for each Australian state highlights interesting 
patterns. Western Australia recorded higher baseline non-B sequences early in the analysis 
reflecting an earlier increase of overseas migration patterns than in other states, however the 
other states in Australia soon followed the pattern albeit at lower proportions. This could be 
attributed to by the economic surge in Western Australia during 2005-2012 and also due to a 
noticeable increase in overseas tourism to Asian countries. During 2006-2011 many overseas 
migrants that settled Western Australia were from South Africa [45] where C subtype 
dominates [9]. More recent supporting data identified Thailand, Malaysia, China and India as 
being in the top 10 main countries where increased visitor arrivals into and resident departure 
from Australia [26] were recorded. A recent report also documented human mobility of 
CRF01_AE subtype into countries previously identified with low rates of CRF01_AE 
transmissions, has traced and confirmed these from Asian countries [30]. By the end of the 
study period the proportions of HIV-1 non-B subtypes identified in Western Australia 
reflected the increased diversity seen in other countries [4,44]. 
This study highlights the growing contribution of migration and travel – both within Australia 
and overseas – to increased HIV-1 subtype diversity within Australian states and at a national 
level. This is consistent with evidence of sharp increases in HIV-1 subtype diversity in the 
United States [4,32,46] and Europe [3,33-35]. Several previous investigations from Australia 
have also recognised the evolution from an early epidemic characterised by predominantly B 
subtype HIV-1 with limited genetic diversity [23] to recent studies showing increased HIV-1 
non-B subtype diversity in Australia [38,39]. 
HIV-1 phylogenetic analysis provides an important objective resource for dynamically 
assessing new HIV infections and monitoring geographical changes in the global HIV 
epidemic. In this study, in which we classified phylogenetic clusters using a conservative 
approach that required low genetic distance between sequences (≤1.5%) as well as high 
bootstrap values (>98%), distinct transmission network patterns for B, C and CRF01_AE 
subtypes were revealed. 
Table 3: A comparison of Stanford HIV-1 subtyping results compared to the consensus reached from COMET, SCUEAL, jpHMM and REGA 
for pure subtypes and inter-subtype recombination. 
 Results from Stanford 
 
 
Same as the Consensus 
(n%) 
Different to the 
Consensus (n,%) 
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27 92 83 202 
As expected, more pairs and large networks were identified within male-only groups in the B 
subtype analysis, with higher proportions of male-and-female clusters in the C subtype 
analysis than in the CRF01_AE analysis.   
A state by state approach revealed distinct dynamics among transmission groups with higher 
proportions of male-only non-B subtype networks represented in Victoria indicating the 
likely establishment of local MSM transmission networks, while the large proportion of 
male-female pairs within non-B transmission networks in western Sydney, South Australia 
and Western Australia suggest limited forward transmission into local networks.  
The observation of a distinctively large and expanding B subtype male network, established 
in 2008 with three patients and evolving to 29 by 2012,  is in line with other epidemiological 
studies [6,44] showing one distinct large population among smaller pairs and networks. The 
impact of this requires further exploration particularly in terms of assessing clinical 
parameters, viral fitness and targeting strategies given a recent US study showed large cluster 
size was associated with CD4+ T cell counts >350 cells/μl and HIV-1 RNA levels >10,000 
copies/mL [32]. This observation is also supported by a recent study within Western 
Australia [37], identifying challenges as well as opportunities to prevent local transmissions 
within the MSM networks.  
The analysis of inter-subtype recombination sequences along with the divergent B subtype 
sequences using COMET, SCUEAL, pgHMM and REGA programs revealed similar findings 
to previous studies, suggesting that no single online tool could accurately subtype 100% of 
the sequences [47]. Each tool performed slightly differently due to unique methods and 
algorithms including differences in access to up-to-date reference sequences. The findings 
from our study support this, as we obtained an overall consensus result of 59.2% which 
diminished to 13.5% when comparing results to the Stanford calibrated tool only.  
Phylogenetic, statistical and similarity-based tools worked well for the identification of more 
common HIV-1 subtypes present in Australia such as B and C and CRF01_AE [47-49], 
however they may be problematic when identifying super infections [50]. 
Understanding patterns associated with HIV-1 subtypes within Australia is of significant 
interest as increased HIV-1 diversity pose new challenges to molecular laboratories as well as 
potentially having unfavourable clinical implications. Inaccurate HIV-1 RNA quantitation on 
non-B subtypes, mostly due to genetic variation at primer sites, has previously been reported 
[20] and this can have adverse outcome on disease progression, effective monitoring of 
treatment and potentially risk of transmissions from mother to child. For these reasons 
thorough evaluation of HIV-1 RNA viral load assays in light of local HIV-1 sequence 
diversity is imperative for laboratories to offer an optimal service. Increased risk of drug 
resistance has been shown in non-B subtypes when treated with integrase inhibitors [51], 
while concerns regarding the potential failure of NNRTI/NRTI treatment within HIV-1 C 
subtype infection has also been described [17]. Overall there are many major drug resistant 
mutations observed in different HIV-1 subtypes and these require careful consideration in the 
context of increasing non-B subtype diversity [52]. HIV-1 D subtype, inter-subtype 
recombinants [13,14] and CXCR4 tropism [16] have been shown to be associated with rapid 
disease progression, noting that CXCR4 tropism has been associated with CRF01_AE 
subtype [53], while HIV-1 A subtype may have slower disease progression. All these factors 
may be important to HIV surveillance and patients care in developed regions where HIV-1 is 
becoming more diverse. 
In this current investigation it is important to recognise each Australian state contributed 
differing numbers of HIV-1 sequences to the analysis, therefore overall proportions was used 
to analyse the data. To the best of our knowledge all the sequences submitted for assessment, 
with the exception of those submitted by Queensland, represented newly acquired HIV-1 
infection. Due to the very strict criteria used to assign networks there is the potential to 
underestimate the number of pairs and networks identified in the study however it would 
prevent the inclusion of unrelated sequences into the results. This present study utilised a 
sizeable collection of sequences obtained from Australian routine clinical laboratories, 
represents a large portion of new HIV-1 diagnosis identified in Australia during 2005-2012 
and using strict phylogenetic approaches demonstrates a comprehensive and updated analysis 
of the changing HIV-1 epidemic across Australia.  
To our knowledge this analysis is the first longitudinal, large-scale assessment of HIV-1 
subtypes and phylogenetic network patterns in Australia over an eight year period. The study 
highlights the key influences of migration and overseas travel on increasing rates of non-B 
infections, and reinforces the importance of Australia’s engagement with regional and global 
aspects of the HIV epidemic, as well as the value of molecular epidemiology surveillance in 
the future.  
The establishment of the Australian Molecular Epidemiology Network, and the results that 
have now been obtained from routine laboratory HIV-1 sequencing from 4,873 individuals, 
provide the basis for a greater understanding of the Australian HIV-1 epidemic that is 
complementary to existing national surveillance methods. The information presented can 
assist in the development of effective strategies for laboratories, as well as inform prevention 
and treatment strategies that can favourably influence the HIV epidemic within Australia and 
beyond. 
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Summary Chapter 6 
The analysis of 4873 national de-identified sequences has provided a broad representation of 
the contemporary HIV-1 epidemic in Australia.  Chapter 6 “Molecular epidemiology of HIV-
1 in Australia 2005-2012: a national collaborative study”, identified the effects of migration 
and travel on the increasing HIV subtype diversity observed throughout Australia with 
particular emphasis on, 1) monitoring HIV-1 subtype diversity across Australia; 2) 
identifying HIV-1 migration patterns, with respect to time, across jurisdictions, and 3) 
recognising distinct dynamics within sequences that form HIV-1 clusters and networks.    
The results indicate that new notifications of HIV-1 infections in Australia remain dominated 
by HIV-1 B subtype virus with increased proportions of HIV-1 non-B subtypes presenting 
over time. When monitoring this by state, the differences in the proportions of non-B 
subtypes present are fascinating. As shown in Chapter 5 and confirmed in Chapter 6 the HIV-
1 epidemic in Western Australia has been confirmed as a national “hotspot” for HIV-1 
subtype diversity, accounting for the largest proportions recognised in Australia. Migrating 
across Australia, higher proportions of non-B subtypes have been shown in South Australia 
and New South Wales (western parts of Sydney) followed by Queensland and Victoria. 
6.1 Analyses of age distribution in the Australian HIV-1 cohort 
The age distribution of the HIV-1 population in Australia is of growing interest particularly 
with respect to increased age-related compilations in this cohort. A wide age distribution at 
the time of diagnosis within the Australian HIV-1 cohort is noted, as shown in the Western 
Australia analysis in Chapter 5, including differences among HIV-1 B and non-B subtypes as 
well as males and females (Figure 1) confirming HIV-1 in Australia does not only occur in 
young gay men.  The analysis in Chapter 6 clearly shows a shift from this perception within 
the Australian cohort ranging from infants to 86 year olds, regardless of HIV-1 subtype 
including 105 children under eighteen (at notification date). Once again the results also 
suggest more children have been infected with HIV-1 non-B subtypes and again as 
previously noted, this is thought to be through perinatal transmissions [3]. From the patients 
in the analysis there are currently 40 children 18 years of age or younger as many have now 
entered adulthood. The age distribution plots from Chapter 5 represent a high proportion of 
children within Western Australia HIV-1 cohort having a non-B subtype. The current 
Australian analysis has confirmed that a greater proportion of children in the Australian HIV-
1 population also have a non-B subtype suggesting the link between imported virus through 
migration. Tying this in with the results from Chapter 5, it can be concluded many reside in 
Western Australia (13/40, 32%) and Queensland (12/40, 30%).  
In terms of age according to network size, females and males in a large B subtype network 
are significantly younger than those in a singleton (females - 30.4 vs 37.0; males – 37.9 vs 
39.7, p<0.01), while males in a large non-B network are significantly younger than those in a 
non-B subtype singleton (34.7 vs 39.4, p<0.01) and males in a B subtype network (34.7 vs 
37.9, p<0.01). HIV-1 B subtype infection is still the predominant subtype amongst men while 
women are more likely to be infected with a non-B subtype. Overall, the trend is that younger 
males and females are presenting in larger networks regardless of having an HIV-1 B and 
non-B subtype. 
Figure 1: Age and gender according to HIV-1 subtype and network size. The age distribution 
plots for males (blue) and females (pink) with HIV-1 non-B subtypes (A-C) and B subtype 
(D-F). The ages for patients in a singleton (A+C), a pair (B+E) or network (C+F) are also 
represented.  
6.2 The analysis of networks within the Australian HIV-1 cohort 
The analysis of HIV-1 subtypes, phylogeny and network size has revealed distinct patterns 
within some states (as summarised in Chapter 6) however this can be further defined by 
assessing the network size within the HIV-1 B or non-B subtypes for each state (Figure 2). 
The results illustrate a large distribution of network size for Victoria within both the HIV-1 B 
and non-B subtypes. The proportion of larger B subtype networks is also evident in the 
Queensland cohort while HIV-1 sequences from the Western Australia cohort were well 
represented in a B subtype cluster of 29 sequences. Likewise, HIV-1 sequences from South 
Australia were well represented in smaller HIV-1 B subtype clusters of 10. 
 
Figure 2: An Australian, state by state approach on network size within HIV-1 B (A) and 
non-B subtypes (B).   
With the increasing rate of HIV-1 diagnoses in Australia continuing against global trends, an 
analysis of HIV-1 subtype pairs and networks detected over time is warranted to determine 
the impact on the HIV epidemic. To identify the era a pair or network appeared, the date of 
the 2nd or 3rd sequence in the pair or network (regardless of size) respectively, defined the 
time era nationally (Figure 3A).    
Remarkably, both pairs and networks have grown over time with the largest proportion noted 
in the most current time era (2011-2012). Defining this further for HIV-1 non-B and B 
subtypes shows non-B subtype pairs and networks continue to appear over time, with 
strikingly large proportions for networks evident in the latest time era (Figure 3B; 2011-2012, 
65%). Many of these larger, non-B subtype networks reside in Victoria and highlight the 
transmission of non-B subtypes into the MSM community. This suggests non-B networks are 
being established in Australia and are being diagnosed and sequenced in recent time. The 
study also established that large networks exist between states (interstate networks) indicating 
across jurisdiction travel exists within the HIV-1 population.  
 
Figure 3: The proportion of HIV-1 subtype pairs and networks established nationally (A), for 
HIV-1 non-B (B) and B subtypes (C) over time.  
The proportion of HIV-1 B subtype pairs was also deemed largest in the latest time era, while 
the largest proportion of networks within the B subtype analysis were present in the 2009-
2010 time era with a slight reduction in the following time era (Figure 3C).  
The mobility of HIV-1 infections within Australia was also studied. Interestingly, we have 
shown across-jurisdiction migration with HIV-1 B subtype sequences in a network size of 5 
or 6 with larger networks more likely to be “intrastate only” (Figure 4A). As the network size 
increases, HIV-1 non-B “interstate” networks are less common, however larger network sizes 
are more likely to include sequences from one state only (Figure 4B). These results suggest 
that there is evidence for imported HIV-1 virus into Australia however, although “interstate” 
networks exist within both HIV-1 B and non-B subtypes, it is generally at a lower proportion 
and occurs more frequently within the HIV-1 B subtype.   
 
Figure 4: The proportion of “interstate” or “intrastate” networks based on the number of 
sequences in the network (>2 in size) and either having an HIV-1 B (A) or non-B (B) 
subtype. 
To conclude, for the first time a retrospective, nation-wide HIV-1 phylogenetic analysis was 
performed to monitor HIV-1 subtype diversity and network dynamics within Australia. This 
analysis was not a contact tracing study but more about highlighting the changing dynamics 
of the HIV-1 epidemic within Australia utilising de-identified baseline viral sequences from 
2005 which accounts for a high percentage of new HIV-1 notifications.  
There are clear state similarities including a wide age distribution, general increases in HIV-1 
non-B subtypes and similar HIV-1 subtype diversity, however there are state differences in 
network size for major subtypes. The analyses confirm the mean age of the Australian HIV-1 
cohort at diagnosis is 38 years, however this only accounts for new notifications since 2005 
and does not include patients notified before 2005 and currently living with HIV. Including 
these patients into the analysis would reveal an ageing population fast approaching a median 
of 50 years. Interestingly however, 16% of patients in this current analysis were older than 50 
years of age (797/4873), which gives rise to a number of important patient care 
considerations, including the impact of age related illnesses and co-morbidity all of which 
add to the complications of current HIV management.  
The impact of this multistate phylogenetic analysis requires further exploration particularly in 
terms of assessing clinical parameters, drug resistance, viral fitness and targeting strategies 
given a recent US study showed large cluster size was associated with CD4 counts 
>350cell/μl and HIV-1 RNA levels >10,000 copies/mL [187] and confirmed with results 
presented in Chapter 5. These studies highlight an ongoing role of research using 
phylogenetic approaches linked in with HIV notification data to inform a prevention response 
in real time. This study also recognises challenges faced to prevent local and across 
jurisdiction transmissions within the MSM networks, imported HIV infections from overseas 
migrants and imported infections from Australian overseas tourism. The changing HIV-1 
subtype diversity demonstrates the requirement for updated prevention strategies to include 


















A collective summary for Chapters 5 and 6 
The spread of HIV-1 variants in Australia has been largely driven by sexual contact within 
MSM and dominated by the HIV B-subtype. Although this remains evident within the current 
analysis, changing trends have been revealed in Chapters 5 and 6 with the main conclusions 
being: 
1) The analysis of the HIV-1 epidemic in Western Australia highlighted a number of 
temporal trends over 15 years specifically revealing it as a “hotspot” for HIV-1 diversity, 
with an increased prevalence of HIV-1 non-B subtypes. 
2) In Western Australia patients with an HIV-1 B subtype generally have earlier diagnosis 
than patients with a non-B subtype representing delayed diagnosis in this group. 
3) Large networks are expanding despite early diagnosis and high uptake of HAART. 
4) Local transmissions remain dominated by HIV-1 B subtype viral strains, mostly within 
male only networks, therefore targeting strategies towards MSM networks remains a 
challenging issue for HIV-1 prevention in Australia. 
5) A distinct relationship between gender and HIV-1 subtypes revealing more females are 
infected with non-B viral strains along with more heterosexuals infected within non-B 
subtype networks. 
6) As revealed in the age distribution plots, HIV-1 is not an infection only observed in 
young men. It is infecting both young and old within various risk groups.  
7) Recognised impact of migration into Australia and Australian overseas tourism on HIV-1 
notifications. 
8) It remains interesting that only one very large cluster of 29 patients has formed within 
Australia over time and, also of interest, is that this cluster consists of sequences from 
only two states (Western Australia and Victoria) highlighting an important role for intra-
state travel. Analysis of the same cluster in the Western Australia analysis revealed this 
cluster has escalated to 53 genetically similar sequences.  
9) These studies highlight the cooperative approach that is required to effectively prevent 
new HIV cases in Australia, involving an increased appreciation of the role played by 




6.3 The challenges surrounding changes in HIV-1 subtype diversity 
When a virus initially enters a host, the HIV viral population adapts rapidly by altering its 
genetic sequence at specific regions [191, 192]. This can potentially result in the inhibition of 
the host’s combat mechanisms (i.e. ISGs), promoting escape from the immune system and 
increasing virus efficiency to enter immune cells. It is therefore critical to identify the HIV-1 
strains circulating among the Australian population as this will aid ongoing HIV-1 
surveillance and phylogenetic analysis that is required to explore biological differences 
between HIV-1 subtypes including differences to highlight what is driving the generation of 
large networks. Differences in HIV-1 genetic sequences among subtypes may carry 
functional differences, with subsequently increased spread through the population, leading to 
important clinical implications relating to the rate of disease progression, particularly in non-
B subtypes [193-195], HIV-1 transmissibility [196], differences in drug-resistant mutations 
and susceptibility to HIV therapy within non-B subtypes [197, 198] and increased virulence 
of HIV-1 as shown by others [199] and in Chapter 5. These highlight the importance of 
monitoring the emerging HIV-1 diversity in real-time to assist in the maintenance of public 
health prevention strategies as well as individual patient care. Including additional data that 
acknowledges and addresses potential confounding influences (Medicare status, mode of 
transmission and host genetics-CCR5∆32 mutation, HLA) may assist in clarifying clinical 
implications further. 
6.4     Impact of HIV-1 inter-subtype recombination 
HIV-1 inter-subtype recombination has contributed to the diversity of HIV-1 variants within 
the Australian epidemic. Currently 72 different inter subtype recombinants exist in the Los 
Alamos National Laboratory repository, with the likelihood that more of these stable 
circulating recombinant forms will be identified over time. These variants may have unique 
properties that could enable them to adapt within a host leading to increased prevalence [5] 
and replication capacity as previously shown in the spread of the CRF01_AE subtype in 
Thailand [200]. The genetic differences identified with inter subtype recombinant forms may 
have important clinical implications relating to the rate of disease progression as shown with 
the evolutionary fit CRF19_cpx strain [201] and CXCR4 tropism association with rapid 
disease progression [202] and CRF01_AE subtype [202, 203]. Increasing HIV-1 surveillance 
within Australia could potentially identify unique recombinants which will assist patient care 
(especially in the current epidemic where CRF01_AE subtype is common in Australia) and in 
the development of an effective vaccine and microbicides. 
6.5     Strength and limitations of phylogenetic approaches 
Assessing sequence similarities has both strengths and limitations. Phylogenetic analysis 
approaches are more successful with large cohorts allowing for accurate identification of the 
overall patterns of HIV epidemiology within a region and have been particularly useful in 
assessing sequences and clustering dynamics from Western Australia and at a national level. 
By employing stringent clustering criteria, phylogenetic analysis provides insight into local 
transmission network patterns including identifying onward transmission of non-B subtypes 
and the evolution of large networks over time. It also provides a robust link between HIV-1 
sequences available in an analysis, making it a useful tool in laboratory practices provided 
that mechanisms are in place to ensure that patient confidentiality is maintained. Although 
not assessed in this dissertation, phylogenetic analysis can also be used to identify HIV 
superinfections. 
The analysis approach used throughout Chapters 5 and 6 does not clearly identify direct 
transmission. This is important given it is estimated that 14% of HIV infections in Australia 
remain undiagnosed therefore there is the possibility of not including genetically similar 
sequences in the analysis. Phylogenetic analysis does not identify when HIV transmission 
occurred or the duration of infection. Added to this, the AMEN analysis included HIV-1 viral 
sequences from western New South Wales, which account for a small set of HIV-1 infections 
diagnosed in New South Wales. Incorporating more viral sequences from this region would 
add valuable data in terms of subtype diversity and network dynamics. The analysis does not 
include the large sequence dataset of baseline sequences notified before 2005 and not all 
HIV-1 patients have a viral sequence. This is due to the constraints surrounding the 
performance of HIV-1 viral sequencing on plasma samples retrieved from patients whose 
HIV-1 RNA level is <1,000 copies/mL, therefore missing these HIV-1 sequences adds to the 
limitations of this study.   
Another limitation of the AMEN study was the lack of clinical data, which would offer added 
value given the significant associations shown in Chapter 5 and other studies [187]. This 
would require partnerships with Ministries of Health at the state and national level, to assist 
in the incorporation of HIV notification and enhance surveillance information, together with 
the phylogenetic data, which would greatly improve public health strategies. 
6.6     Overview of automated HIV-1 subtype sequence tools 
The current laboratory practice in most Australian capital cities is to use the Stanford HIV 
database tool to assign HIV-1 subtypes generated from sequences used in the routine 
monitoring of drug resistant mutations. The AMEN-HIV study revealed problems associated 
with this database when assigning some inter-subtype recombinant sequences. The Stanford 
database assigned a group of 69 samples with a B subtype. These sequences were visually 
divergent from the main HIV-1 B subtype analysis and therefore warranted further 
investigation. Utilising four alternative assigning tools, a consensus was achieved for many of 
the samples most of which were not HIV-1 B subtype. Analysis of HIV subtyping tools has 
been previously addressed and showed similarity and that statistical based tools (COMET and 
jpHMM) were highly reproducible when compared to phylogenetic based tools (REGA and 
SCUEAL) [204-206]. The results presented in Chapter 6 were not as conclusive but 
confirmed the limitation with the Stanford tool. For this reason laboratories should adopt an 
alternative procedure to assign subtypes which will be discussed further in Chapter 7. 
6.7     Implications for successful vaccine development 
The ultimate control of the HIV-1 epidemic in the future is to eliminate transmission by 
developing an effective vaccine. This has become very challenging since traditional vaccine 
development approaches to date have failed and one approach raised the concern of possible 
increased risk to HIV-1 transmission due to pre-existing immunity [207]. One of the greatest 
challenges standing in the way of this achievement is HIV-1 diversity. The ability to identify 
HIV-1 genetic differences, to produce a broad neutralising antibody response [208] that is 
present at the time of HIV-1 infection and to generate strong T cell responses [209] could be 
important to the success of a vaccination program, however all these approaches will need to 
be assessed in a population where HIV-1 diversity is evident. 
6.8     Updating strategies to assist in reducing the rate of HIV transmissions and end 
HIV in Australia 
It is known that high rates of forward transmissions can occur during acute and early HIV 
infection [210, 211] and that diagnosing and treating individuals early can potentially reduce 
HIV transmissions [212] along with having additional benefits including improve health and 
long term outcomes [141, 213]. It is thought that HIV transmission risk is highest in early 
HIV infection due to the advantages of HIV founder viruses during early transmission [214] 
and high HIV-1 RNA levels [215], as well as the fact that the assessment of transmission risk 
is not appropriately informed by knowledge of HIV status. 
For these reasons new strategies focusing on reducing HIV transmissions should be adopted 
and include; 
1. Recognising high risk groups have expanded to include heterosexuals and MSM of a 
wide age range, along with migrants and short term visitors from areas where HIV 
rates are on the rise and where HIV is prevalent. 
2. Increased rollout of testing to all risk groups to increase the rate of diagnosis and to 
identify those with early stage infection. Identifying those in early HIV infection may 
also assist in contact tracing, in turn identifying increased numbers of people at risk. 
3. Implement HAART immediately after diagnosis so patients achieve an “undetectable” 
HIV-1 RNA level during earlier infection to reduce the risk of onward transmission 
and to reduce detrimental immune activation. 
 
Early HIV treatment and increased treatment coverage has been successful in reducing the 
rate of new infections around the world however it appears some countries, including 
Australia would benefit greatly by introducing early treatment strategies to all patients. 
In conclusion, the studies within Chapters 5 and 6 demonstrate the changing nature of HIV-1 
diversity within Australia, indicating the increasing influence of migration and travel 
including local transmission network dynamics linked to specific gender patterns. This up-to-
date HIV-1 subtype and phylogenetic analysis allows for a greater understanding of the 
Australian HIV-1 epidemic that is not readily attainable under existing national surveillance 
methods. The analyses not only deepen the understanding of the epidemic in Australia and 
Western Australia, it also directs attention to the paramount importance of continuous 
surveillance and phylogenetic analysis of HIV-1 variants to assist in adapting transmission, 
adherence, treatment and vaccine strategies. The information presented in Chapters 5 and 6 
can assist in the development of effective strategies for laboratories, clinical requirements, 
improve population target strategies, preventing new HIV-1 infections and improving the 
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7.1 Final Discussion 
In the current era of HIV-1 infection, monitoring HIV-1 progression and treatment response, 
at least within the developed world, has been successfully achieved due to the development 
of reliable HIV-1 RNA detection methods, the sequencing of HIV-1 pol region for the 
determination of developing drug resistant mutations, and the use of flow cytometry based 
assays to routinely monitor CD4+ T cells. Through the use of combination antiretroviral 
therapy, guided by these laboratory techniques to monitor HIV-1 disease progression, 
patients can experience a near normal level of lifestyle comparable to uninfected persons. 
Modelling studies, however, have suggested that life expectancy could improve further if 
there was increased uptake of HIV testing, better antiretroviral regimens and treatment 
strategies, and the adoption of healthier lifestyles by those living with HIV. In particular, 
earlier diagnosis is one of the most important factors associated with better life expectancy 
[216] as is earlier treatment initiation [141]. 
This final chapter summarises the results presented throughout the dissertation and finalises 
discussions regarding the outcomes relating to the;   
1) Implications of achieving HIV-1 RNA levels below the detectable range of routine 
laboratory tests (Chapter 2);  
2) Role monocyte activation markers play in innate immune dysfunction during chronic HIV 
infection and determining the potential roles that soluble markers of monocyte activation play 
in contributing to cardiovascular disease risk in these patients (Chapter 3 and 4); and  
3) Temporal trends relevant to the evolution of the Western Australian and Australian HIV-1 
epidemic (Chapter 5 and 6).  
Each of these studies is linked to the main theme driving this dissertation being “Filling the 
gaps; towards improved surveillance and monitoring of immunological status relevant to 
long term co-morbidities in HIV infection”. 
This thesis began by examining the determinant of HIV-1 RNA below the threshold of the 
routinely used method to determine the long term consequences that persistent low level 
viraemia has throughout HIV disease progression. The results extrapolated from the Western 
Australian experience presented in Chapter 2 support results from modelling studies and are 
summarised in Box 1. Taken together, the results from the study have interesting implications 
for the timing of treatment (supporting the SMART study and now reinforced by the START 
study findings) and identified treatment strategies to potentially further improve the 
management of people living with HIV. Unfortunately there are limitations when using 
HAART as their clinical utility can be restricted due to drug resistance, toxicity and 
adherence, and antiretroviral regimens cannot eliminate HIV from infecting some cells 












We have demonstrated that the average age of patients in the Royal Perth Hospital HIV 
cohort is approaching 50 years of age and they are at risk of developing age related disease, 
with high CVD risk (>10%; 5-year risk), suggesting that there is a significant risk of long-
term illness in this population that is not fully explained by the increased uptake of treatment 
or HAART, therefore further studies are required to determine possible links between non 
AIDS defining illnesses and HIV infection.  
During the early years of the HIV epidemic, the innate immune system was recognised as an 
important player in the progression of HIV-1 [217-219] however over the past 15 years this 
area has received less attention as an important factor associated with HIV disease 
progression. The main reasons behind this stem from studies focusing on the adaptive 
immune system as the CD4+ T cells are the main target of HIV-1 infection, replication and 
finally, destruction as well as the role T cells play in generating immune memory (important 
for vaccine design success). Recently, there has been mounting interest pertaining to the role 
Box 1: Key findings from chapter 2; 
 During 2007-2010, around 75% of patients had well controlled HIV RNA to 
undetectable levels (<40copies/ml) whilst a remarkable percentage (70%) had no 
detectable HIV RNA target.  
 A strong association of pre-treatment HIV-1 RNA with the detection of persistent 
HIV RNA among patients with HIV-1 RNA <40 copies/ml. 
 Findings suggest earlier treatment initiation based on level of HIV viraemia rather 
than CD4 T cell count may have long term benefits on viral response. 
 Choice of antiretroviral treatment regimen may influence the likelihood of 
achieving no target HIV-1 RNA, although pre-treatment viral load remains the 
dominant determinant of ‘residual viraemia’. 
 Results support the concept of residual viraemia and potentially of long lived 
reservoirs of latently infected cells. 
 
the innate immune system has during the chronic inflammatory component of HIV infection 
(which can be observed among those who have residual viraemia) by studying the role 
monocytes play throughout HIV-1 infection.   
Chapter 3 addressed the potential biological relevance and clinical utility of performing 
assays to determine the level of monocyte activation during HIV infection. Innate immune 
cells, like CD16+ subsets of monocytes, have been shown to be highly pro-inflammatory 
leading to immune activation. Incorporating the monitoring of monocyte immune activation 
markers into a research cohort like the WA HIV cohort enables large scale assessments that 
may clarify whether monocyte activation serves as a better predictor of HIV disease 
progression than some current diagnostic approaches. The primary concern addressed in 
Chapter 3 was to evaluate methods relevant to monocyte activation which could be readily 
adopted into routine laboratory practice. A summary of the major findings are presented in 











Exploring novel aspects of chronic HIV infection that remain currently invisible in routine 
care is an area of growing interest in the current era of treatment and monitoring of HIV-1 
patients. This is particularly important since the availability of durably effective antiretroviral 
therapy has brought into question the prognostic value of performing CD4+ T cell counts 
when a patient achieves and maintains treatment goals and is able to maintain virological 
suppression [101].  
Box 2: Key findings from Chapter 3. 
 The results support the concept that monocytes are phenotypically altered with 
HIV infection. 
 CD16+ monocytes showed increased expression of CD64, CD163 and CD143 that 
was not reduced to normal levels with HAART.  
 There are distinct associations between plasma biomarkers and HIV disease and 
HAART. 
 CD16+ monocytes and sCD14 did not correlate with gender, age or CD4+ T cell 
count and were not corrected by HAART therefore including them into HIV 
monitoring systems may provide additional prognostic information and also 
highlight opportunities for therapeutic intervention beyond the current 
antiretroviral treatment paradigm. 
 
Chapter 4 further explored the role that plasma biomarker levels of monocyte activation may 
play in the setting of cardiovascular disease risk during well controlled HIV infection. 
Circulating biomarkers of monocyte activation like sCD14 have been shown to be predictors 
of HIV disease progression [220] and mortality [28], while sCD163 has been shown to be 
significantly associated with non-calcified coronary plaques in HIV patients in a setting 
where HIV infection is well controlled [221] and all cause mortality [222]. Furthermore, 
CXCL10 has been associated with immune activation in HIV elite controllers [223], with 
rapid disease progression in acute HIV [121]. In the case of HIV and CVD, there are 
emerging concerns that patients are at risk even after adjusting for traditional risk factors 
[222]. It is evident, HIV patients have increased risk for coronary heart disease when 
compared to the general population and the risk may be present for males and females [224, 
225]. The results from Chapter 4 indicate a complex array of associations between the three 










Adding to the concept of “making the invisible visible”, the idea behind Chapter 5 was to 
identify temporal trends that are relevant to the evolution of the Western Australian HIV-1 
epidemic over the past 15 years. Baseline HIV-1 partial pol sequences (protease and reverse 
transcriptase) and HIV clinical parameters were examined from 1,021 consecutive patients 
(814 male, 207 female) through the Royal Perth Hospital HIV service, to investigate HIV-1 
subtype diversity and local phylogenetic networks from 2000-2014. The main findings, 
outlined in Box 4, highlight the changes in HIV-1 subtype distribution from the growing 
Box 3: Key findings from Chapter 4. 
 Three levels of effects played by plasma biomarkers in HIV infection. 
 CXCL10 was most readily explained by routinely monitored variables (ie. 
viral load, CD4+ T cell count or CD4:CD8 ratio). 
 sCD163 appears to reflect a deeper level of virological suppression and  is 
also associated with traditional CVD risk factors. 
 sCD14 was the least associated with routinely monitored variables but was 
strongly associated with smoking. 
 Lower levels of sCD14 were associated with treatment using an integrase 
inhibitor. 
 

















To date there have been large population-based studies that have investigated HIV-1 diversity 
including an international study [226], a study from the United States [187], the United 
Kingdom [227], Europe [188, 228] Africa [9] and Asia [8, 229] however a national 
perspective from Australia is lacking and would add to important information pertaining to 
the global epidemic. For this reason HIV-1 subtype diversity and phylogenetic network 
characteristics within HIV-1 B and non-B subtypes within an Australian HIV cohort were 
investigated in Chapter 6, with the aim of highlighting new challenges in HIV-1 prevention 
that may inform strategies to treat HIV and to end HIV-1 transmissions in Australia. The 
results highlight the increasing diversity of HIV-1 subtypes within the Australian epidemic, 
as well as differences in transmission networks within Australia that are associated with these 
HIV-1 subtypes. The main findings obtained from the national analysis are summarised in 
Box 5. 
Box 4: Key findings from Chapter 5. 
 HIV-1 genetic diversity has increased over time with HIV-1 non-B subtypes 
accounting for approximately 40% of HIV-1 infections from 2000-2014. 
 The non-B subtypes are known to be from regions where HIV-1 is highly prevalent 
and corresponds with the increased migration from sub-Saharan African regions 
(subtype C) and overseas travel to South East Asia.  
 Local HIV-1 transmissions remain dominated by B subtype viral strains, mostly 
within male networks. 
 The level of HIV-1 RNA has increased over time coinciding with minimal changes 
in CD4+ T cell counts, indicating earlier HIV-1 diagnosis. 
 In non-B HIV-1 infections however, CD4+ T cell count levels were lower 
representing delayed diagnosis among this group. 
 Despite being diagnosed early, large HIV-1 B subtype transmission networks are 
expanding and show significant associations with higher HIV-1 RNA levels and 
higher CD4+  T cell counts at time of diagnosis but not with age or gender, 
suggesting there are some “hard to reach” patients. 
The extent of HIV-1 diversification continues within the M group due to mutations, 
nucleotide substitutions, insertions and deletions as high error rates of reverse transcriptase 
occur during HIV replication. Diversity also occurs as a result of the recombination events 
transpiring between two or more HIV viruses within a cell, however, regardless of the causes 
the recognition of extensive and increasing HIV-1 diversity identified within the Australian 
HIV cohort is particularly important in relation to successful prevention, treatment and 











The findings in Chapters 5 and 6 provide epidemiological insights not readily available using 
standard surveillance methods and can inform the development of effective strategies for 
prevention of new HIV-1 diagnoses across Australian state boundaries.   
7.2 Translating science into laboratory practice 
This dissertation has highlighted the potential role of both monitoring immune activation and 
performing reliable HIV-1 subtyping and phylogenetic analysis within the laboratory to assist 
with improved monitoring of patient care and monitoring the HIV epidemic. A number of 
changes could possibly be implemented into standard laboratory practices to assist with this 
translation. 
Monitoring monocyte activation markers, both plasma biomarkers and proportions of CD16+ 
monocytes by flow cytometry methods would be beneficial particularly as high sCD14 levels 
Box 5: Key findings from Chapter 6. 
 HIV-1 diversity is increasing in Australia with more non-B subtypes being 
recognised within all states.  
 Similar HIV-1 subtypes are represented in all states however differences lie in the 
proportions of these subtypes present. Western Australia has the largest proportion 
of non-B subtypes. 
 There is a wide age distribution across all states including juveniles and over 55’s.  
 Phylogenetic analysis revealed differences in network size among B and non-B 
subtypes.   
 The data is valuable now and can be assessed in real time in future to assist with 
clinical care, educating and intervention strategies.  
are associated with increased mortality in HIV [26, 28] while sCD163 is associated with 
residual viraemia as shown in Chapter 4 and non-calcified coronary plaques [131, 221]. 
Higher proportions of CD16+ monocytes have been found to independently predict CVD in a 
non HIV setting [85, 230], are more permissive to HIV infection [23] and preferentially 
harbour HIV-1 [23, 231]. For these reasons, sCD14, sCD163 and a new 8 colour flow 
cytometry panel are warranted and should be incorporated into the routine monitoring of HIV 
infection. The new TBM (T cell, B cell and monocyte) 8 colour flow cytometry panel (Figure 
1) would consist of CD14, CD16 and CD57 antibodies along with currently monitored 
antibodies (CD4, CD3, CD8, CD45, CD19). It will, however, require further validation 
before implementation into laboratory practice.  
 
Figure 1: A potential T, B and monocyte (TBM) flow cytometry panel matching primary and 
secondary antigens to an acceptable fluorochrome based on intensity. 
As highlighted in Chapter 6 the use of the Stanford HIV database for accurately assigning 
HIV-1 subtypes may not always be appropriate especially when assigning circulating inter 
subtype recombinants and unique forms of HIV-1. Implementing an alternative strategy into 
laboratory practice is warranted. Model I, proposed in Figure 2, utilises the Stanford database 
and MEGA analysis to determine subtype and HIV-1 maximum likelihood tree structure to 
identify any outlying and divergent branches. Sequences clustering with minimal divergence 
require no further action and the initial HIV-1 subtype would be reported. Sequences in any 
divergent branch undergo further analysis by submitting them to an alternative database 
(COMET, REGA, jpHMM or SCUEAL) to determine subtype and breakpoints. If no 
consensus is reached a comment “unable to assign an HIV-1 subtype” should be reported.  
 
Figure 2: Model I - A proposed protocol for HIV-1 clinical laboratories to follow for the 
accurate assignment of HIV-1 subtypes. 
Implementing a change to the procedure currently used for monitoring new HIV infections is 
also required. The proposed flow chart shown in Figure 3 identifies current (HIV-1 RNA 
levels, genotyping and the western blot assays) and new assays (2LTR, TBM panel and 
ELISAs; including sCD14 and sCD163) suitable for laboratory monitoring and based on 
results from this dissertation. Additionally, given the results presented in Chapter 2, the 
current reporting strategy (reporting absolute HIV-1 RNA level or <40 copies/mL should be 
adjusted to reflect the residual viraemia detected using the current Cobas Taqman. This 
change should include the comment “Residual viraemia was detected below 40 copies/mL” 
or “no residual viraemia was detected”. This minor change would be highly advantageous to 
clinicians. Furthermore, the assays presented in the proposed flow chart would not always be 
required at all patient visits therefore Table 1 shows the proposed assays required per visit 
and those to be determined by the clinician at the consultation.  
 
Figure 3: A proposed flow chart representing the possible laboratory assays to be requested 
upon new HIV diagnosis including new monitoring assays, TBM panel, ELISAs, 2LTR and 
phylogenetic analysis procedure. 
7.3 Costs  
Reduced CD4+ T cell monitoring would provide a substantial cost saving without impacting 
HIV clinical care. Data from the Royal Perth Hospital/Fiona Stanley Hospital Department of 
Immunology HIV laboratory show that in 2015, the TBNK test (which includes CD4+ T cell 
counts) was performed 2951 times for 1174 patients at an average of 2.5 tests per patient. 
This was at a total cost of $88,530. Of these tests, 81.9% of patients always had an absolute 
CD4+ T cell count above 500, 8.1% never had an absolute CD4+ T cell count >500 and 10% 
had fluctuating CD4+ T cell counts. A saving of $43,290 would be made if the frequency of 
the TBNK assay was reduced to an annual test for patients with CD4+ T cell counts 
maintained above 500 (81.9% of the cohort). The NK component of this test is rarely utilised 
in clinical practice, therefore eliminating NK monitoring from the current TBNK flow 
cytometry panel would allow for the inclusion of monitoring monocytes with no additional 
costs (when taking into account the savings on annual testing). Another benefit would be the 
potential to alleviate patient anxiety due to fluctuations in absolute CD4+ T cell counts due to 
assay and laboratory variability. Allowing resources currently used for CD4+ T cell 
monitoring to be redirected to other clinical needs and replacing the TBNK panel with the 
proposed panel (Figure 1) including an antibody to detect senescence would be advantageous 
to patient care. The proposal would be to implement routine assessments for monitoring 
soluble monocyte activation markers (sCD14 and sCD163) at a cost of $24.50 per patient 
($28,763.00 for 1174 patients/year).  
Table 1: A representation of when HIV-1 monitoring assays should be performed within the 
first three years after diagnosis. 
 
7.4 Future studies 
The work undertaken throughout this dissertation has highlighted interesting aspects of HIV 
pathogenesis that remain unresolved. Future research should build on work around reducing 
residual viraemia focusing on the role that unintegrated and integrated proviral DNA plays. 
Reducing residual viraemia would be a major step towards eliminating HIV-1 viral 
replication. For this reason future work should be continued towards HIV-1 treatment 
intensification, which could be informed by recent research that has highlighted the role of 
TREX1 in preparing viral DNA for integration into the host genome [156, 157]. Identifying 
ways to inhibit TREX1 during early HIV infection may offer an important immune based 
therapy, however improved understanding of how TREX1 pathways function is required. An 
interesting study would be the analysis of TREX1 gene sequences of high risk-uninfected 
subjects and HIV-infected subjects, to determine sequence differences associated with HIV 
infection, DNA integration and residual viraemia. 
Additionally, with the ongoing identification of pathways leading towards monocyte 
activation, targeting these factors (i.e.ADAM17, IFNλ3, IFN-α, TNF-α) could lead to useful 
therapeutic strategies to reduce immune activation. A recent study showed a link between the 
monocyte activation marker sCD163 to clinical outcomes in treated HIV cases [222]. This 
supports the work presented in this thesis but requires further investigation into the potential 
mechanisms driving the increased sCD163 levels. As described in the summary of Chapters 
2-4, mechanisms providing plausible links between cell-associated HIV proteins (Nef in 
particular) and the release of sCD163 from its membrane-bound precursor have been 
identified however, ongoing work focusing on the impact that ADAM17, the Nef complex 
and exosomes have during HIV pathogenesis is required. Interestingly, monocyte ADAM17 
facilitates endothelial migration by accelerating the rate of diapedesis [137] by cleaving Mac-
1 therefore regulatory mechanisms of diapedesis may be important for the development of 
therapy to decrease CVD risk and for atherosclerosis; all of which warrants further 
investigation. 
The future work surrounding the role monocytes play in promoting immune activation 
remains vastly unresolved and holds great interest. Continued studies focusing on the role 
CD14++/CD16+ and CD14+/CD16+ monocytes play especially in the context of co-infections 
is worthy with specific focus on immune modulating approaches and how they impact 
monocyte activation in early acute and chronic HIV-1 infections. Also monitoring CXCL10 
levels during primary infection could also be beneficial, as would monitoring the effect of 
early HIV treatment with HAART on immune activation and residual viraemia. 
In terms of immune modulation, IFNλ3 offers strong antiviral effects and the expression 
pattern of IFN-λ3 receptors is very cell specific [181] therefore studying its use as a 
therapeutic option demands further attention especially as it may have fewer side effects over 
other IFNs hence making it more attractive to use. Another potential immune based therapy 
that has previously been assessed in SIV infected macaques but not in humans is IL-21 
treatment [182]. This study revealed a link between immune activation and residual viraemia 
and showed that IL-21 effectively reduced both while infected macaques were on ART. 
Interestingly, plasma viraemia and cell associated SIV DNA levels remained low, for eight 
months after ART was ceased therefore monitoring IL-21 treatment in humans may prove to 
be advantageous.  
Immune modulation could also be controlled with the use of aspirin as previously described 
[171]. The use of aspirin may have a place in effectively reducing immune activation and 
inflammation, although further studies are needed on a large scale to expand on the 
mechanisms and pathways. 
Finally the data presented in Chapters 5 and 6 provided a solid foundation to propose 
continued HIV-1 surveillance in Australia. Adding clinical and notification data (as present in 
Chapter 5) and evaluating HIV-1 baseline drug resistant mutations in this cohort will only 
strengthen the analysis and provide a comprehensive HIV-1 epidemiological surveillance 
system, currently missing in Australia.     
7.5 Final Conclusion  
With more than 33 million deaths from HIV/AIDS worldwide and with the failure to reduce 
new HIV infections in Australia, to produce an adequate vaccine to curb new infections or to 
cure current infections, those infected who do have access to life changing HAART will 
experience persistent immune activation and immune dysfunction. This is largely mediated 
by the activation of monocytes, therefore alternative strategies must be adopted to prolong the 
health of patients ageing with HIV. Immunomodulating therapies and strategies with 
pharmacological or biological agents could be a way forward in the future to treat HIV 
patients. Adding to this the demonstration of increased HIV-1 diversity and increased HIV 
new infections in Australia is alarming. Safe sex campaigns should emphasise that HIV does 
not discriminate according to age, gender or sexual preference. Descriptive campaigning 
messages should reinforce the possibility and risk of becoming infected with HIV overseas 
regardless of sexual preference or age and the increased risk of acquiring HIV in Australia.  
From the information and results presented in this thesis, “filling the gaps” is a critical step 
towards achieving the goals of the UNAIDS current strategy of achieving “90, 90, 90” by 
2020 and the 7th Australian National strategy by 2017 and further improving the quality of 
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